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Abstract 
T-lymphocytes play a pivotal role in the orchestration of allergic immune responses and 
thus critically contribute to immediate phase reactions as well as late phase allergic 
reactions. Consequently, strategies to modulate the pathological T helper 2 (Th2)-biased 
response might be of therapeutic benefit for allergic individuals. However, until today 
model systems for allergic T-cell responses based on human-relevant allergens and the 
corresponding human restriction elements and T-cell receptors (TCR) are still missing. For 
that reason we cloned and functionally characterized such relevant molecules involved in 
antigen-presentation and recognition (i.e. the HLA restriction elements and the 
corresponding TCR alpha and beta chains) from mugwort pollen and birch pollen allergic 
individuals. By generation of artificial antigen-presenting ells (APC) based on transfection 
of 293 cells with the HLA molecules, allergenic peptides and costimulatory molecules in 
concert with retroviral transduction of human T-cells with corresponding TCR we 
succeeded in rebuilding the ‘allergen-specific synapse’. This defined in vitro model 
system allowed us to study signal requirements and plasticity of allergen-specific T-cells. 
In fact, we could show that TCR transgenic T-cells were strictly dependent on presentation 
of cognate peptide and costimulatory signals to mount their effector functions. Using this 
system we tested the capacity of 293 cell-derived virus-like particles (VLP) with distinct 
compositions of HLA/allergen complexes and accessory molecules to modulate allergen 
specific T-cell responses.  In this context we could demonstrate that allergen-presenting 
VLP were perfectly suited to assume the role of antigen-presenting cells and to expand, 
anergize or polarize TCR transgenic T-cells depending on their pre-defined set-up. 
Similarly, decoration of VLP with the high affinity interleukin-2 receptor allowed for the 
depletion of IL-2 from T-cell cultures thus mimicking an important effector mechanism of 
regulatory T-cells (Treg). In a different approach we hypothesized that ectopic expression 
of transgenes associated with Treg function would enable us to develop also allergen-
specific Treg. To that end we applied a multicistronic expression strategy, putting the α 
and β chains of a Bet v 1 (birch pollen allergen)-specific TCR plus Foxp3, the master 
regulator of Treg function, along with an IRES-GFP cassette under the control of a 
retroviral to transduce CD4+CD25- T-cells. These TCR/Foxp3 transgenic T-cells displayed 
the typical phenotypic profile of Treg, showed hyporesponsiveness in response to 
polyclonal and allergen-specific stimulation and were able to suppress the effector 
function of Bet v 1-specific T-cells in an activation-dependent manner. The establishment 
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of such novel T-cell modulatory strategies based on artificial antigen-presenting platforms 
and regulatory T-cells could possibly lead to novel therapeutic applications in allergic 
diseases and other immune-mediated disorders.  
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Kurzbeschreibung 
T-Lymphozyten spielen eine wichtige Rolle in der Regulation von allergischen 
Immunantworten und tragen daher entscheidend sowohl zur Sofort-Typ Reaktion als auch 
zu den allergischen Spät-Phasen Reaktionen bei. Daher könnten Strategien, die darauf 
abzielen, die pathologische T Helfer 2 (Th2)- Antwort zu verändern von therapeutischem 
Wert für allergische Individuen sein. Dennoch fehlen bis heute Modell-Systeme für 
Allergen-spezifische T-Zell Antworten, die auf human-relevanten Allergenen und den 
dazugehörigen HLA Restriktionselementen und T-Zell Rezeptoren (TZR) basieren. Daher 
klonierten und charakterisierten wir solche relevanten Moleküle, die in Antigen-
Präsentation und -Erkennung involviert sind (das sind die präsentierenden HLA-Moleküle 
und die dazu gehörigen TZR α and β Ketten) aus dem Blut von Beifusspollen und 
Birkenpollen Allergikern. Indem wir 293 Zellen mit den HLA Molekülen, den Allergenen 
und kostimulatorischen Molekülen transfezierten, und gleichzeitig durch retrovirale 
Transduktion von humanen T-Zellen mit dem dazugehörigen TZR allergen-spezifische T-
Zellen herstellten, gelang es uns, die ‚Allergen-spezifische Synapse’ auf molekularer 
Ebene zu rekonstruieren. Dieses definierte in vitro Modellsystem erlaubte uns das 
Verhalten und die Plastizität von allergen-spezifischen T-Zellen nach Stimulation mit 
unterschiedlichen Konditionen zu untersuchen. Tatsächlich konnten wir zeigen, dass TZR 
transgene T-Zellen auf die Präsentation des korrekten Peptids und auf kostimulatorische 
Signale angewiesen waren, um ihre Effektor-Funktion initiieren zu können. In diesem 
System testeten wir zunächst, ob Virus-ähnlichen Partikeln (‚virus-like particles’; VLP), 
die wir in 293 Zellen produzierten und mit definierten Zusammensetzungen an 
HLA/Allergen Komplexen und accessorischen Molekülen ausstatteten, die Kapazität 
hatten, allergen-spezifische T-Zellen zu modulieren. In diesen Studien konnten wir 
beobachten, dass allergen-präsentierende VLP perfekt geeignet waren, die Rolle von 
antigen-präsentierenden Zellen zu übernehmen, und TZR transgene T-Zellen zu 
expandieren, zu anergisieren oder zu polarisieren, abhängig von der vordefinierten 
molekularen Ausstattung. Außerdem konnten  VLP, die mit dem hochaffinen Interleukin-2 
(IL-2) Rezeptor ausgestattet waren, dieses Zytokin in T-Zell Kulturen neutralisieren, 
womit sie eine wichtige Effektor-Funktion von regulatorischen T-Zellen (Treg) 
übernehmen konnten. In einem anderen Ansatz verfolgten wir die Hypothese, ob Transfer 
von Genen, die mit der Funktion von Treg assoziiert sind, uns erlauben würde, allergen-
spezifische Treg zu generieren. Dafür verwendeten wir eine multicistronische Expressions 
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Strategie, indem wir die α und β Kette eines Bet v 1 (Birkenpollen-Allergen)-spezifischen 
TZR über 2A Elemente mit Foxp3, dem Hauptregulator-Gen der Treg Funktion, 
verbanden. Diese Expressionskassette wurde gemeinsam mit einem IRES-GFP Element in 
einen retroviralen Expressionsvektor kloniert und in CD4+CD25- T-Zellen transduziert. 
Diese Foxp3/TZR transgenen T-Zellen zeigten das charakteristische phänotypische Profil 
von Treg und stark verminderte Proliferation nach allergen-spezifischer und polyklonaler 
Stimulation, und konnten Bet v 1-spezifische T-Zellen Aktivierungs-abhängig regulieren. 
Die Etablierung von solchen neuen T-Zell modulierenden Strategien basierend auf 
artifiziellen Antigen-präsentierenden Plattformen und regulatorischen T-Zellen könnte zur 
Entwicklung von neuen Therapien für die Behandlung von Allergien, aber auch von 
Autoimmunerkrankungen und Episoden von Transplantatabstossung, führen.  
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Structure of the thesis 
 
The Introduction provides a brief overview about the role of T-lymphocytes in allergic 
reactions, the topic of immunomodulation and the aims of this thesis. 
 
Chapter 1 gives an in depth review about the current knowledge of regulatory T-cells 
with special emphasis on strategies to propagate, induce or generate regulatory T-cells. 
This manuscript has been invited to be submitted to the FASEB Journal. 
 
Contribution: study of the literature, preparation of the manuscript; first author   
 
Chapter 2 describes the generation of an in vitro model system for human allergen-
specific T-cell responses. To that end, the relevant HLA restriction element (HLA-DR1), 
the allergen-derived peptide (Art v 125-36) and a corresponding human T-cell receptor 
(TRAV17/TRBV18) were cloned. T-cell receptor transgenic Jurkat T-cells and peripheral 
blood T-cells were analyzed for their antigen-specificity and costimulation-dependency. 
The resulting manuscript was published in J Allergy Clin Immunol 2008; 121:64-71 
 
Contribution: establishment of retroviral transduction protocols for peripheral blood T-
cells, phenotypic analysis of transgenic peripheral blood T-cells, T-cell proliferation 
experiments, contribution to the analyses of data and the preparation of the manuscript; 
co-author 
 
Chapter 3 deals with the potential of virus-like particles as artificial allergen-presenting 
platforms to modulate human allergen-specific T-cell responses in vitro. The capacity of 
virus-like particles decorated with HLA-DR1 presenting Art v 125-34 in concert with 
different combinations of costimulatory molecules to anergize or polarize Art v 1-specific 
T-cells was analyzed. The obtained results were published in J Allergy Clin Immunol 
2009; 124:121-128 
 
Contribution: establishment of T-cell anergization and polarization protocols, provision 
of allergen-specific transgenic T-cells, T-cell proliferation, restimulation and polarization 
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assays, contribution to the analyses of data and the preparation of the manuscript; co-
author 
 
In the Chapter 4 we assessed, in a project not directly related to the modulation of 
allergen-specific T-cells, the molecular requirements for HLA Class II expression using B-
cell lines from seven HLA Class II deficient individuals. We especially focused on 
phenotypic differences regarding invariant chain expression in B-cell lines from the four 
known different complementation groups. The resulting observations were published in 
the Int Arch Allergy Immunol 2010; 152:390-400 
 
Contribution: establishment of B-cell lines, cloning of CIITA and RFX, retroviral 
complementation and phenotypic analyses of B-cell lines, preparation of genomic DNAs 
for sequencing, statistical analyses and contribution to the preparation of the manuscript; 
first author 
 
Chapter 5 addresses the feasibility to decorate virus-like particles with multimeric 
receptors such as the interleukin-2 receptor. Binding kinetics of VLP decorated with IL-
2R variants of differential affinity were analyzed. Furthermore, the potential of virus-like 
particles decorated with the high-affinity IL-2R to deplete IL-2 from activated T-cell 
cultures and the consequently induced T-cell hyporesponsiveness were assessed. The 
resulting manuscript was published in FASEB J 2010; 24:1572-1582 
 
Contribution: provision of allergen-specific transgenic T-cells, T-cell proliferation and 
restimulation assays, contribution to the analyses of data and preparation of the 
manuscript; co-author 
 
Chapter 6 describes the generation of transgenic allergen-specific regulatory T-cells by 
co-introduction of a Bet v 1142-153 specific TCR in concert with Foxp3 using a 
multicistronic expression element. Human TCR/Foxp3 transgenic peripheral blood CD4+ 
T-cells were analyzed for their proliferation, cytokine secretion and suppressive capacity 
towards allergen-specific effector T-cells. The resulting observations were published in 
the J Allergy Clin Immunol 2009; 127:238-245 
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Contribution: construction of multicistronic expression elements and retroviral vectors, 
analyses of transgene expression and phenotype, T-cell proliferation and suppression 
assays, the analyses of data and the preparation of the manuscript; first author 
 
The chapter Conclusion and Synopsis outlines the essential findings and gives a synopsis 
of the thesis. Furthermore, the ‘open ends’ of this research project are thoroughly 
discussed. 
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Introduction  
 
Under physiological conditions a delicate balance between different CD4+ T-cell subsets 
governs adaptive immune responses to foreign antigens. The interplay of T helper subsets 
(such as Th1, Th2 and Th17) in combination with naturally-occurring and inducible T 
regulatory cell (Treg) subsets guarantees an appropriate response which serves to eradicate 
potential pathogens while keeping the integrity of the organism intact. Consequently, 
imbalances in the CD4+ T-cell compartment can promote autoinflammatory, autoimmune 
and allergic disorders. Indeed, the T-cell response to allergens is dominated by Th2 
polarized CD4+ T-cells1 and an apparent lack of Treg numbers and/or function2. Following 
allergen-specific activation, the secretion of Th2 cytokines such as IL-4, IL-5 and IL-13 
mediates IgE class switching, activation of eosinphils and basophils and hyperreactivity of 
epithelial tissues, thereby contributing to the sensitization phase as well as to late-phase 
reactions and allergic inflammation3 (Fig.1). In this light, strategies to modulate the Th2 
CD4+ T-cell response to allergens or to induce allergen-specific Treg should present as 
promising therapeutic options. Evidence for this notion also comes from observations in 
patients undergoing specific immunotherapy (SIT), in whom amelioration of clinical 
symptoms was accompanied by an increase in allergen-specific Treg4-7 as well as Th1 
polarized CD4+ T-cells8-10 (and reviewed in Larche et al11).  
 
Fig.1 Role of T 
helper 2 (Th2) cells in 
allergic immune 
responses. In allergic 
individuals, processed 
allergen is presented 
to unpolarized CD4+ 
T helper cells by 
antigen - presenting 
cells (APC), which 
induces polarization. 
Consequently, release 
of Th2 - specific 
cytokines promotes 
IgE class switching in 
B-cells, activation of 
eosinophils and mast 
cells and metaplasia 
and mucus production 
in epithelial cells.  
 
(adapted from Holgate and Polosa, Nat Rev Immunol 2008; 8:218-230) 
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Although the central importance of CD4+ T-cells in allergic responses is thus indisputable, 
molecular information about the actual composition of the ‘allergen-specific synapse’ are 
still scarce. Recent efforts have identified HLA restriction and allergen-derived T-cell 
epitopes for several clinically relevant allergens12-16, yet the T-cell side of the synapse has 
been largely uncharacterized.  Consequently, we set out to clone and ectopically express 
allergen-specific T-cell receptors derived from allergic patients in order to rebuild the 
allergen-specific synapse at the molecular level and create an in vitro model system to 
study allergen-specific T-cell activation and modulation. 
 
Transfer of TCRαβ genes to generate large numbers of antigen-specific T-cells was 
established in the mid 1980ies17. Since then, numerous TCR-transgenic murine model 
systems have been developed and have helped to elucidate mechanisms of T-cell 
development18, 19 and the immune response to autoantigens20, 21 and infectious diseases22. 
More recently, techniques to transfer human TCRαβ genes have been reported as a novel 
tool to generate large numbers of tumor-reactive CD8+ T-cells23-25. Importantly, those 
studies could show that TCR-transfer led to the desired transfer of antigen-specificity 
while leaving key physiological properties of T-cells, such as requirement for 
costimulation, intact.  
 
As model allergens we chose the major mugwort pollen allergen Art v 1 and the major 
birch pollen allergen Bet v 1, which both represent clinically relevant entities in the 
European and American temperate climate zone26. Art v 1 constitutes an ideal model 
allergen as more than 95% of mugwort pollen allergic patients are sensitized to Art v 1 
and the T-cell response is dominated by one immunodominant epitope, Art v 124-36. 
Additionally, several studies have indicated that presentation of this peptide is highly 
associated with HLA-DRB1*0112, 14. Consequently, we cloned a TCR 
(TRAV17/TRBV18), which recognizes Art v 124-36 in the context of HLA-DR1. In 
contrast, the T-cell response to birch pollen allergens is more diverse with three frequently 
recognized epitopes (Bet v 14-15, Bet v 1112-123, Bet v 1142-153) contained within the major 
birch pollen allergen Bet v 115, 16. Similarly, restriction elements are more diverse. For 
initial studies with focused on a TRAV6/TRBV20 T-cell receptor, which recognizes the 
C-terminal Bet v 1142-153 peptide presented by HLA-DR7.  
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Once appropriately activated via the TCR, the fate of the T-cell response is dependent on 
the milieu of costimulatory and accessory signals27. Antigen-presentation in the absence of 
costimulation induces a state of hyporesponsiveness, called ‘anergy’ in T-cells28, 29, which 
serves as a major mechanism of T-cell tolerance. Similarly, qualitative differences in 
costimulation have been described to differentially shape the ensuing T-cell response. In 
this respect, costimulation solely via the CD58-CD2 axis induces a phenotype 
characterized by the production of high levels of IL-10 and IFN-γ and low levels of IL-2 
and IL-430. This phenotype is of special interest, as it resembles T regulatory type I cells, 
which have been implied to play a role in the regulation of immune responses in allergy4, 5, 
11. 
Apart from APC derived signals, the T-cell response is also influenced by the interplay 
with different T helper subsets and by regulatory T-cells populations, which can suppress 
T-cell activation even under optimal stimulation from APC31. Consequently, multiple 
points of modulation exist during a T-cell response, all of them representing potential 
targets for therapeutic intervention.  
 
In order to assess the modulatory potential of artificial antigen-presenting platforms, we 
relied on our recently described virus-like particle (VLP) technique32, 33 (Fig.2). In these 
studies we had proven the feasibility to decorate lipid-raft derived VLP with 
immunostimulatory factors such as HLA molecules, costimulatory ligands, accessory 
molecules33 and cytokines32 by anchoring them to GPI-anchor acceptor sequences. Thus 
equipped VLP constitute modular artificial antigen-presenting platforms that can be 
decorated with a distinct composition of molecules which allows to shape the VLP 
induced T-cell response. First formal proof for this capacity was obtained in in vitro33 as 
well as in in vivo32 experiments using antigen-specific activation and lytic function of 
CD8+ T-cells as readout. We hypothesized that HLA Class II decorated VLP should be 
equally capable of presenting antigen and modulating the effector function of allergen-
specific CD4+ T-cells. Apart from costimulation via CD80, which promotes robust T-cell 
activation and thus represents an ideal reference molecule, we focused on allergen-
presentation in the absence of costimulation to induce anergy and on CD58 costimulation 
to induce the above-mentioned Tr1-like T-cell phenotype.  
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Fig. 2. Scheme for production of cytokine-decorated VLP. Cytokines or immune receptors of interest are 
modified by GPI anchor acceptor sequences, which, upon transfection into 293 cells, target them to lipid 
rafts of the plasma membrane. Coexpression of original MoMLV gag-pol (OGP) induces the secretion of 
plasma membrane-derived VLP by the producer cell line. VLP harvested from the supernatant can be used 
directly or purified by ultracentrifugation in order to stimulate target cells. (adapted from Kueng et al., J 
Virol 2007; 81:8666-76) 
 
Due to their capacity to also accommodate multimeric molecules, VLP are potentially 
suited to provide, apart from serving as artificial APC, other functions of the immune 
system. We aimed to use this capacity of VLP to deplete the important survival factor IL-2 
from cultures of activated T-cells, thereby mimicking one of the key effector mechanisms 
of regulatory T-cells34. For that purpose, VLP equipped with the high affinity IL-2 
receptor were assessed for their binding capacity and their influence on antigen-specific T-
cell activation. 
 
In a second line of strategy we planned to assess the potential of our system to generate 
allergen-specific regulatory T-cells by genetic engineering. We based our working 
hypothesis on recent key findings that ectopic overexpression of Foxp3 in CD4+ T-cells 
was sufficient to induce a naturally-occurring Treg (nTreg)-like phenotype and function35, 
36. An important feature of nTreg is their property to exert their suppressive function 
strictly upon appropriate activation via the TCR/CD3 complex31, 37, 38. In this light we 
hypothesized that co-expression of an allergen-specific TCR in concert with Foxp3 would 
generate allergen-specific Treg with the TCR serving as a molecular ‘on-switch’ and 
Foxp3 enforcing the regulatory program. In the light of experimental data that favor the 
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use of antigen-specific Treg for therapeutic application, strategies to generate antigen-
specific human Treg should be of general interest. The current translation of Treg-based 
therapies from ‘bench to bedside’ with first clinical studies being finished could thus profit 
from such approaches in the long term. An in-depth review about this topic is given in 
Chapter II. 
 
In a side project we also studied regulation of MHCII expression, from which we hoped to 
gain insights into how to further develop and improve artificial antigen-presenting 
systems. For that purpose, we used EBV transformed B-cell lines from three newly 
defined Austrian MHCII deficiency patients and four prototype cell lines which had been 
described before. MHC Class II deficiency is caused by mutations in the genes of four 
trans-acting factors, the Class II transactivator (CIITA) and three molecules of the 
restriction factor X complex (RFX), RFXANK, RFX5 and RFXAP, which non-
redundantly control expression of the MHCII locus39. Accordingly, four complementation 
groups can be designated. While expression of HLA-DR, -DP, -DQ and -DM is tightly 
governed by these factors, expression of the invariant chain (Ii), although located in the 
MHCII gene cluster, seems to be somewhat independent of the intact CIITA-RFX 
complex. Indeed, several reports suggest that Ii mRNA can be detected in cell lines from 
MHC Class II deficient patients40, 41. Consequently, we focused on analysis of invariant 
chain expression in different complementation groups, which could ultimately also help to 
improve diagnosis in this rare disease. 
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ABSTRACT 
Naturally-occurring CD4+CD25high forkhead box protein 3 (FOXP3)+ regulatory T-cells 
(nTreg) are key mediators of immunity which orchestrate and maintain tolerance to self 
and foreign antigens. In the recent 1 1/2 decades, a multitude of studies has aimed to 
define the phenotype and function of nTreg and to assess their therapeutic potential for 
modulating immune mediated disorders such as autoimmunity, allergy and episodes of 
transplant rejection. In this review we summarize the current knowledge on the biology of 
nTreg. We address the exact definition of nTreg by specific markers and combinations 
thereof, which is a prerequisite for the state-of-the-art isolation of defined nTreg 
populations. Furthermore, we discuss the mechanism by which nTreg mediate 
immunosuppression and how this knowledge might translate into novel therapeutic 
modalities. With first clinical studies of nTreg-based therapies being finished, questions 
concerning the reliable sources of nTreg are becoming more and more eminent. 
Consequently, approaches allowing conversion of CD4+ T-cells into nTreg by co-culture 
with antigen-presenting cells, cytokines and/or pharmacological agents are discussed. In 
addition, genetic engineering approaches for the generation of (antigen-specific) nTreg are 
described. 
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General Introduction 
Regulatory T-cells (Treg) play a fundamental role in the development and maintenance of 
immunological tolerance. First data about the suppressive capacity of T-cells were already 
acquired in the late 1960s to early 1980s using mouse thymectomy models1, 2. However, 
the advent of modern day Treg research can be dated to the year 1995 when Sakaguchi et 
al. first described the anergic and suppressive function of CD4+CD25+ T-cells in mice and 
could convincingly show that depletion of these cells resulted in multiorgan autoimmune 
disorders upon adoptive transfer3. CD4+CD25+ were defined to express the forkhead box 
P3 (Foxp3) transcription factor4-7 and form a distinct thymus-derived lineage in both mice8 
and healthy human individuals9 and were consequently termed naturally-occurring Treg 
(nTreg). Similar to effector T-cell subsets, the function of nTreg (i.e. suppression of 
immune responses) was shown to be dependent on activation via the TCR/CD3 complex. 
However, once appropriately activated, this regulatory function was found to be antigen 
non-specific3, 10, 11. Thus, upon antigen encounter, nTreg create a tolerogenic milieu in 
order to down-regulate aberrant or harmful immune responses. 
In addition to nTreg, the existence of several different inducible Treg subsets has been 
reported, which are generated in the periphery under tolerogenic conditions. Among them 
the T regulatory type I (Tr1) subset that produces high levels of IL-10 has been best 
defined (reviewed by Roncarolo et al.12).  
Treg were demonstrated to restrain the evolution and progression of autoimmune 
disorders13, to play a key role in tolerance against allo-antigens after transplantation14 and 
to modulate allergic immune responses15. Furthermore, several primary 
immunodeficiencies present with an apparent lack of functional Treg subsets, e.g. Omenn 
syndrome, Wiskott-Aldrich syndrome, hyper IgE syndrome and the IPEX syndrome 
(immune dysregulation, polyendocrinopathy, enteropathy, X-linked)16. Thus autoimmune 
disorders, allergies and distinct disorders of the immune system can be attributed to 
inadequate Treg number and/or function. Consequently, protocols to induce or generate 
Treg function and/or to expand Treg numbers have gained increased attractiveness as 
therapeutic options for a broad range of diseases. Such technologies should include the 
ability to generate large numbers of highly suppressive and antigen-specific Treg that 
remain stable and viable in vivo. In this review we aim to define the two major Treg 
subsets, i.e. nTreg (naturally-occuring T reg) and TR1 (T regulatory type I) cells, describe 
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their effector mechanisms and summarize the so-far used strategies to expand, induce or 
generate Treg. 
 
Naturally occurring Treg (nTreg) 
 
Naturally occurring CD4+CD25+ Treg (nTreg) constitute a distinct thymus-derived T-cell 
lineage that possesses the capacity to suppress activation and function of effector T-cells 
as well as antigen-presenting cells such as dendritic cells (DC), B-cells and monocytes. In 
peripheral blood of rodents about 8-10% of lymphocytes express the CD4+CD25+ 
phenotype17-22. However, this subset constitutes a heterogeneous population of nTreg and 
activated T-cells in human blood and thus some authors estimate the actual number of 
nTreg at 1-2%9. Consequently, the more pure nTreg population is confined to the 
CD4+CD25high T-cell subset. Functionally, nTreg show a marked hypoproliferation upon 
TCR/CD3-mediated stimulation3, 9, 17-19, 21, which can be overcome by the addition of high 
doses of IL-217, 23 or a strong costimulatory signal17, 23. In contrast to effector T-cells, 
nTreg also secrete minimal amounts of IL-2 as well as helper subset specific cytokines 
such as IFN-γ (Th1), IL-4, IL-5 and IL-13 (Th2) and IL-17 (Th17). In co-cultures with 
CD4+CD25- effector T-cells (Teff), nTreg efficiently suppress Teff proliferation3, 9, 17 and 
cytokine production24. This regulatory function is an activation-dependent process that 
requires cell-cell interactions as shown by experiments in which separation of nTreg and 
Teff by a semi-permeable membrane and/or transfer of nTreg supernatants do not lead to 
Teff suppression9.  
The transcription factor forkhead box protein 3 (Foxp3) is constitutively expressed in 
nTreg and acts as the master regulator in Treg development and function7. Foxp3 contains 
three discernible functional domains, a single C2H2 zinc-finger motif, a leucine-zipper-
like motif and a C-terminal forkhead domain, thereby exerting its positive and negative 
function as transcription factor. Among those target genes, Foxp3 acts as transcriptional 
activator for genes that are typically up-regulated in nTreg (e.g. CD25, CTLA-4; see 
below) while it represses transcription of both Th1 and Th2 cytokines in nTreg7. Recent 
work on the IL-2 promoter in nTreg has shown that Foxp3 physically interacts with NFAT 
thus displacing AP-1 from the complex and thereby repressing the induction of IL-2 
transcription. Similar mechanisms may also contribute to the repression of other 
cytokines25, 26.  
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The importance of Foxp3 in Treg development is highlighted by the fact that the scurfy 
mouse strain that carries a loss-of-function mutation in the Foxp3 gene completely lacks 
nTreg cells and develops a lymphoproliferative disease characterized by multi-organ 
infiltration of T-cells, leading to the death of mice at 3-5 weeks of age27. Similarly, human 
patients suffering from the IPEX syndrome carry mutations in the Foxp3 gene and present 
with a broad range of autoimmune symptoms that is consistent with the lack of Treg28-30.  
nTreg express a broad repertoire of α/β TCRs with specificities for both self and non-self 
antigens. While TCR diversity is similar between Treg and Teff, their repertoire is 
different with nTreg showing higher TCR affinities for MHC class II/peptide complexes 
than effector T-cells. However, other studies have indicated that this distinction is not 
complete and overlaps in the repertoire do exist (reviewed by Pacholczyk and Kern31 and 
Ohkura and Sakaguchi32). Especially a Foxp3low subpopulation of CD4+CD25+ nTreg has 
been reported to show a high degree of TCR similarity with effector T-cells33.  
 
Markers 
While it is now widely accepted that nTreg constitute an independent T-cell lineage, so far 
no consensus about a distinct phenotype has been reached. The IL-2 receptor α chain 
(CD25) was the first surface marker on CD4+ T-cells, which was proposed as nTreg 
marker3. CD25 is constitutively expressed on nTreg and most work on nTreg relies on 
their purification via the CD4+CD25+ phenotype. However, CD25 is also transiently up-
regulated on human effector T-cells upon activation34. Thus, the CD4+CD25+ population 
does not represent a pure Treg population but also contains activated T-cells, which can 
‘contaminate’ Treg assays. In peripheral blood CD4+ T-cells, the CD25+ subset represents 
no distinct population but contains cells expressing the CD25 molecule at different 
expression levels from low to high. Among these cells the CD25high subset represents the 
most reliable Treg population. However, no common directive exists as to which 
expression level constitutes ‘CD25high’ cells. Consequently, most researchers use 1-2% of 
CD4+ T-cells, which express the highest CD25 levels.  
As stated above, the transcription factor Foxp3 plays an integral role in the development 
and function of nTreg4-6, 35. Therefore, intracellular Foxp3 expression is now routinely 
assessed as a marker to define nTreg. However, similar to CD25, Foxp3 is not only 
constitutively expressed in nTreg but also transiently up-regulated in human effector CD4+ 
T-cells upon activation36, 37. Foxp3, especially in combination with CD4 and CD25 is now 
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commonly used to monitor Treg numbers, e.g. in comparison between healthy individuals 
and patients suffering from autoimmune diseases. However, due to its cellular localization, 
Foxp3 expression can only be detected after permeabilization and thus cannot be used to 
sort viable nTreg for further functional analyses. In this respect, a useful tool in the basic 
research of Treg function has been the Foxp3/GFP mouse, which expresses the fluorescent 
marker GFP under the control of the Foxp3 promoter allowing the purification of nTreg 
via flow cytometry-based sorting35. 
Two further surface markers for the assessment of nTreg are the cytotoxic lymphocyte 
antigen-4 (CTLA-4/CD152) and the glucocorticoid-induced TNF-receptor related protein 
(GITR). CTLA-4 is a structural homologue of the costimulatory receptor CD2838 and 
binds to the two major costimulatory molecules CD80 and CD86 on antigen-presenting 
cells39-41 and is implied to play a crucial role in Treg function (see below). GITR belongs 
to the TNF receptor superfamily and has been implied as costimulatory receptor on T-
cells42. Several reports suggest that GITR may act as a negative regulator of Treg function 
as ligation of GITR on nTreg has been shown to abrogate their suppressive function in the 
murine system43-46, while experiments performed with human nTreg could not confirm 
these findings47. Both, CTLA-448, 49 and GITR45 are constitutively expressed on nTreg but 
are also up-regulated on CD4+ effector T-cells following activation, which compromises 
their suitability as Treg markers.   
In contrast to the molecules described above, which show constitutive expression on Treg, 
expression of the IL-7 receptor α chain (CD127) was found to inversely correlate with the 
nTreg status50. However, this phenotype is not unique for nTreg, as activation of effector 
T-cells also results in down-regulation of CD127. Yet, the marker combination 
CD4+CD25+Foxp3+CD127- is ccurrently considered to define the most pure and reliable 
nTreg population. 
While Treg generally show a surface phenotype resembling activated effector T-cells, 
expression of L-selectin (CD62L) has been described as another marker expressed on 
Treg. CD62L generally mediates the homing of T-lymphocytes to secondary lymphoid 
tissues and expression of CD62L is a hallmark of naïve effector T-cells. On CD4+CD25+ 
nTreg, the CD62L+ phenotype can be used to identify a subpopulation, which has been 
found to show supreme regulatory capacity in vitro51 as well as in murine models of type-
1 diabetes52 and GVHD53, when compared to the CD62L- subset. Thus, CD62L is a 
suitable additional marker in the analysis or purification of murine nTreg. While CD62L is 
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now routinely assessed on human nTreg as well, no clear-cut correlation to a specific Treg 
(sub-)set has so far been established. 
In recent studies it was observed that surface expression of the ectonucleoside triphosphate 
diphosphohydrolase-1 (CD39) and ecto-5’-nucleotidase (CD73) are strongly enhanced on 
nTreg54, 55. Importantly, expression of CD39 was observed to highly correlate with 
expression of Foxp3 in CD4+ nTreg showing an even higher correlation than CD25 and 
Foxp355. However, recent research has indicated that CD39 expression does not identify 
nTreg per se but CD39 expression generally defines a memory subset within the CD4+ T-
cell compartment56. Thus, sorting for CD39 expression on CD4+ T-cells is not sufficient to 
purify nTreg but requires additional markers. 
Similar to CD39, the homing-associated cell adhesion molecule CD44 (H-CAM) has 
recently been described as a marker for a special subset among murine CD4+CD25+ 
nTreg. CD44 expression was found to strongly correlate with Foxp3, but among 
CD4+CD25+ T-cells CD44 levels were found to be varying between low, intermediate and 
high expression57. In functional studies the CD4+CD25+CD44high subset showed the 
strongest regulatory capacity, which was mainly mediated by the secretion of IL-10 in 
vitro 57. However, so far no data have been obtained concerning the origin of this nTreg 
subset and whether these observations can also be verified in human nTreg. 
Another marker that identifies a special nTreg subset is the latency-associated peptide 
(LAP)58. LAP constitutes the amino-terminal domain of the transforming growth factor-
beta (TGF-β) precursor peptide58. After cleavage LAP remains non-covalently associated 
with the TGF-β peptide forming the latent TGF-β complex. In studies on murine T-cells in 
vitro and in a murine experimental autoimmune encephalomyelitis (EAE) model it was 
established that CD4+LAP+ T-cells, independently of CD25 expression, display regulatory 
capacity, which critically depends on the secretion of TGF-β. The additional inclusion of 
CD25 as a further sorting criterion allowed the isolation of nTreg with strongly enhanced 
suppressive potential compared to CD4+CD25+ T-cells58. This was not due to differential 
Foxp3 levels, which were found to be similar in LAP+ or LAP- CD4+CD25+ Treg. While 
these initial studies were performed using murine nTreg, LAP has now also been 
established as an nTreg marker on human T-cells59.  
The αE integrin subunit (CD103) was identified as a putative nTreg marker by 
comparative gene expression analyses between CD4+CD25- and CD4+CD25+ T-cells44. In 
subsequent studies, CD103 was found to be expressed on about 30% of murine 
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CD4+CD25+ nTreg and seems to be involved in the accumulation and retention of Tregs at 
certain sites within the body60. CD103+ nTregs have been implied to be beneficial for the 
amelioration of graft-versus-host disease61 but also to be highly expressed on tumor-
infiltrating nTreg62.  
Two surface molecules, LAG-3 and GARP have been described to selectively identify 
activated nTreg. Lymphocyte activation antigen-3 (LAG-3/CD223) is a transmembrane 
CD4-related protein that contacts MHC class II molecules on antigen-presenting cells63. 
LAG-3 is expressed on activated effector and regulatory T-cells with activated Tregs 
showing a higher and more persistent expression64. Glycoprotein A repetitions 
predominant (GARP, LRRC32) is a transmembrane protein that is rapidly up-regulated on 
nTreg after TCR-mediated stimulation65, 66. GARP provides a highly selective marker, as 
it strongly correlates with Foxp3 and CD25 expression in nTreg. This specificity of 
expression is restricted to bona fide nTreg underlined by the fact that effector T-cells but 
also TGF-β induced Foxp3+ T-cells and Foxp3-transgenic engineered Treg do not express 
GARP after activation66. Interestingly, retroviral transduction of GARP was sufficient to 
induce Foxp3 expression and regulatory capacity in CD4+CD25- T-cells67. 
Several molecules of the galectin family have been described as Treg specific markers, 
among them galectin-168 and galectin-10. The Charcot-Leyden crystal protein galectin-10 
was identified as nTreg marker by differential proteomics comparing CD4+CD25- and 
CD4+CD25+ T-cells69. Galectin-10 is specifically expressed by nTreg and, in contrast to 
other markers described above, is not up-regulated by activated effector T-cells. 
Interestingly, galectin-10 is differentially expressed in two further nTreg subsets, which 
can be distinguished by their expression of either α4β1 or α4β7 integrin69. However, 
expression of galectin-10 is restricted to intracellular compartments, which renders 
galectin-10 unsuitable to enrich viable nTreg populations.  
Several DNA microarray studies have identified the transcription factor Helios as nTreg 
marker70, 71. Indeed, recent work could convincingly show, that Helios is strongly 
expressed in both murine72 and human73 CD4+CD25+ nTreg but not in activated human 
Teff or TGF-β induced Foxp3+ T-cells. Furthermore, Helios was shown to bind to the 
Foxp3 promoter and may thus be involved in the maintenance of Foxp3 expression73. 
However, similar to Foxp3, the absence of surface expression limits its use as an nTreg 
sorting marker. 
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In a recent study, the TNF receptor superfamily member 25 (TNFRSF25, DR3) has been 
identified as a putative marker on murine Treg74. In comparison to CD4+ effector T-cells, 
which showed only basal expression levels, murine nTreg strongly expressed DR3, and 
the relation of DR3 expression between nTreg and effector T-cells was clearly superior to 
GITR74. However, whether DR3 represents a suitable marker for human Treg remains to 
be determined. A list of all described nTreg markers is given in Table I. 
 
Table I. List of nTreg markers  
Molecule expression mouse human comment reference 
CD25 high; surface x x also expressed on activated 
Teff 
3,34 
Foxp3  high; 
intracellular 
x x also expressed on activated 
Teff 
4-6,35 
CTLA-4 high; surface x x also expressed on activated 
Teff 
48,49 
GITR high; surface x x also expressed on activated 
Teff 
45 
CD127 low; surface x x  50 
CD62L high; surface x n.e. expressed on naïve Teff, 
denotes Treg subset with 
superior suppressive capacity 
51-53 
CD39 high; surface x x  54,55 
CD44 high; surface x n.d. denotes IL-10 producing 
subset 
57 
LAP high; surface x x denotes Treg subset with 
superior suppressive capacity 
58,59 
CD103 high; surface x n.d. expressed on 30% of 
CD4+CD25+ 
44, 60-62 
LAG-3 high; surface x n.d. expressed on activated Treg 64 
GARP high; surface n.d. x expressed on activated Treg 65-67 
Galectin-1 high; surface x x  68 
Galectin-10 high; 
intracellular 
n.d. x  69 
Helios high; 
intracellular 
x x expressed exclusively in 
nTreg, not in iTreg or Foxp3 
tg Treg 
70-73 
TNFRSF25 high; surface x n.d.  74 
 
Teff, effector T-cells; n.e., not established; Treg, regulatory T-cells; n.d., not determined 
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Effector Mechanisms 
- surface molecules  
One key finding in the early functional definition of nTreg effector mechanisms was that 
in vitro nTreg were not able to suppress effector T-cell function after separation through a 
semi-permeable membrane. Similarly, transfer of supernatants from nTreg cultures to 
effector T-cell cultures did not prevent effector T-cell proliferation. Consequently, it was 
assumed that suppression by nTreg is a ‘contact-dependent’ process and that specific cell-
surface molecules must be responsible for the suppressive effects of nTreg. 
 One of the most attractive targets of interest was the inhibitory B7-superfamily molecule 
CTLA-4. CTLA-4 contacts the costimulatory molecules CD80 and CD8639-41 and due to 
its superior affinity out-competes the activating receptor CD28 for binding to these two 
ligands thereby abrogating the activating signal39-41. The constitutive expression of CTLA-
4 on nTreg does not only keep them in their hyporesponsive state but also crucially 
contributes to their suppressive function. CTLA-4 knockout mice develop fatal multiorgan 
inflammatory diseases75, 76. Along those lines, blocking of CTLA-4 using specific 
monoclonal antibodies can elicit autoimmune disorders77, 78 and enhance anti-tumour 
immunity79 in murine models. Similarly, conditional knockout of CTLA-4 in murine 
nTreg severely impairs their suppressive capacity resulting in autoimmune pathology with 
splenomegaly, lymphadenopathy, autoimmune gastritis and more than 1000-fold increased 
IgE levels80. The suppressive mechanism of CTLA-4 seems to be two-fold: first, CTLA-4 
on nTreg ligates CD80 and CD86 on activated T-cells and thereby transmits inhibitory 
signals directly into effector T-cells81. A second mechanism is the indirect suppression of 
T-cell responses via modulation of APC function. Such CTLA-4 mediated mechanisms 
include the inhibition of DC maturation82, 83, the down-modulation of CD80/CD86 on 
DC80, 84and the induction of the immune-regulatory enzyme indoleamine desoxygenase 
(IDO) in DC85.  
Although deletion of no other surface molecule than CTLA-4 nTreg results in spontaneous 
development of autoimmune disorders, several other molecules are reported to contribute 
to the suppressive function of nTreg. The CD4-related protein LAG-3 has been implied to 
contribute to nTreg suppressive function via direct Treg-Teff interactions and via the 
modulation of APC function. In this respect, engagement of LAG-3 to MHC class II on 
dendritic cells has been reported to result in the down-regulation of costimulatory 
molecules86.  In a murine model, knockout of LAG-3 severely impaired nTreg suppressive 
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capacity, while retroviral transduction of LAG-3 into CD4+ T-cells was sufficient to 
induce a hyporesponsive and regulatory function64. LAG-3 expression is controlled by the 
early growth response gene-2 (Egr-2) and over-expression of Egr-2 in murine CD4+ T-
cells generates CD4+CD25-LAG-3+ regulatory T-cells, which secrete high amounts of IL-
1087. Studying tumor-infiltrating nTreg in patients suffering from melanoma or colorectal 
cancer, Camisaschi et al. showed that LAG-3+ nTreg form a distinct subset that produces 
significantly increased amounts of IL-10 and TGF-β. However, the in vitro suppressive 
capacity of LAG-3+ nTreg was contact-dependent and not mediated by these two 
cytokines88. 
The Ig-like type I transmembrane protein CD83 is another molecule that is involved in the 
regulatory function mediated by nTreg. Several studies have indicated that a soluble form 
of CD83 (sCD83) is released by B-cells and dendritic cells89 and acts as a potent 
immunosuppressive molecule90-93. More recent evidence indicates that CD83 is also 
expressed on the surface of nTreg and directly contributes to contact-dependent 
suppression94. Interestingly, retroviral transduction of CD83 into CD4+ T-cells did not 
only endow them with regulatory function but also led to the up-regulation of CTLA-4 and 
Foxp394. Consequently, CD83 may also act as an autocrine factor, which regulates the 
nTreg phenotype. However, so far no receptor has been identified for CD83 and thus the 
regulatory interaction between CD83 on Treg and a putative receptor on Teff or Treg 
remains to be investigated. 
 
- cytokines (IL-10, TGF-β, IL-35) 
While most in vitro assays identified the regulatory capacity of nTreg to be contact-
dependent, several soluble factors have been implied in Treg function and are classically 
associated with nTreg mediated suppression. 
One of the most common cytokines mentioned in the context of nTreg is IL-10. IL-10 is a 
potent immunoregulatory cytokine, which is attributed with anti-inflammatory functions. 
Along those lines, IL-10 down-modulates the production of Th1 polarizing cytokines such 
as TNF-α, IL-1, IL-12 and IFN-γ by antigen-presenting cells95. IL-10 has also been 
described to decrease the expression of MHC class II and costimulatory molecules on 
dendritic cells thereby keeping them in a tolerogenic state96-98. Apart from APC function, 
IL-10 also regulates the activation and function of mast cells99 as well as cytokine 
production by eosinophils100 and has been shown to directly suppress T-cell 
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proliferation101. The immunomodulatory relevance of IL-10 is highlighted by the fact that 
IL-10 knockout mice spontaneously develop inflammatory bowel disease-like 
pathology102. 
Various immune cells including monocytes, dendritic cells, B-cells and activated T-cells 
produce IL-10, but the role of IL-10 in Treg is not fully established as of today. Indeed, 
several seminal papers, which were the first to functionally assess human nTreg function, 
could not find any significant secretion of IL-10 upon stimulation9, 17. Along those lines, 
the regulatory capacity of nTreg was shown to be independent of IL-10103, 104. However, 
several other studies have proposed important roles for IL-10 for the modulatory function 
of nTreg both in vitro22 and in vivo. Taken together, these data suggest that IL-10 plays a 
role in specialized nTreg subsets or in a distinct tissue-specific milieu but is not essential 
for nTreg-mediated suppression. 
A second soluble factor that is commonly associated with nTreg function is TGF-β. So far, 
three members of the TGF-β family (TGF-β1, TGF-β2, TGF-β3) have been identified 
which have pleiotropic physiological effects on a broad range of different cell types. TGF-
β is synthesized as a precursor harboring a pre- and a pro-peptide. Upon processing in the 
Golgi, the N-terminus of pro-TGF-β is removed, forming a novel homodimeric protein 
called the latency-associated protein (LAP). Via non-covalent association, a homodimer of 
the mature TGF-β binds to LAP, and can be either secreted or further associates with the 
latent-TGF-β-binding protein (LTBP). These associations keep TGF-β in an inactive state 
and in order to bind its receptors, TGF-β has to be dissociated from LAP and/or LTBP via 
proteolysis or conformational change (reviewed in Li and Flavell105). 
In the immune system, TGF-β1 is the predominantly expressed isoform and displays 
mainly regulatory functions. TGF-β knockout mice develop an early fatal 
autoinflammatory disorder, similar to Foxp3-knockout scurfy mice, which is marked by T-
cell hyperactivation and excessive multiorgan inflammation106. In studies using TGF-β II-
receptor knockout mice it was similarly established that nTreg derived TGF-beta is critical 
for the regulation of auto-reactive effector T-cells107-109 (and reviewed in Li and 
Flavell105). This TGF-β dependency of Treg function could also be shown in murine 
models of colitis110, anti-tumor immunity111 and type I diabetes112 using mice expressing a 
dominant negative form of the TGF-β II-receptor. However, the situation is not as clear-
cut for human CD4+CD25+ nTreg. Several reports suggest that human nTreg do not 
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secrete TGF-β and that TGF-β blocking antibodies cannot abrogate regulation21, 22, 103, 104, 
113 while other groups have gathered exactly contrary data114. The debate is further 
complicated by the fact that studies with murine Treg suggest that TGF-β may attach to 
the cell membrane and may thus contribute to the contact-dependent regulatory 
mechanisms115. In this context, GARP has been described as a receptor for latent human 
TGF-β on activated nTreg116.  
While the role of TGF-β as Treg effector cytokine is still disputed, it has become evident, 
that TGF-β also plays a role in the induction of Foxp3 expression and regulatory capacity 
in peripheral T-cells, which are consequently termed induced Treg (iTreg). This effect can 
be augmented by co-factors such as IL-2 and retinoic acid (RA)(see below). While such 
induced Treg remain stable and functional in several mouse models, the stability and 
function of human iTreg has been cast into doubt. Indeed, activation of human 
CD4+CD25- T-cells in the presence of TGF-β does not create functional iTreg and the 
additional administration of RA seems to be a prerequisite for the induction of a somewhat 
stable and functional iTreg population.  
In two recent works a novel cytokine, termed IL-35, was identified as additional factor 
important for nTreg function117, 118. IL-35 contains the p35 subunit of IL-12 and the 
Epstein-Barr-Virus induced gene-3 (Ebi3 which also constitutes the IL-27 beta subunit). 
IL-35 was found to be constitutively released from murine nTreg but not from effector T-
cells. Knockout of either IL12p35 or Ebi-3 severely impaired the regulatory capacity of 
nTreg in vitro and in vivo while over-expression conferred regulatory activity to naïve 
CD4+ T-cells117. Interestingly, human nTreg were not found to express Ebi3119 disputing 
the relevance of IL-35 in human Treg. In contrast to these observations a recent report 
shows that rhinovirus-treated DC induce IL-35 production in CD4+ T-cells120 thus 
indicating that human Treg may produce IL-35 under distinct conditions. Interestingly, in 
the murine system, IL-35 does not only act as a regulatory cytokine on Teff, but was also 
found to expand CD4+CD25+ Treg and to induce CD4+Foxp3- Treg with IL-35 dependent 
regulatory function121. Thus, IL-35 does not only act as an effector cytokine from Treg but 
also regulates Treg homeostasis.   
 
- killing  
Based on the observation that nTreg express granzyme A and B and perforin122, 123, it was 
proposed that killing of target cells might be a possible regulatory mechanism exerted by 
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Treg. Indeed, several studies have convincingly demonstrated that both murine124, 125 and 
human122 nTreg at least partially regulate effector T-cell responses by inducing apoptosis. 
However, the exact contribution of each apoptosis-inducing molecule is still under 
dispute. While in some mouse models regulation is mainly mediated by granzyme B124, 125, 
human Treg seem to utilize the complete granzyme/perforin machinery but not FasL 
(CD95L) in the killing of CD4+ effector T-cells122. In contrast, more recent reports 
indicate that nTreg have the capacity to kill CD8+ T-cells via FasL-Fas interactions126. The 
induction of apoptosis is not restricted to effector T-cells but also involves antigen-
presenting cells. In this respect, human Treg were found to induce apoptosis in B-cells, 
monocytes and dendritic cells, thereby mediating indirect regulation of T-cell responses122.  
 
- cytokine depletion 
One of the key features of nTreg is their hyporesponsiveness, which is reflected by their 
low degree of proliferation in response to stimulation but also by their lack of cytokine 
secretion. Interestingly, nTreg confer this hyporesponsiveness onto effector T-cells as 
shown in experiments in which effector T-cells both produce and secrete lower amounts of 
IL-2 when co-cultured with nTreg23. Apart from this direct effect, nTreg have also been 
shown to act as ‘cytokine sinks’ by depleting IL-2 through binding to their constitutively 
highly expressed IL-2 receptor and subsequent internalization. Consequently, effector T-
cells, which are deprived of IL-2 by this mechanism undergo apoptosis after 72 hours of 
co-culture127. Along those lines, we have shown that neutralization of IL-2 from T-cell 
cultures by IL-2 receptor decorated virus-like particles (VLP), which we use as a 
convenient platform to display immune receptors of choice, blocks T-cell proliferation. 
However, in contrast to Pandiyan et al., such treated T-cells did not undergo apoptosis but 
were anergic upon re-stimulation128. 
 
- nucleotides and metabolites 
The finding that nTreg express high levels of CD39 and CD7354, 55, two ectonucleotidases 
that are involved in the generation of extracellular adenosine, has led to the assumption 
that Treg released adenosine might play a role in the suppressive function of Treg. 
Adenosine is known to exert immunosuppressive activity on T-cells via ligation of 
adenosine receptors, including A2AR129, which leads to an increase in intracellular cAMP. 
Indeed, nTreg express constitutively high levels of A2AR and effector T-cells rapidly up-
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regulate A2AR upon activation. Generation of adenosine by Treg is crucial for their 
suppressive function and knockout of CD39 in murine Treg partially abrogates their 
regulatory function both in vitro and in vivo55, an effect that can also be reached by using 
A2AR antagonists130.  
In a separate study, Bopp et al. assessed the role of cAMP for nTreg function. They could 
show that nTreg contain highly increased levels of cAMP and that cAMP levels also 
increased in effector T-cells following co-culture with nTreg. Further results demonstrate 
that effector T-cells and nTreg communicate via the formation of gap-junctions, which 
allows the transfer of cAMP from Treg to effector T-cells131. Along those lines, blockade 
of gap-junction formation could abrogate the regulatory capacity of nTreg thus 
highlighting the importance of this mechanism in the suppressive repertoire of nTreg131.  
 
- induction of IDO in APC 
The regulatory function of Treg is not restricted to the suppression of effector T-cell 
responses but they also modulate APC function. As described above, several molecular 
mechanisms contribute to this function, leading to the down-regulation of stimulatory 
molecules such as MHC and CD80 and thus keeping the APC in a non-stimulatory or even 
tolerogenic state. In this respect, induction of the enzyme indoleamine-2,3-dioxygenase 
(IDO) in dendritic cells upon co-culture with Treg seems to form an important bilateral 
feedback loop involved in the establishment of immune tolerance132-135. IDO is a key 
enzyme in the tryptophan metabolism, converting tryptophan to formylkynurenine136, 
which acts as a strong immunosuppressive agent137-139. Apart from its inhibitory effect on 
effector T-cells, this metabolite has also been shown to induce regulatory T-cells140, 141. 
While this potent IDO-Treg axis is important for the prolongation of allograft survival, it 
may also pose a major impediment to anti-tumor immunity and thus remains of interest in 
several fields of clinical immunology82, 140, 141. 
 
- Modulation of microenvironment 
Several biochemical factors in the microenvironment of effector T-cells strongly regulate 
their capacity to fully mount proliferative and functional responses. One limiting factor of 
crucial importance is the availability of cysteine. T-cells cannot take up cystine, the major 
extracellular form and consequently critically rely on the secretion of cysteine by co-
localized dendritic cells142, 143. In this respect, Treg have been described to suppress this 
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function in DC, thereby indirectly depleting Teff of cysteine144, 145. Interestingly, this 
seems to be a general pathway of immunosuppression as similar mechanisms have also 
been proposed as mode of action of myeloid derived suppressor cells146.  
In another study it was shown that NADPH oxidase derived reactive oxygen species 
(ROS) produced by nTreg were involved in the suppression of CD4+ Teff. Along those 
lines, murine nTreg have been observed to alter the intracellular distribution of glutathione 
in Teff upon co-culture thus efficiently inhibiting Teff activation and proliferation147. 
Taken together, interference of Treg with both dendritic cell and Teff redox environment 
seem to emerge as a novel mechanism how Treg create an immunosuppressive milieu. 
 
- Out-competition of APC stimulation 
In vivo observations on the reconstitution of immune homeostasis in lymphopenic mice 
have suggested that T-cells are constantly competing for immunological niches and that 
limitations of such niches may contribute to immune regulation. In this respect, nTreg 
seem to be especially suited to ‘take up space’ as their higher avidity for MHC:peptide 
complexes on APC may allow them to preferentially access T-cell stimulatory niches148.    
Along those lines recent results from in vitro experiments suggest that Treg preferentially 
aggregate with dendritic cells in an LFA-1 dependent manner84. Consequently, effector T-
cells are out-competed for interaction with stimulatory molecules and thus kept in an 
inactive state both in vitro84 and in vivo149, 150. While the hypothesis of out-competition 
seems intriguing in the light of these studies, it cannot explain how Treg regulate effector 
T-cells in response to cell-free stimuli such as anti-CD3 antibodies. A scheme of the 
described regulatory mechanisms can be seen in Fig.1. 
 
Klaus Schmetterer                                                                                                    Chapter 1 
 
      
 38  
 
 
Fig.1 Scheme of suppressive mechanisms of naturally-occuring Treg; left: direct suppression and induction 
of apoptosis, right: indirect modulation via antigen-presenting cells; A, adenosine; ATP, adenosine 
triphosphate; A2A-R; adenosine receptor 2A; APC, antigen-presenting cell; cAMP, cyclic adenosine 
monophosphate; CTLA-4, cytotoxic T-lymphocyte antigen-4; IDO, indoleamine-2,3-dioxygenase; IL-2R, 
interleukin-2 receptor; IL-10R, interleukin-10 receptor; LAG-3, lymphocyte-activation antigen-3; TCR, T-
cell receptor; Teff, effector T-cell; TGF-β, transforming growth factor beta; TGF-βRII, transforming growth 
factor beta receptor II; Treg, regulatory T-cell 
 
 
Relevance and evidence for therapeutic benefit 
- Autoimmunity 
Apart from negative selection in the thymus, which deletes most auto-reactive T-cell 
clones, peripheral mechanisms, among them regulatory T-cells, are additionally needed to 
maintain the immunological integrity of the organism. Most notably, breakdown of nTreg 
mediated immune-regulation, as found in scurfy mice27 and human IPEX patients28-30, 
leads to the development of fatal autoimmune disorders, which affect multiple organs. 
Similarly, experimental depletion of nTreg in murine models was shown to induce the 
spontaneous onset of autoimmune diseases. Defects in Treg numbers or function were also 
noted in patients suffering from established autoimmune diseases such as SLE151-153, type I 
diabetes154 and multiple sclerosis155, 156. In contrast, early post-natal inoculation of mice 
with indigenous intestinal Clostridium bacteria led to an increased number of colonic 
Foxp3+ Treg, which was sufficient to suppress inflammatory bowel disease (IBD). Thus, 
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physiological Treg homeostasis is also governed by exogenous signals such as 
microbiota157. In this light, it can be argued that autoimmunity is a consequence of 
insufficient immune tolerance and that consequently re-establishment of tolerance 
mechanisms can prevent or even cure such diseases. Indeed, some of the the first 
functional observations about the regulatory capacity of CD4+CD25+ nTreg were observed 
upon adoptive transfer of Treg in a murine model of autoimmune gastritis3. Since then, 
nTreg have been assessed for their preventive or curative capacity in a plethora of mouse 
models of different autoimmune diseases, both spontaneous and induced. Reconstitution 
of nTreg in murine models of Type I diabetes124, 158-160, multiple sclerosis (EAE)161, 162, 
rheumatoid arthritis163, 164 and systemic lupus erythematodes (SLE)165 could efficiently 
prevent disease before onset, however, only in a few studies established disease could 
actually be reverted by adoptive transfer of nTreg159, 166, 167. In this respect, antigen-
specificity of the transferred regulatory T-cell population seems to be of crucial 
importance, as remission in most models could only be reached by nTreg specific for the 
pathognomonic antigen (reviewed in Roncarolo and Battaglia168). Interestingly, in one 
study using a collagen-induced arthritis model, TCR tg Treg recognizing a non-collagen 
auto-antigen induced remission of the collagen-induced disease163. Similarly, nTreg 
expanded with dendritic cells pulsed with a single auto-antigen were sufficient to suppress 
autoimmune diabetes in the non-obese diabetic (NOD) mouse model160. These data 
suggest that once appropriately targeted and activated, mono-specific Treg are sufficient to 
create an immunomodulatory milieu, which abrogates multi-factorial immune responses at 
the site of Treg activation.  
 
- Allergy 
Similar to autoimmune and autoinflammatory disorders, IgE-associated allergies represent 
disorders of the immune system where crucial mechanisms of immunotolerance are 
apparently non-functional leading to an aberrant and harmful immune response. Several 
lines of evidence suggest that allergic disorders might be partially attributed to a 
dysregulation of regulatory T-cells and that induction and/or propagation of Treg might 
thus be of therapeutic relevance in allergic patients.  
In murine studies, mouse CD4+CD25+ T-cells were reported to suppress pathognomonic 
immune parameters such as differentiation and cytokine production of Th2 cells169 and 
production of IgE170. In several inhaled allergen challenge models, it could be shown that 
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transfer of CD4+CD25+ T-cells could suppress airway inflammation171, 172. Similarly, 
repeated exposure to allergen at low doses prior to Th2 sensitization induced tolerance173, 
which was attributed to the induction of Foxp3+ regulatory T-cells174. While this 
modulatory capacity of nTreg on Th2 responses and airway inflammation is thus well 
defined, a beneficial effect on airway hyperresponsiveness could not be observed in all 
studies171, 172, 174, 175. Indeed, the best effects on clinical symptoms could be observed when 
IL-10 producing regulatory T-cells (mainly Tr1 cells; see below) were used176-179. 
Similar to their murine counterparts, human CD4+CD25+ Treg are implicated to play a 
beneficial role in the suppression of allergic immune responses. In vitro, CD4+CD25+ Treg 
can efficiently suppress proliferation and cytokine production of Th2 cells180, 181. A 
hallmark study on 12 atopic and 11 patients with seasonal allergic rhinitis to grass pollen 
demonstrated that nTreg from atopic individuals and allergic patients after allergen-
exposure were impaired in their regulatory capacity compared to non-atopic individuals182. 
Along those lines, Treg were found to be absent in the skin of atopic dermatitis patients183 
while outgrowth of cow’s milk allergy in initially allergic children is associated with 
higher numbers of CD4+CD25+ Treg184.  
Another compelling line of evidence for the importance of Treg in allergy comes from 
studies on allergic patients undergoing specific immunotherapy (SIT). SIT involves the 
repetitive, dose-increasing administration of purified allergens to affected individuals 
thereby leading to tolerance induction and clinical de-sensitization of the patient. 
Numerous groups have observed the induction/expansion of regulatory T-cells after SIT to 
a broad range of allergens and using different ways of application185-191. Thus induced 
Treg seem to mediate, apart from direct suppression of Th2 cells, the suppression of 
allergen-specific IgE production and the concomitant switch to protective IgG4, the down-
modulation of mast cell, eosinophil and basophil function and the amelioration of airway 
remodeling (reviewed in Akkoc et al.192). However, whether all these effects are mediated 
by CD4+Foxp3+ naturally-occurring Treg is still a matter of debate. Indeed, the 
immunomodulatory cytokine IL-10 seems to play a crucial role in the efficacy of SIT185, 
186, 193. Along those lines, some authors have described the induction CD4+Foxp3+IL-10+ 
T-cells187, 194. However, given the still disputed relation between nTreg and IL-10 
production, Tr1 cells (see below), which are marked by their high level production of IL-
10, might be (at least complementarily) required for efficient immunomodulation of 
allergic responses.  
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- Transplantation 
Although modern day regimen of immunosuppressive medication have significantly 
prolonged the survival of allografts and decreased the incidence of rejection episodes, the 
requirement for lifelong medication also bears major disadvantages such as increased 
susceptibility to infections and increased occurrence of tumors. In this respect, induction 
of long-lasting tolerance against allografts might offer an attractive therapeutic strategy. 
Initial observations that regulatory T-cells were enriched in tolerated rat kidney grafts195 
and murine skin grafts196 have provided first evidence that regulatory T-cells may be 
major players in transplantation tolerance. Since then a multitude of studies in rodent and 
primate model systems have addressed this issue and suggested that Treg based therapies 
could indeed be beneficial for allograft survival. In mouse models of bone marrow 
transplantation (BMT), concomitant transfer of freshly purified CD4+CD25+ T-cells 
together with the bone-marrow allograft was found to facilitate engraftment and 
ameliorate graft-versus-host disease (GVHD)197-199. Similarly, nTreg, which were 
polyclonally expanded ex vivo prior to transfer, also showed curative potential in GVHD 
models200-202. Interestingly, Treg populations enriched for alloantigen-specific T-cells 
showed only slightly improved efficacy over polyclonal Treg populations in this setting203. 
This observation may be due to the fact that polyclonal Treg populations contain a 
sufficiently large proportion of alloreactive Treg to prevent GVHD. Other theories argue 
that the lymphopenic environment after conditioning for BMT might favor the expansion 
of Treg resulting in a more beneficial Treg to Teff ratio (reviewed in Roncarolo and 
Battaglia168). 
In contrast to BMT, antigen-specificity of transferred Treg populations seem to be a 
prerequisite for the induction of long-lasting tolerance following solid organ 
transplantation. In several rodent models of pancreatic islet204-206, liver207, heart208, 209 and 
skin210 transplantation, transfer of alloantigen-specific CD4+CD25+ Treg proved to be 
superior to transfer of polyclonal nTreg populations. In this respect, positive effects could 
be shown for both Treg with direct allo-specificity and indirect allo-specificity, i.e. 
peptides of donor allo-antigens presented by recipient HLA-molecules. Of note, BALB/c 
mice, which had been tolerized to B10.BR skin grafts using non-depleting anti-CD4 and 
anti-CD8 monoclonal antibodies, were shown to subsequently tolerate skin grafts of 
B10.D2 mice, which share the same minor histocompatibility genes with B10.BR mice211. 
Similarly, a TCR-transgenic CD4+CD25+ Treg line with specificity for one indirect allo-
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antigen was sufficient to induce long-lasting tolerance to MHC-mismatched heart 
allografts212. Thus, similar to autoimmune models described above, appropriately located 
and activated Treg of a singular specificity might be sufficient to create an 
immunomodulatory milieu, which prevents graft rejection.  
Evidence for the importance of nTreg in transplantation tolerance also stems from clinical 
observations on transplanted patients. In clinically stable kidney transplanted patients, 
several independent studies have described an increased number of functionally active, 
alloreactive regulatory T-cells compared to patients suffering from acute or chronic 
rejection episodes213, 214. In another study on liver transplant recipients, the spontaneous 
development of tolerance to the graft was strongly associated with increased numbers of 
graft-infiltrating Treg215. Similarly, the outcome of lung transplantation was found to 
correlate with the frequency of CD4+CD25+ T-cells in the blood of lung transplant 
recipients216. 
These promising experimental results have spurred considerable hope that Treg-based 
therapies could become a standard regimen for the management of the post-transplant 
period and several clinical trials are currently underway. A first published study using ex 
vivo expanded Treg for the treatment of GVHD following BMT has been published 
recently. In this trial, alleviation of symptoms allowing reduction of immunosuppressive 
medication could be achieved in the two treated patients217. 
 
  
T-regulatory Type 1 cells (Tr1) 
In 1997, a novel subset of regulatory T-cells was discovered, which was marked by the 
high expression of IL-10 and found to prevent colitis after transfer of CD4+CD45RBhigh T-
cells into SCID mice218. This subset, termed T regulatory type 1 cells (Tr1), was also 
found in humans and defined by its unique cytokine profile, which includes secretion of 
high levels of IL-10 and TGF-β, intermediate levels of IL-5 and IFN-γ but no/low 
secretion of IL-2 and IL-4219. In contrast to nTreg, Tr1 cells do not form a unique lineage 
but are induced in the periphery in the presence of tolerogenic APC and high amounts of 
IL-10219. Similar to nTreg, Tr1 cells are hyporesponsive to stimulation and their regulatory 
function is dependent on appropriate TCR-mediated activation219-221. However, once 
appropriately activated, Tr1 cells mediate bystander suppression irrespective of the 
antigen-specificity of the co-localized effector T-cells. The main regulatory mechanism of 
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Tr1 cells is their release of the immunosuppressive cytokines IL-10 and TGF-β as shown 
by studies using neutralizing antibodies222-224. However, additional mechanisms such as 
the release of granzyme A and B may also contribute to suppression by Tr1 cells225. So 
far, no specific cell surface markers have been defined, which would allow for the 
selective assessment and enrichment of Tr1 cells. Unlike nTreg, Tr1 cells do not express 
the transcription factor Foxp3, and no Tr1-specific transcription factor has been defined 
until today (reviewed in Allan et al.226).  
Under physiological conditions Tr1 cells are the main source of IL-10 and thus play an 
important complementary role to nTreg in the establishment and maintenance of 
immunological tolerance. Indeed, as described above knockout of IL-10 results in the 
spontaneous development of IBD in mice102. In humans, Tr1 cells specific for self MHC 
molecules227 and pancreatic-island derived peptides228 were found in healthy individuals, 
while patients suffering from rheumatoid arthritis have significantly lower numbers of 
synovial Tr1 cells229. In transplantation settings, the induction of Tr1 cells correlates with 
a lower frequency of GVHD in SCID patients undergoing allogeneic SCT230. Similarly, 
Tr1 cells may play a role in the spontaneous development of tolerance to kidney or liver 
allografts231. In allergic patients, the activity of both nTreg and Tr1 cells is compromised. 
Following specific immunotherapy (SIT) the number of regulatory T-cells is increased and 
the concomitant increase of IL-10 and TGF-β correlates with the amelioration of clinical 
symptoms. In a seminal study by Akdis and co-workers it was demonstrated that de-
sensitization of beekeepers to bee venom following multiple bee-stings correlated with an 
increase in IL-10185. In more recent works, Tr1 cells were found to be induced following 
SIT to house dust mite188, cat232, 233, birch pollen186, 188, 234, grass pollen235 and food 
allergens188 (reviewed in Jutel and Akdis236). In summary, Tr1 cells seem to play a crucial 
role in modulating allergen-specific immune responses and thus represent attractive 
therapeutic targets. 
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Inducible and engineered Treg (iTreg, tg Treg) 
 
Expansion of Treg 
As described above, one of the hallmarks of CD4+CD25+ nTreg is their hypoproliferative 
state upon stimulation in vitro. However, several experimental data gathered from in vivo 
mouse models have shown that nTreg can proliferate under conditions of lymphopenia237 
or when stimulated with antigen238. These observations suggest that standard in vitro 
culture conditions do not support Treg propagation and that additional factors or signals 
are needed. Indeed, several studies on human Treg have since then shown that expansion 
of purified CD4+CD25+ Treg can be achieved using dendritic cells239, 240, B-cells241, EBV 
transformed B-cell blasts242 or anti-CD3/CD28 coated microbeads243-245 and that such 
protocols allow an up to 1.3 x 104-fold expansion of functional Treg within three to four 
weeks. In all these studies, expansion of Treg relies on strong TCR stimulation and 
costimulatory signals and the presence of high concentrations of exogenous IL-2. 
Strategies to expand antigen-specific Treg include the use of tetramer-sorted Treg as 
starting population239, 240 or allogeneic APC241, 242 as stimulator cells. Importantly, 
regulatory function was found to be maintained or in some cases even enhanced245 in 
expanded Treg. However, as phenotypic analyses showed that the expression of Treg 
markers like Foxp3 and CD25 was rather heterogenous in expanded Treg populations, 
concerns about their stability and about the potential outgrowth of ‘contaminating’ 
effector T-cells have been raised (reviewed by Allan et al.226). In order to address these 
issues and to optimize expansion protocols the additional use of cytokines (IL-7 and IL-
15246, 247), costimulatory ligands (4-1BBL248, 249) and pharmacological agents 
(dexamethasone250) has been proposed. 
 
Induction of Treg using APC 
Although nTreg constitute a thymus-derived distinct T-cell lineage, several findings also 
suggested that conversion of effector T-cells into regulatory Foxp3-expressing T-cells may 
take place in the periphery. Indeed, several specialized DC subsets were described to 
induce a CD4+CD25+Foxp3+ phenotype from CD4+CD25- effector T-cells in the 
periphery251-254. This effect was found to be dependent on cofactors such as TGF-β, the 
vitamin A metabolite retinoic acid and IL-10. Due to these observations it was assumed 
that dendritic cells could be used for the in vitro induction of Treg from CD4+CD25- 
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effector T-cells. A number of studies on murine and human cells has addressed this issue 
using different approaches to generate ‘tolerogenic’ dendritic cells. Generally, the 
tolerogenicity of dendritic cells is governed by their costimulatory setup, with low levels 
of costimulatory molecules and high levels of inhibitory ligands such as PD-L1 and ILT-
3/4 favoring Treg induction. Other mechanisms include the up-regulation of IDO and the 
secretion of cytokines such as IL-10 and TGF-β (reviewed in Maldonado and von 
Adrian255). Similarly, induction of the tolerogenic state in dendritic cells can be 
experimentally achieved using pharmacological compounds (such as glucocorticoids256, 
257, cyclooxygenase inhibitors258, 259 or thiazolidinediones, e.g. rosiglitazone260), hormones 
(VIP261, HGF262), soluble molecules (HLA-G263) or cytokines (IL-10264, 265, TGF-β266, 267, 
TNF-α268, 269) and vitamin D3270. Other research has resorted to genetic engineering to 
generate tolerogenic dendritic cells. Combined knockdown of the costimulatory molecules 
CD40, CD80 and CD86271 or of intracellular factors such as RelB272 or SOCS3273 has led 
to considerable success in murine models of EAE273, CIA271 and experimental 
autoimmune myasthenia gravis272. Similarly, the transduction of IL-10 has led to ‘semi-
mature’ dendritic cells, which potently induced CD4+CD25+Foxp3+IL-10+ Treg274. Of 
note, transduction of human mdDC with Foxp3 and co-culture of such DC with Teff led to 
the induction of Foxp3+ iTreg275, which showed potent regulatory capacity in vitro. While 
the exact mechanism of this Treg induction is not yet understood it is intriguing to 
speculate that the function of Foxp3 may not be solely restricted to the T-cell 
compartment.  
These cumulative observations promise a huge potential for tolerogenic dendritic cells in 
the induction of Treg and subsequently the establishment of immunological tolerance. 
However, no comparative analyses on the efficacy of the different strategies exist as of 
today and no consensus has been reached so far concerning the optimal source of dendritic 
cells and the exact protocols to induce tolerance. A further point of concern is the type of 
iTreg generated by tolerogenic dendritic cells. A broad range of different phenotypic 
entities has been described ranging from CD4+CD25+ cells (with or without analysis of 
Foxp3 expression) to CD4+IL-10+ Treg, which thus resemble a Tr1-phenotype255. In this 
respect, regulatory capacities as well as stability of iTreg phenotype remain issues, which 
clearly warrant further assessments.      
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Induction using Cytokines, Pharmacological Compounds and Vitamins  
As described above, the immunoregulatory cytokine TGF-β is a crucial factor involved in 
the generation of iTreg. Thus it was hypothesized that addition of TGF-β to T-cell cultures 
may be sufficient to induce Treg and might offer an attractive strategy to create large 
numbers of iTreg in vitro. First formal proof for this hypothesis was provided, when three 
groups independently showed that activation of murine CD4+CD25- T-cells in the 
presence of recombinant TGF-β led to the up-regulation of Foxp3 and concomitantly the 
acquisition of a Treg phenotype172, 276, 277. Functional analyses on these nTreg showed that 
they were anergic to T-cell receptor mediated stimulation and suppressive upon co-culture 
with responder T-cells in a cell-contact dependent way, thus sharing the typical traits of 
nTreg. Importantly, the regulatory activity of TGF-β induced iTreg was not restricted to in 
vitro cultures but could be also observed in an ovalbumin peptide TCR transfer model and 
in a mouse model of house dust mite allergy172. Since then, successful therapeutic 
application of iTreg has been assessed in numerous mouse models of autoimmune disease 
such as type I diabetes278, experimental colitis279, autoimmune gastritis280, EAE281 and 
transplantation settings282.  
Mechanistically, several molecules have been assessed for their role in the TGF-β 
mediated generation of iTreg. A crucial co-factor, which synergizes with TGF-β is IL-2. 
Neutralization of IL-2 during iTreg induction abolished the development of suppressive 
function, while iTreg induction using allo-stimulated CD4+CD25- T-cells requires IL-2 
and TGF-β282-284. Another factor with an implied role in iTreg generation is CTLA-4 as 
shown by experiments where CTLA-4 deficient murine T-cells could not be converted 
into iTreg285. According to this study, TGF-β accelerates the expression of CTLA-4 during 
T-cell activation, which, when ligated by CD80 or CD86, induces expression of Foxp3. 
Foxp3 in turn further up-regulates CTLA-4 thus leading to a positive feedback loop 
between TGF-β/CTLA-4/Foxp3/CTLA-4285.  
While these experiments have clearly underlined the importance of TGF-β for the 
generation of murine iTreg, the situation is not as clear-cut for human Treg. Indeed, one 
study by the Shevach group indicated that the addition of TGF-β during T-cell stimulation 
could induce Foxp3 expression in CD4+CD25- T-cells, but these T-cells did not show 
regulatory capacity286. In contrast, other reports have described the induction of fully 
functional Treg using similar protocols172, 287 or repetitive stimulation in the presence of 
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TGF-β288. However, observations that additional presence of pro-inflammatory cytokines 
such as IL-1β and IL-6 can divert the induction of Treg towards the induction of Th17 
cells289 have raised considerable concern whether iTreg would be stable and functional in 
vivo. In this context, vitamine A derivatives such as retinoic acid (RA) seem to play an 
essential role in generation, stability and expansion of iTreg. First observations that 
addition of CD103+ murine DC from the lamina propria markedly increased TGF-β 
induced conversion of murine CD4+ T-cells into iTreg, could be ascribed to the production 
of all-trans retinoic acid in these cells290, 291. Several independent studies on murine iTreg 
suggested that the use of RA independently of accessory cells in combination with TGF-β 
generated higher numbers of iTreg, which showed enhanced stability upon expansion 
while at the same time suppressing conversion into Th17 cells 292-294. In the human system, 
RA could be shown to enhance histone acetylation at the Foxp3 promoter and induce 
Foxp3 expression in human CD4+ T-cells295 and to promote in vitro expansion of human 
nTreg296. More recent reports indicate that similar to murine iTreg, RA synergizes with 
TGF-β in the generation of highly suppressive and functionally stable human iTreg 297, 298. 
While this effect was initially described to be caused by relieving the inhibitory function 
of CD4+CD44high T-cells, which prevent conversion of CD4+ T-cells into iTreg298, more 
recent studies have found direct effects of RA on the converted T-cells297. Importantly, 
RA plus TGF-β induced human Treg also showed high immunoregulatory capacity upon 
transfer in a human anti-mouse GVHD model297.  
While iTreg generated according to these protocols show so far the most potent and stable 
suppressive function among iTreg, several points of concern remain. Reports that addition 
of RA during iTreg generation stabilizes Foxp3 expression but essentially inhibits IL-10 
transcription in murine T-cells have pointed out that thus converted iTreg may not be 
suitable in all therapeutic contexts294. Similarly, comparisons of the gene profile between 
nTreg and iTreg have shown that the presence of RA slightly reinforced Treg gene-
signature but could not overcome certain ‘holes’ in the expression pattern70. In this respect 
it remains to be assessed whether iTreg can fulfill the full regulatory repertoire of nTreg in 
therapeutic settings. 
Apart from vitamin A derivatives such as RA, vitamin 1,2(OH)2D3, which constitutes the 
biologically active form of vitamin D, has been implied in the generation of iTreg. 
Vitamin D3 has potent immunomodulatory potency and can induce tolerogenic function in 
dendritic cells270. Interestingly, similar effects were also observed when purified human 
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CD4+ T-cells were activated in the presence of IL-2 and vitamin D3299. Thus induced Treg 
showed reduced secretion of IFN-γ and IL-17 and up-regulation of the Treg-specific 
markers Foxp3 and CTLA-4. Importantly, these cells also showed a highly suppressive 
capacity in co-cultures stimulated with DC plus anti-CD3 even at a responder:regulator-
ratio of 10:1. Similar results could be observed when a synthetic vitamin D analogue, 
TX527, was used300.  
Another pharmacological compound that has been implied to be involved in the induction 
and/or expansion of regulatory T-cells is rapamycin. Bound in complex with the FK506-
binding protein-12, rapamycin inhibits kinase activity of the mammalian target of 
rapamycin (mTOR), a serine/threonine protein kinase, which is essential for cell cycle 
progression in effector T-cells but not in regulatory T-cells301. Due to this difference in 
sensitivity, addition of rapamycin to CD4+ T-cell cultures from rodents205, non-human 
primates302 and humans303 has been described to result in the outgrowth of regulatory T-
cells from these cultures. While these regulatory T-cells do not represent pure populations, 
repetitive activation in the presence of rapamycin resulted in sufficiently high percentages 
to suppress effector T-cell responses in vitro and in vivo 205. In contrast to these 
observations, other reports describe the de novo induction of nTreg in rapamycin-treated 
cultures of CD4+CD25- T-cells304, 305, indicating that Treg induction rather than expansion 
might be the main mechanism of action of rapamycin in T-cells.  
Taking into account that rapamycin-treated T-cell cultures are Treg enriched but not pure 
populations, this significantly hampers their therapeutic potential. However, given its 
described functions, the use of rapamycin, possibly in combination with other factors such 
as RA, may be well warranted in expansion protocols of pre-sorted regulatory T-cell 
populations.   
In this respect direct mTOR-inhibition by application of therapeutic levels of rapamycin or 
other mTOR-inhibitors such as everolimus in vivo has been reported to lead to increased 
Treg conversion, which can be attributed to direct conversion of effector T-cells to Treg306, 
307. Thus it remains to be seen whether rapamycin-mediated in vitro or in vivo conversion 
or combinations thereof eventually present highly efficient strategies. 
Another immunosuppressive agent that has been implied in the generation of iTreg is anti-
thymocyte globulin (ATG). ATG is a polyclonal rabbit, horse or goat IgG preparation 
derived from animals immunized with peripheral blood T-cells or the Jurkat T-cell line. 
While originally believed to exert its immunosuppressive activity by depletion of 
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lymphocytes upon therapeutic administration308-310, increasing data now also point at a 
potential role in Treg induction. Several independent studies have reported that in vitro 
culture of human peripheral blood mononuclear cells or purified CD4+ T-cells in the 
presence of ATG results in a dramatic increase in CD4+CD25+Foxp3+ Treg, which display 
potent regulatory activity in vitro311, 312.  Along those lines, murine Treg induced by 
rabbit-anti-murine thymocyte globulin could efficiently inhibit GVHD upon adoptive 
transfer in vivo313.  
While this effect of ATG is thus well established, several points remain unresolved. It is 
still unclear whether ATG induces de novo generation of Treg from CD4+CD25- T-cells or 
whether it promotes the expansion of pre-existing nTreg in the treated population. A 
recent report, that ATG-mediated induction of Foxp3 in T-cells is due to activation and 
not due to induction of bona fide Treg has cast doubt on the concept of ATG-induced 
Treg314. Given that ATG is a very heterogenous product with possibly considerable 
variability between different preparation methods and batches, it seems possible that not 
all ATG products may display similar functional activity. This is also supported by reports 
that rabbit but not horse ATG promotes Treg induction315. In this light the exact molecular 
targets of Treg induction by ATG remain to be determined.  
Another disease modifying agent, which has been reported to induce the generation of 
nTreg is copolymer-I (COP-I). COP-I is a random polypeptide composed of four amino 
acids and has proven efficacy in the treatment of multiple sclerosis. Mechanistically, the 
therapeutic value of COP-I is attributed to inducing a shift of the pathological Th1 
responses towards a Th2 T-cell response316, 317. Other reports also indicate that treatment 
with COP-I leads to a decreased production of the pro-inflammatory cytokines IL-6 and 
IL-17 in murine EAE models318, 319. In 2005 Hong et al. described that culture of both 
murine and human CD4+CD25- T-cells in the presence of COP-I led to the up-regulation 
of Foxp3 in these cells accompanied by the acquisition of regulatory capacity320. 
Interestingly, this effect was highly dependent on IFN-γ as shown by the use of IFN-γ 
deficient murine T-cells or by the addition of recombinant IFN-γ to T-cell cultures. These 
data have been supported by in vivo studies in mouse models of type 1 diabetes321 and 
EAE322, where therapeutic efficacy of COP-I administration was associated with induction 
of CD4+CD25+Foxp3+ Treg. However, further research on the exact functional qualities 
and the long-term stability of COP-I induced Treg are well warranted.  
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The peptide hormone vasoactive intestinal peptide (VIP) is another factor that has been 
implied to play a role in the in vitro induction of CD4+CD25+Foxp3+ Treg. First 
indications about the immunomodulatory capacity of VIP were obtained in murine models 
of GVHD323, EAE324 and CIA325 in which application of VIP showed therapeutic efficacy 
via the in vivo induction of CD4+CD25+ Treg. Along those lines it could be shown that 
alloantigen-specific stimulation of human CD4+ T-cells resulted in the de novo induction 
of CD4+CD25+ iTreg, which expressed high levels of Foxp3 and CTLA-4 and showed 
potent suppressive capacity in allogeneic MLR cultures326. Similar to COP-I induced 
iTreg, the study of Pozo et al. so far represents a singular finding and further assessments 
on the phenotype, function and stability of VIP-induced iTreg are clearly needed. 
An overview of all described protocols to induce Treg via addition of cytokines, 
pharmacological agents and vitamins is provided in Table II. 
 
Table II. In vitro Treg induction using cytokines, pharmacological substances and 
vitamins  
 
Compound Starting population Species Culture Conditions Ref 
TGF-β1 
CD4+CD25- (C57BL/6) 
splenocytes (DO11.10) 
mouse 
anti-CD3 (0.5 µg/ml)+ APC + TGF-β1 (2 ng/ml) 
OVA (100 µg/ml) + TGF-β1 (2 ng/ml) 
172 
TGF-β1 CD4+CD25-  
mouse, 
human 
anti-CD3/anti-CD28 + TGF-β1 (1 ng/ml) 276 
TGF-β1 CD4+CD25-  mouse 
anti-CD3 (plate-bound, 5 µg/ml) + anti-CD28 (soluble 0.5 
µg/ml) + TGF-β1 (5 ng/ml) 
277 
TGF-
β1+IL-2 
T-cells mouse 
irradiated non-T-cells + TGF-β1 (1-10 ng/ml)  
+ IL-2 (10 U/ml)  
282 
TGF-
β1+IL-2 
T-cells mouse 
anti-CD3/CD28 coated microbeads + TGF-β1  
(2 ng/ml)  + IL-2 (20 U/ml) 
284 
TGF-
β1+IL-2 
CD4+CD45RA+ human 
anti-CD3 and anti-CD28 (plate-bound, 5 µg/ml each) + TGF-
β1 (32 U/ml) + IL-2 (65 U/ml) + IL-9 (42 U/ml) + IL-15 
(4500 U/ml) + anti-IFN-γ (20 µg/ml) + anti-IL-12 (10 µg/ml) 
287 
TGF-
β1+RA 
CD4+CD62LhighCD25-  mouse 
anti-CD3 (plate-bound, 2 µg/ml) + anti-CD28 (soluble 2 
µg/ml) + TGF-β1 (2 ng/ml) + all-trans RA (10 nM) 
292 
TGF-β1 
+RA+IL-2 
CD4+Foxp3-  mouse 
anti-CD3 (plate-bound, 10 µg/ml) + anti-CD28 (plate-bound 1 
µg/ml) + TGF-β1 (20 ng/ml) + all-trans RA (10 nM) + 100 
U/ml IL-2 
293 
TGF-
β1+RA 
CD4+CD44loGFP- 
(10BiT.Foxp3gfp.OT-II mice) 
mouse DC + 1 µg/ml OVA + TGF-β1 + all-trans RA (100 nM) 294 
TGF-β1 CD4+CD45RO-CD25- human anti-CD3/CD28 coated microbeads + TGF-β1  297 
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+RA+IL-2 (5 ng/ml)  + all-trans RA (100 nM) + IL-2 (50-100 U/ml) 
Vitamin D CD4+CD25- human anti-CD3/CD28 coated microbeads + 1,25(OH)2D3 299 
 
TX527  
 
CD4+CD25highCD127low 
 
human 
 
anti-CD3 and anti-CD28 (plate-bound, 5 µg/ml each) + IL-2 
(12.5 ng/ml) + 10-8 M TX527 
 
300 
Rapamycin CD4+ mouse 
anti-CD3 (plate-bound, 10 µg/ml) + anti-CD28 (soluble 1 
µg/ml) + IL-2 (50 U/ml) + Rapamycin (100 nM) 
205 
Rapamycin CD4+ baboon 
anti-CD3/CD28 coated microbeads + irradiated pig PBMC + 
IL-2 (500 U/ml) + Rapamycin (0.1-10 nM) 
302 
Rapamycin CD4+ human 
anti-CD3 (plate-bound, 10 µg/ml) + anti-CD28 (soluble 1 
µg/ml) + IL-2 (100 U/ml) + Rapamycin (100 nM) 
303 
Rapamycin CD4+ human 
anti-CD3 (plate-bound, 0.4 µg/ml) + anti-CD28 (soluble 1 
µg/ml) + IL-2 (100 U/ml) + Rapamycin (100 nM) 
304 
Rapamycin CD4+CD25- human 
anti-CD3 (plate-bound, 5 µg/ml) + anti-CD28 (soluble 1 
µg/ml) + IL-2 (200 U/ml) + Rapamycin (100 nM) 
305 
ATG PBL human Thymoglobulin (10 µg/ml) 311 
ATG PBMC human Thymoglobulin (100 µg/ml) 312 
ATG splenocytes mouse mATG (100 µg/ml) + IL-2 (200 U/ml) 313 
ATG PBMC human rabbit-derived but not horse-derived ATG (10 µg/ml) 315 
COP-I PBMC/T-cells human irradiated T-cell depleted PBMC + COP-I (40 µg/ml) 320 
VIP CD4+CD25- human HLA-mismatched irradiated PBMC + VIP (100 nM) 326 
 
APC, antigen-presenting cell; RA, retinoic acid; DC, dendritic cells; PBMC, peripheral blood mononuclear 
cells; PBL, peripheral blood lymphocytes; ATG, anti-thymocyte globulin; mATG, anti-murine thymocyte 
globulin; VIP, vasoactive intestinal peptide 
 
 
Induction of Treg via Genetic Engineering 
The development of modern techniques to genetically modify peripheral blood 
lymphocyte populations has also opened intriguing possibilities for the development of 
genetically engineered regulatory T-cells. Observations that forced over-expression of 
Foxp3 in murine CD4+ T-cells could transfer the key features of nTreg phenotype and 
function, i.e. expression of CD25, CTLA-4 and other markers, hyporesponsiveness to 
TCR-mediated stimulation and regulatory capacity4-6, spurred hope that similar results 
could be achieved with human T-cells. In first experiments, retroviral over-expression of 
either of the two common isoforms of Foxp3, i.e. Foxp3 and Foxp3ΔE2, in CD4+ T-cells 
failed to generate regulatory T-cells327. However, the use of a lentiviral-vector system, 
which was designed to allow higher and more stable expression of the Foxp3 transgene, 
led to the successful generation of engineered regulatory T-cells242. Such artificial 
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regulatory T-cells showed a typical nTreg phenotype with up-regulation of CD25, GITR 
and CTLA-4. Following TCR-mediated stimulation, Foxp3-transgenic Treg were 
hyporesponsive and secreted only low amounts of IL-2, IL-4, IFN-γ and IL-10 compared 
to control-transduced cells. Upon co-culture with CD4+CD25- effector T-cells, Foxp3 
transgenic (tg) T-cells were highly suppressive and this suppressive capacity was equal to 
purified CD4+CD25high nTreg. Importantly, the phenotype and function of such artificial 
Treg were stable even after repetitive expansion over several weeks. At the same time, 
similar results were obtained independently by Aarts-Riemens et al. who showed that 
retroviral over-expression of either of the two isoforms of Foxp3 was equally sufficient to 
generate potent engineered Treg328. These data imply that retroviral expression systems 
are similarly suited for the generation of engineered Treg as long as stable, high-level 
expression of Foxp3 can be achieved. 
While Foxp3-transduction has been shown to generate T-cells with regulatory function, 
these cells represent a polyclonal population with the endogenous TCR repertoire of the 
purified peripheral blood T-cells used as starting population. In this respect, it seems 
highly probable that such Treg populations will contain a broad range of specificities, 
some representing important targets for normal immune function. On the other hand, Treg 
with the desired antigen-specificity (autoreactive, allergen-specific or allo-specific) would 
most probably only be found at a low frequency. To address this problem, several studies 
have resorted to the genetic modification of CD4+CD25+ T-cells in order to introduce 
antigen-specificity into Treg. In one study, receptor-modified murine CD4+CD25+ T-cells 
were transduced with an antigen-MHC class II-TCR-ζ fusion-construct and upon transfer 
could prevent and cure EAE induced by vaccination with myelin basic protein329. 
Similarly, transduction of murine nTreg with a chimeric receptor recognizing 
trinitrophenol (TNP) generated regulatory T-cells, which could ameliorate TNBS-induced 
colitis330.  
In the human system, the transduction of CD4+CD25+ nTreg with a multicistronic 
expression construct encoding the α- and β-chain of a melanoma antigen-reactive TCR led 
to the generation of engineered antigen-specific human Treg, which could potently 
suppress anti-tumor immune responses in a murine melanoma model331. Along those lines 
Hombach et al. recently described the generation of engineered carcinoembryonic antigen 
(CEA)-specific human Treg by introduction of a chimeric receptor into purified human 
CD4+CD25+ nTreg332. While these approaches have proven the feasibility to engineer 
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nTreg with a specific reactivity, they may bear several shortcomings. The purification of 
nTreg is a tedious process, which is considerably hampered by the low frequency of nTreg 
in peripheral blood and the need to select for several surface markers in order to exclude 
‘contaminating’ activated effector T-cells. Secondly, nTreg from patients suffering from 
autoimmune or allergic disorders may be compromised in their function, which would 
significantly impede their usefulness for therapeutic approaches. 
In this light, we have recently developed a novel strategy to engineer allergen-specific 
regulatory T-cells from peripheral blood CD4+CD25- T-cells. Using a retroviral vector-
based multicistronic expression element, we have introduced the regulatory factor Foxp3 
and the α- and β-chain of a TCR specific for the birch pollen allergen derived peptide Bet 
v 1142-153 into human CD4+ T-cells. The accordingly modified engineered Treg potently 
suppressed the proliferation and cytokine production of human TCR-transgenic effector T-
cells in an activation-dependent manner333. In our opinion this approach offers the 
advantage that CD4+ T-cells could be used as starting population, which should in 
principle be more readily available from any patients’ blood than naturally occurring Treg. 
A major impediment for the use of human Foxp3-tg Treg may come from studies 
comparing CD4+CD25+ nTreg and Foxp3+ engineered Treg, which have shown that the 
gene signature between these two populations differs significantly70. Thus it remains to be 
investigated, whether Foxp3-tg Treg can fulfill the full physiological repertoire of 
functions of nTreg. Table III gives an overview of the genetic manipulation of human 
Treg cells.  
Apart from Foxp3 over-expression, approaches to exploit other Treg related molecules for 
genetic engineering have so far been scarce. In murine CD4+ T-cells, the over-expression 
of LAG-3 has been shown to generate a T-cell population with regulatory properties64. 
Similar observations have been described for T-cells engineered to over-express the LAG-
3 regulating factor Egr-264. However, expression of the nTreg-associated marker CD25 
was found to be low on these cells, thus raising questions whether such engineered Treg 
constitute bona fide nTreg with similar physiological properties. Additionally, no data 
about the overexpression of LAG-3 or Egr-2 in human T-cells have so far been published.   
Another intriguing molecule for the generation of engineered Treg is CD83. In a study on 
murine CD4+CD25- T-cells, ectopic over-expression of CD83 was shown to result in T-
cells, which exerted regulatory function towards CD4+CD25- effector T-cells in vitro and 
could suppress disease in mouse models of contact-hypersensitivity of the skin and in 
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EAE94. Importantly, over-expression of CD83 also resulted in up-regulation of Foxp3 
indicating that these cells may share features with nTreg.   
In another study using human T-cells, it could be shown that siRNA-mediated knockdown 
of the novel Treg marker galectin-10 reversed the anergic and suppressive function of 
human nTreg. However, in the reverse experiment over-expression of galectin-10 in 
CD4+CD25- effector T-cells led to the induction of apoptosis even when using a range of 
different viral and non-viral delivery methods69. In this light it seems probable that nTreg 
express a network of factors that are non-redundantly involved in the maintenance of their 
regulatory function. While the ablation of one factor might be sufficient to significantly 
disturb this regulatory network, the isolated over-expression of a singular factor may have 
different consequences in CD4+CD25- effector T-cells. 
 
Table III. Transgenic human Treg  
Transgene(s) Starting population 
Regulatory 
function 
Antigen-
specificity 
Suppression 
model 
Ref 
Foxp3 CD4+CD25-CD45RO- engineered polyclonal in vitro 242,328 
melanoma-antigen 
tyrosinase specific 
TCR  
CD4+CD25+CD127low/- endogenous engineered enhanced tumor 
progression in mice 
331 
CEA-specific 
chimeric receptor 
CD4+CD25high endogenous engineered enhanced tumor 
progression in mice 
332 
birch-pollen 
allergen (Bet v 1) 
specific TCR and 
Foxp3  
CD4+CD25- engineered engineered in vitro 333 
 
  CEA, carcinoembryogenic antigen; TCR, T-cell receptor 
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Conclusion 
The definition of regulatory T-cell subsets and the subsequent elucidation of their crucial 
contribution to peripheral tolerance have spawned hope for the applicability of such 
regulatory T-cells as therapeutic tools in still badly controllable diseases and medical 
conditions. Indeed accumulating evidence suggests, that at least at the experimental level, 
Treg-based therapies can have preventive or even curative effects. In this respect, several 
strategies have been proposed to achieve sufficiently high Treg numbers, which would be 
needed for therapeutic application.  Isolation and subsequent expansion of nTreg has been 
so far the method of choice and clinical studies on GVHD patients are currently underway. 
Other proposed strategies include the induction of nTreg from effector T-cells using 
antigen-presenting cells, cytokines and pharmacological agents or genetic engineering of 
Teff or Treg. While all approaches bear their specific advantages and disadvantages, 
several common problems exist. Under the protocols currently used, no method of Treg 
induction has been shown to lead to the generation of 100% Foxp3+ nTreg. Although 
suppressive capacity in vitro does not require this level of purity, ‘contaminating’ effector 
T-cells could pose a severe impediment upon adoptive transfer into patients. In this 
respect, it remains to be determined, which thresholds for nTreg purity must be imposed in 
order to achieve an acceptable ratio between efficacy and side effects. Given the different 
entities and subpopulations of Treg cells, it seems conceivable that different therapeutic 
applications may require different types of Treg. Especially the requirement for the 
secretion of certain cytokines such as IL-10 and TGF-β, which are necessary for the 
disease-modifying quality of Treg in some studies, remains a challenge. Consequently, a 
better definition of subset markers and of signals, which govern site-specific Treg 
function, is well warranted and requires further efforts in basic research. Another 
challenge for the therapeutic application of regulatory T-cells is antigen-specificity. A 
multitude of murine disease models has shown that antigen-specific Treg are superior in 
their disease-modifying quality as well as their required number when compared to 
polyclonal Treg populations. While use of TCR-transgenic mouse strains has helped to 
elucidate these requirements, more elaborate strategies have to be applied for human Treg 
therapies. Until today, the most promising prospects lie in the field of transplantation 
tolerance where host Treg can be either induced or expanded using donor APC thus 
guaranteeing a large percentage of donor/allo-reactive Treg. Other options include the 
cloning and subsequent expansion of self- or allergen-reactive regulatory T-cells or gene-
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transfer of TCR α/β-chains or surrogate T-cell receptors. While all these approaches are 
technically feasible, it remains to be determined, which strategy offers the best results in 
regard to yield, applicability for GMP production and safety (reviewed in Riley et al.334 
and Bluestone335).  
Along those lines, more insight into the pathophysiology of human autoimmune diseases, 
allergies and the processes involved in transplant rejection in respect to which antigens 
should be the targets of Treg therapies is clearly needed. Currently, such research projects 
on allergic disorders have defined that some allergies might be rather uniform disorders 
with a high percentage of allergic individuals reacting to one or only a few 
immunodominant peptides336, 337.  
In conclusion, development of different strategies to isolate, induce, expand or modify 
regulatory T-cell function and numbers has opened an exciting field of research, which 
holds great promise for the development of therapies in severe diseases. However, current 
research has not exceeded the basic level and further assessments as to the detailed 
definition of specific pathologies and the behavior of differently modified Treg in 
therapeutic settings is warranted. 
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ABSTRACT  
 
Background: Ninety-five percent of mugwort allergic patients are sensitized to Art v 1, 
the sole major allergen in mugwort (Artemisia vulgaris) pollen. Sixty-nine percent of 
patients recognizing the single immunodominant T-cell epitope Art v 125-36 have an HLA-
DRB1*01 phenotype. 
Objective: Cloning and functional expression of a human αβ T-cell receptor (TCR) 
specific for Art v 125-36. 
Methods: TCR chains were RT-PCR-amplified from an Art v 125-36-specific T-cell clone, 
retrovirally transferred and functionally tested in Jurkat T-cells or alternatively in PB T-
lymphocytes of non-allergic individuals. 
Results: The α-chain of the TCR is composed of TRAV17 and TRAJ45 segments, the β-
chain uses TRBV18, TRBD1 and TRBJ2-7. Analyses of 23 other Art v 1-specific T-cell 
clones did not reveal preferential usage of the TRAV17, TRBV18 or other TCR-gene 
families. Efficient TCR-transfer into Jurkat T-cells was shown by binding of TCR Vβ18-
specific mAb and DRB1*0101/Art v 1 tetramers. Transgenic (tg) Jurkat T-cells 
specifically recognized syngeneic EBV B-cells pulsed with Art v 125-36 peptide and 
artificial antigen presenting cells (aAPC) expressing invariant chain::Art v 1 fusion 
proteins. Moreover, transfer of the TCR into PBL generated T-cells that were Art v 1-
reactive. Activation of tg T-cells by aAPC was strictly dependent upon co-stimulation. 
Conclusion: For the first time, a detailed molecular and functional analysis of a human 
allergen-specific TCR is presented.  
Clinical Implication: Expressible allergen-specific TCRs may contribute to a better 
definition of the ‘allergen-specific synapse’ and thus the processes leading to allergic 
diseases and their cure. 
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INTRODUCTION 
 
T lymphocytes play a central role in the pathogenesis of allergic diseases. During the 
sensitization, priming of allergen-specific (CD4+) T helper 2 (TH2) cells results in the 
production of TH2 cytokines, which are responsible for class switching to the ε Ig heavy 
chain, allowing IgE production by B-cells. 1 Once primed, allergen-specific T-cells 
critically contribute to late phase reactions and allergic inflammation in target organs, e.g. 
in the airways and the skin. 2 The clonotypic specificity of T-cells is brought about by the 
TCR, which shows dual specificity for the antigen (allergen) and for self (MHC) 
determinants.3 Signal transduction by the TCR is conducted by non-covalently associated 
invariant CD3 subunits.4-6  
 
The antigen specificity of T-cells can be transferred to other T-cells by TCRαβ gene 
transfer.7-9 TCR transgenic (tg) model-systems have contributed greatly to our 
understanding of the immune response to autoantigens and infectious agents10-12 and have 
shed light on fundamental processes in T-cell development.5, 13, 14 Although TCR gene 
usage by allergen-specific T lymphocytes has been studied to a considerable degree in the 
past 15-19, no molecular or functional analyses of cloned and ectopically expressed human 
allergen-specific TCR have been reported so far. Consequently, biological model systems 
based on human allergen-specific TCRs are still missing.  
 
An ideal human allergen-specific model system would be comprised of an 
immunodominant epitope, which is presented by a well-characterized restriction element 
expressed by the majority of the individuals affected. These features apply to mugwort 
pollen allergy: mugwort (Artemisia vulgaris) is widely spread throughout the European 
temperate climate zone, North America and parts of Asia and is one of the main causes of 
hay fever in late summer and autumn. 20 More than 95% of mugwort allergic patients are 
sensitized to Art v 1, the major allergen in mugwort pollen. Analyzing the T-cell response 
to Art v 1 using a panel of specific T-cell lines and clones revealed that the presentation of 
the sole immunodominant epitope (Art v 125-36) is highly associated with HLA-DRB1*01. 
21, 22 Thus, allergy to Art v 1 is characterized by a uniform T-cell response. 
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In the present study we addressed the feasibility of engineering allergen-specific T 
lymphocytes by genetic TCR transfer. The molecular and functional characterization of 
human allergen-specific TCRs - as critical tools of defined model systems in which all 
three components of the ‘allergen-specific synapse’ are well defined, i.e. restriction 
element, immunodominant peptide, TCR - shall provide important insights into the 
pathophysiology of allergic diseases and their possible cure in the future. 
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RESULTS 
 
Molecular cloning of the αβ TCR of an Art v 125-36-specific, HLA-DRB1*0101-restricted 
T-cell clone 
The Art v 1 specific CD4+ T-cell clone (SSR20) was isolated from the blood of a mugwort 
pollen-allergic individual (HLA-DRB1*0101, *0301; DRB3*0101; DQB1*0201, *0501) 
shortly after the mugwort pollen season. The clone specifically reacted to stimulation with 
the immunodominant peptide of Art v 1, i.e. Art v 125-36, in an HLA-DRB1*0101 
restricted manner. 21 The TCR α- and β-chains of SSR20 were RT-PCR amplified, ligated 
into the retroviral expression vector pMMP412 and DNA sequenced. The functional α-
chain gene of SSR20 was formed by the rearrangement of a Vα gene segment of the 
TRAV17 gene family to a TRAJ45 segment (Fig 1, nomenclature according to Lefranc 29). 
The β-chain of SSR20 is derived from a TRBV18-TRBD1-TRBJ2-7-TRBC2 
rearrangement (Fig 1). The junctional or N-diversification in CDR3s is low for both 
chains. In the a-chain three non-germline encoded codons are present, while the two C-
terminal TRAV17 codons have been deleted. CDR3b is composed of germline sequences 
except for the addition of a single arginine. Assessment of 23 T-cell clones of ten 
additional Art v 1 allergic individuals revealed that 12% of the clones expressed TRAV17 
and 9% of the clones expressed TRBV18 indicating that Art v 125-36-specific T-cell 
responses are not confined to TCRs consisting of TRAV17 and TRBV18 gene families.  
 
Retroviral transfer and expression of the Art v 1-specific TCR 
In a first instance, expression of the cloned TCR was tested by retroviral transduction of 
Jurkat T-cells harboring a human IL-2 promoter/enhancer controlling luciferase 
expression.23 Immunofluorescence staining of bulk-transductants revealed stable TCR 
Vβ18 expression in ~60% of cells (Fig 2). Expression levels of CD3, pan TCRαβ and 
CD4 were comparable in wild type (wt) and TCR tg Jurkat cells in bulk transductants as 
well as in single cell clones, whereas e.g. CD2 expression levels showed considerable 
variations (Fig 2). A similar variability was observed for Vβ8 and Vβ18 expression on 
single cell clones. Clone #3 showed residual co-expression of the endogenous Vβ8 chain, 
whereas clones #5 and #7 showed mutual exclusive expression of the tg Vβ18 chain (Fig 
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2), which might be caused by different levels of over-expression (LTR-driven or via copy-
number) of the tg TCR and competition for the  
 
 
FIG 1. Nucleotide and predicted amino acid sequence of the HLA-DRB1*0101 restricted TCR of the Art v 
1-specific T-cell clone SSR20. (A) TCR α-chain sequence; (B) TCR β-chain sequence. Codon numbering 
and nomenclature according to IMGT-TR 29. Only the 5’-ends of the constant region sequences are shown. 
Complementarity determining regions are boxed. 
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constitutively expressed CD3 complex. HLA-DRB1*0101/Art v 119-36-specific tetramers 
bound to TCR transductants exclusively (Fig 2) indicating that upon transfer the tg TCR 
retained its capability to specifically interact with the restriction element/peptide-complex 
against which it had been selected in vivo. 
 
 
FIG 2. Expression pattern of endogenous TCR, Art v 1-specific tg TCR and accessory molecules on wt, 
bulk TCR tg and TCR tg single cell clones (#3, #5 and #7) of Jurkat T-cells are shown. Binding of specific 
mAbs or Art v 1-specific tetramers (HLA-DRB1*0101/Art v 119-36) (bold lines) is compared to control 
antibody binding (thin lines). Two-parameter dot-plot analysis of Jurkat cells stained with TCR Vβ8 and 
TCR Vβ18 mAb (right panel). Data are representative of two independently performed experiments.  
 
 
The allergen-specific TCR is functionally intact in TCR tg Jurkat T-cells 
To determine whether Jurkat T-cells transduced with the allergen-specific TCR recognize 
the HLA-DRB1*0101-restricted immunodominant T-cell epitope Art v 125-36 21, 22 also in 
functional terms, the TCR transductants (subclone #5) were co-incubated with syngeneic 
EBV B-cells that had been pulsed with saturating concentrations of Art v 125-36 or control 
peptides from Art v 1 (Art v 119-30, Art v 194-105) or influenza hemagglutinin (HA306-318). 
Fig 3, A shows specific recognition of Art v 125-36 by the TCR tg Jurkat T-cells as revealed 
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by IL-2 promoter driven luciferase activity. Similar results were obtained with other 
subclones or the bulk transductants (not shown). Of note, residual co-expression of 
endogenous TCR chains as observed for clone#3 did not influence subsequent antigen-
specific activation (not shown). EBV B-cells pulsed with control peptides from Art v 1 
(Art v 119-30 or Art v 194-105), the DRB1*0101/0401-restricted peptide from influenza 
hemagglutinin (HA306-318) 30, or medium alone were unable to stimulate TCR tg T-cells. 
Cellular activation induced by Art v 125-36 was strictly dependent on the presence of APC 
as no T-cell stimulation was observed upon co-incubation of TCR tg Jurkat T-cells with 
peptides in the absence of EBV B-cells (Fig 3, A). The immunodominant Art v 125-36 
peptide did not activate wt Jurkat T-cells, which were perfectly able to mount HLA class II 
dependent responses in the presence of SEE (Fig 3, B). Dose-response determinations 
revealed that TCR tg Jurkat T-cells required between 7.6 - 33.4 µM (12.4-54.8 µg/ml) 
peptide for half-maximal stimulation (not shown).  
 
 
 
FIG 3. The Art v 1-specific TCR in tg Jurkat T-cells is functionally active. (A) IL-2 promoter activity of Art 
v 1 TCR tg or wt Jurkat T-cells upon co-culture with or without HLA-DRB1*0101+ EBV B-cells and the 
indicated peptides or with medium alone. (B) Similar to A but supplemented with SEE. Data show mean 
values + SD of triplicate cultures representative for several independently performed experiments. 
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TCR tg Jurkat T-cells recognize Art v 1 borne by engineered invariant chains (Ii) 
The HLA class II-associated Ii peptide (CLIP) occupies the peptide binding groove during 
assembly and transport and becomes exchanged to antigenic peptides in endo-
/lysosomes.24 Does the allergen-specific TCR also recognize Art v 1 which was 
genetically exchanged against CLIP in Ii expression constructs?  
To answer this question we generated aAPC by transfecting human 293 cells with HLA-
DRA*0101, HLA-DRB1*0101, CD80, CD54, cathepsin S (CatS) plus Ii constructs 
harboring different length-variants of a codon-optimized version of the Art v 1 gene. 25 
Alternatively, 293 cells were transfected with the control Ii constructs Ii::HA309-317 or 
Ii::CLIP. 293 cells transfected with the Ii::Art v 1 versions – all harboring the minimal Art 
v 127-34 epitope 21- were able to stimulate the Art v 1-specific tg Jurkat T-cells similar to 
the positive control PHA/PMA (Fig 4, A). No stimulation was induced by 293 cells 
transfected with Ii::HA309-317, Ii::CLIP or control vector, although these cell types were 
perfectly able to functionally bind SEE (Fig 4, B). No SEE dependent response was, 
however, observed in the absence of aAPC. Fig 4, C shows that HLA Class II expression 
was similar on all aAPC types whereas Ii expression levels gave a more heterogeneous 
picture (Fig 4, D). Ii::Art v 11-109 fusion protein repeatedly showed the weakest expression, 
which also resulted in a weaker stimulatory capacity of Ii::Art v 11-109 transfected aAPC. 
Significantly, T-cell activation was only moderate in the absence of co-stimulation 
(stimulation index (SI): 3.2 ± 0.34), however, became clear-cut when co-stimulatory 
molecules such as CD80 were co-expressed (SI: 44.7 ± 8.7) (Fig 5). In our system, co-
expression of CD80 together with the intercellular adhesion molecule-1 (ICAM-1, CD54) 
on aAPC revealed only moderate additional synergy (SI: 58.1 ± 15.2, Fig 5), which may 
reflect already maximal stimulation by CD80 alone making a further enhancement by 
CD54 impossible. 
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FIG 4. Art v 1-specific TCR tg Jurkat T-cells recognize Ii encoded allergenic peptides presented by aAPC. 
(A) IL-2 promoter activity of TCR tg Jurkat T-cells (bulk) co-cultured with 293 cells expressing HLA-
DRA*0101, HLA-DRB1*0101, CD80::GPI, CD54::GPI, cathepsin S and the indicated forms of Ii or 
controls. Co-culture with Raji B-cells, PHA plus PMA or medium served as controls. (B) Similar to A, but 
supplemented with SEE. (C) Expression levels of HLA-DR1 or (D) Ii in 293 aAPC transfectants (bold lines) 
superimposed by negative control staining (thin lines). 
 
 
FIG 5. Efficient stimulation of Art v 1-specific Jurkat T-cells requires co-stimulation. IL-2 promoter activity 
of TCR tg Jurkat T-cells incubated with 293 cells co-transfected with DRA*0101, DRB1*0101, Ii::Art v 125-
34, CD54, CD80, GFP or control plasmid alone or combined as indicated or PMA plus PHA. Data show 
mean values + SD of triplicate cultures representative of three independently performed experiments. 
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Transfer of allergen-specific TCR into human peripheral blood lymphocytes 
In a next step it was tested whether it was possible to generate human Art v 1-specific T 
lymphocytes from non-allergic individuals. For that purpose PBL from six donors (HLA-
DRB1*0101 positive or negative) were transduced with the Art v 1-specific TCR. 
Transduction efficiencies ranged from 10-30 % as determined by flow cytometry of 
CD3+TCR Vb18+ T-cells (Fig 6, A). TCR tg T-cells from all donors specifically 
proliferated upon co-incubation with aAPC expressing Ii::Art v 125-36 but not with aAPC 
expressing Ii::HA309-317. Control-transduced T-cells (GFP) of HLA-DRB1*0101 negative 
donors showed residual reactivity with HLA-DRB1*0101 expressing aAPCs, possibly 
reflecting alloreactivity, which was not observed with responder T-cells from HLA-
DRB1*0101 positive donors. Moreover, stimulation of TCR tg PB T-cells was strongly 
dependent on CD80 mediated co-stimulation (Fig 6, B). Within ten days, up to 1 x 107 Art 
v 1-specific T-cells can be generated from 10 ml of peripheral blood of various donors. 
This cell number can be further increased by a factor of ~3 by supplementation of TCR tg 
T-cells with growths factors, e.g. IL-2. Thus, PB T-cells from non-allergic donors can be 
genetically modified to react with a well-defined allergen such as Art v 1. 
 
 
FIG 6. TCR tg PB T-cells proliferate upon challenge with Ii::Art v 125-36 expressing aAPC. (A) Expression 
levels of TCR Vβ18 and CD3 on control and tg PB T-cells. Numbers indicate percentage of CD3+TCR 
Vβ18+ cells. (B) Proliferation of human PBMC transduced with Art v 1-specific TCR co-cultured with 
aAPC co-expressing the indicated molecules or alternatively with microbeads coated with CD3 plus CD28 
mAbs, or with medium alone. Data show mean values + SD of triplicate cultures corrected by mean values 
(2.6 kcpm, range: 0-8.2 kcpm) of GFP-transduced tg T-cells. Data are representative of several 
independently performed experiments. 
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DISCUSSION 
 
We cloned, sequenced and transferred the TCR αβ-chain genes of a CD4+ T-cell clone 
(SSR20) specific for the immunodominant T-cell epitope of the major mugwort pollen 
allergen Art v 1 to human T lymphocytes. The human Jurkat T-cell line as well as PB T-
cells of non-allergic individuals showed clear-cut expression of the tg TCR and 
specifically reacted with Art v 125-36 peptide-pulsed autologous EBV B-cells as well as 
with aAPC expressing Ii::Art v 1 fusion proteins. Significantly, stimulation of TCR tg T-
cells was dependent on co-expression of co-stimulatory molecules, such as CD80 or CD86 
(not shown) and to a much lesser degree on CD58 (not shown). To our knowledge, this is 
the first report describing the successful genetic transfer of a human allergen-specific TCR 
into human T lymphocytes.  
 
We here attempted to contribute to a better definition of the critical molecular players 
within the ‘allergen-specific synapse’ formed between APCs and T-cells. Whereas 
immunodominant peptides and corresponding restriction elements of major allergens have 
been characterized in detail during the past two decades 31, 32 the information on the 
molecular and functional definition of human allergen-specific TCRs remained scarce. 
The availability of recombinant, allergen-specific TCRs will allow us to set up biological 
model systems in the future, in which all three components of the allergen-specific 
synapse, i.e. the restriction element, the immunodominant peptide as well as the 
corresponding TCR, are defined at a molecular level and are based on a relevant allergic 
disease. Currently, allergen-specific T-cells have to be expanded from blood of patients 
with clinically well-defined allergy, a cumbersome task, which is only successful shortly 
after the pollen season. In addition, the overall cell yields are often negligible. The 
transgenic approach allows the generation of high numbers of allergen-specific T cells in a 
short period of time, independently of the allergic status of the donor and of the allergy 
season. Future studies will have to show, whether and how allergen-specific TCR tg T-
cells can be polarized to exert defined effector functions. The steadily growing number of 
modified/recombinant allergens 33 (allergen (peptide)-fragments, 34 -trimers, 35 -
conjugates, 36 shuffled-allergens, 37 or hybrid molecules 38) demands for test systems able 
to predict their immunological behaviour. Allergen-specific tg T-cells might represent 
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such a standardizable tool to e.g. test for retained T-cell reactivity of 
modified/recombinant allergens.  
In addition, the Ii-based sensitization strategy, 24 which we adapted for allergenic peptides 
in this report, might prove to be useful to define by recombinant DNA-technology altered 
peptide ligands (APL) of immunodominant allergens. Conventionally, APL are created by 
introducing single amino acid changes into peptide-ligands of MHC, generating peptides 
able to influence autoimmune diseases but also allergies. 39-42 The Ii-based allergen 
(peptide) expression system in combination with e.g. error-prone PCR approaches 43 might 
serve as a novel high-throughput screening approach for such purposes. 
 
Moreover, expressible allergen-specific TCRs might also lay the ground for the generation 
of valuable in vivo systems in the future, such as TCR tg ‘Allergy-Mice’ based on a 
human disease and based on human immune receptors. ‘Allergy-Mice’ shall represent 
powerful biological systems to analyze T-cell dependent (but also independent) pathways 
influencing allergic diseases with the required profoundness in the future. 
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METHODS 
 
Cell lines and primary cells. 293 cells, 293 OKT3scFv::GPI transfectants, 23 Raji and 
Jurkat clone 41-19 expressing an IL-2 enhancer/promoter driving luciferase were cultured 
as described.23 Art v 1-specific T-cell lines, T-cell clones, and immortalized B-cells were 
established from PBL of mugwort pollen allergic individuals with typical clinical history 
and positive skin prick tests to mugwort pollen extract as described. 22 The TCR gene 
usage was determined by RT-PCR with TRAV and TRBV primers (Clonetech, 
Heidelberg, Germany) as described. 22 
 
Cloning and Characterization of αβ TCRs. mRNA from the Art v 1-specific TH0-cell 
clone SSR20, which upon antigen-specific stimulation produced 22 pg/ml IL-4 and 75 
pg/ml IFN-γ, was amplified with: TRAV17-for: 5’-
CGCGGGAAGCTTGCCACCATGGAAACTCTCCTGGGAGTG-3’ and TRAC-rev: 5’-
CCCGCGGCGGCCGCTTTAGCTGGACCACAGCCGC-3’, or 
TRBV18-for: 5’-CGCGGGAAGCTTGCCACCATGGCCAACTCTGCTATGGAC-3’ 
and TRBC-rev: 5’-CCCGCGGCGGCCGCTTTAGAAATCCTTTCTCTTGACCATG-3’, 
digested with Nco I (bold) and Not I (underlined) and gel-purified. DNA-fragments were 
ligated into the retroviral expression vector pMMP412 (R.C. Mulligan, Childrens 
Hospital, Boston, MA) and DNA-sequenced (VBC Genomics, Vienna, Austria). 
 
Cloning of HLA-DR constructs. SSR (EBV immortalized B-cells) mRNA was amplified 
with: HLA-DRA-for: 5’-
CGCGGGAAGCTTGCCACCATGGCCATAAGTGGAGTCCC-3’ and  HLA-DRA-rev: 
5’-CCCGCGGCGGCCGCTTTACAGAGGCCCCCTGCG-3’; or HLA-DRB1*0101-for: 
5’-CGCGGGAAGCTTGCCACCATGGTGTGTCTGAAGCTCCC-3’ and HLA-
DRB1*0101-rev: 5’-CCCGCGGCGGCCGCTTTAGCTCAGGAATCCTGTTGGCT-3’, 
digested with Hind III (bold) and Not I (underlined) and gel-purified. DNA-fragments 
were ligated into pEAK12 expression vector (EdgeBio, Gaithersburgh, ME) and DNA-
sequenced. 
 
Generation of invariant chain constructs. pcDNA1.1/Amp containing an Ii with a Sfu I – 
Eco 47III cassette instead of CLIP was kindly provided by J. vanBergen 
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(Immunohematology and Blood Transfusion, Leiden, The Netherlands). 24 Double 
stranded Art v 125-34 oligonucleotides: Art v 125-34-upper: 5’-
CGAAGTGCATCGAGTGGGAGAAGGCCCAGCACCAGGC-3’, Art v 125-34-lower: 5’-
GCCTGGTGCTGGGCCTTCTCCCACTCGATGCACTT-3’ were inserted into Sfu I/Eco 
47III digested pcDNA1.1/Amp-Ii. CLIP and HA309-317 containing Ii were constructed as 
described. 24 Length variants of Art v 1 were constructed by PCR using humArt v 1 25 as 
template amplification with the following primers: humArt v 11-109-for: 5’-
CGCGGGTTCGAAGATGGCCGGCAGCAAGCTG-3’, humArt v 11-109-rev: 5’-
GGGCGCGGGCAGCGCTTGGTGGGTGCTGGGGGG-3’; 
humArt v 115-50-for: 5’-CGCGGGTTCGAAGAGCGGCAAGTGCGACAACAAG-3’, 
humArt v 115-50-rev: 5’-
GGGCGCGGGCAGCGCTTGGCAGAAGCAGCTCTCCTTGCC-3’; 
humArt v 120-45-for: 5’-CGCGGGTTCGAAGAACAAGAAGTGCGACAAGAAG-3’, 
humArt v 120-45-rev: 5’-GGGCGCGGGCAGCGCTTGCTTGCCGGCCTCCCGCTT-3’; 
humArt v 11-57-rev: 5’-GGGCGCGGGCAGCGCTTGGCTCTTGCTGCAGTCGAAGTA-
3’. After PCR amplification, digestion and gel-purification, the DNA-fragments were 
ligated into the pcDNA1.1/Amp-Ii expression vector followed by DNA-sequencing (VBC 
Genomics). 
 
Transduction of αβ TCRs into Jurkat and PB T-cells. Amphotropic TCRαβ delivering 
retroviruses were produced by transient transfection using standard procedures. 26 Briefly, 
293 OKT3scFv were transfected with pMD.gagpol (Moloney murine leukemia virus 
(MoMLV) gag-pol) pMD-VSV-G (Vesicular stomatitis virus protein G; both provided by 
Dr. R.C Mulligan) 27, pMMP412.TRAV17 and pMMP412.TRBV18. Alternatively, 
pMMP412.GFP was used as control. Jurkat clone 41-19 or PB T-cells were transduced 
with viral supernatant in the presence of 8 µg/ml polybrene (Sigma, St. Louis, MO). Prior 
to transduction PB T-cells were pre-stimulated with anti-CD3/CD28 substituted 
microbeads (Dynabeads, Dynal Biotech) and optionally with 300 U/ml IL-2 (Peprotech, 
London, UK). Jurkat clones were obtained by limiting dilution.  
 
Immunofluorescence analyses. MAbs CD3-FITC (UCHT1), pan TCRαβ-PE (BMA031), 
CD2-FITC (TS2.18), CD4-FITC (VIT4), CD8-PE (VIT8b) and control Ig FITC and PE 
were obtained from ADG (Kaumberg, Austria). TCR Vβ8-FITC (56C5) and TCR Vβ18-
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PE (BA62) were from Immunotech (Marseille, France). HLA class II-FITC (1/47) and Ii-
FITC (5-329) were provided by O. Majdic (Institute of Immunology, MUV, Vienna, 
Austria). Surface and intracellular staining as well as flow cytometric analyses were 
performed as described. 28 For tetramer staining Jurkat cells (4 x 105) were incubated with 
4 µl of PE-labelled DRB1*0101/Art v 1 peptide specific tetramer (Beckman Coulter, 
Marseille, France) containing Art v 119-36 (NKKCDKKCIEWEKAQHGA) at 37°C in the 
dark for 2 hours, washed once and fixed in 200 µl of 0.5 % paraformaldehyde-PBS at 
room temperature for 1 hour followed by immediate flow cytometric analysis.  
 
Jurkat luciferase activity assays. SSR EBV immortalized B-cells (5 x 104, HLA-
DRB1*0101+) were pre-incubated with the peptides (3 x 10-5M) Art v 119-30, Art v 125-36, 
Art v 194-105, influenza HA306-318 or medium alone, respectively, for three hours. 
Subsequently, TCR tg Jurkat cells or wt Jurkat cells (1 x 105) were added and co-cultured 
with pre-sensitized, syngeneic EBV cells or peptide alone for 6 hours. Alternatively, 
aAPC (5 x 104) expressing HLA-DR1, CD54, CD80 and Ii constructs served as 
stimulators. Staphylococcal enterotoxin E (SEE, 0.3 x 10-6M, Toxin Technologies, 
Sarasota, FL) or PHA (5 µg/ml) plus PMA (10-7 M) served as positive controls. Luciferase 
activity was assayed as described. 28 
 
Generation of aAPC. 293 cells (3 x 106) were transiently co-transfected  with HLA-
DRA*0101, HLA-DRB1*0101, CD54, CD80, cathepsin S 28 and Ii constructs or empty 
control vector in combinations as indicated and used 72 hours after transfection. 
 
T-cell proliferation assays. TCR tg T-cells (5 x 104/well) were incubated with aAPC (5 x 
104/well, irradiated with 60 Gy) expressing HLA-DRA*0101, HLA-DRB1*0101, Ii::Art v 
125-34, Ii::HA309-317, CD80, CatS combined as indicated in 96-well flat bottom tissue 
culture plates for three days. Cells were pulsed with methyl-[3H]-thymidine (1 µCi/well) 
for another 18 h and processed as described. 23 Medium alone or anti-CD3/CD28 
microbeads (5 x 104) served as controls.  
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ABBREVIATIONS: 
APC: antigen presenting cell; aAPC: artificial antigen presenting cell; AU: arbitrary 
unit; CD: cluster of differentiation; CDR: complementarity determining region; CLIP: 
Class II associated invariant chain peptide; GFP: green fluorescent protein; HA: 
Influenza hemagglutinin; HLA: human leukocyte antigen; Ii: invariant chain; IL: 
interleukin; kcpm: kilo counts per minutes; MHC: major histocompatibility complex; PB: 
peripheral blood; PBL: peripheral blood lymphocytes; PHA: phytohemagglutinin; PMA: 
phorbol myristate acetate; RT-PCR: reverse transcriptase polymerase chain reaction; SD: 
standard deviation; SEE: Staphylococcal enterotoxin E; SI: stimulation index; TCR: T-
cell receptor; tg: transgenic; wt: wild type 
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ABSTRACT 
Background: TH2 lymphocytes play an important role in the induction and maintenance 
phase of type I allergy. Modulation of the responses of TH2 lymphocytes by novel forms 
of antigen-presenting platforms may help shape the immune response to allergen and 
palliate allergic diseases. Objective: To present HLA class II/allergen-peptide complexes 
on virus-like particles (VLPs) and to evaluate their potential to modulate allergen-specific 
T-cell responses. Methods: Virus-like particles that express the immunodominant T-cell 
epitope Art v 125-34 of the major mugwort pollen allergen in the context of HLA-DR1 
and costimulatory molecules were produced by transfection of 293 cells. The effect of 
VLPs on IL-2 promoter activity, proliferation, and cytokine production of allergen-
specific T cells derived from donors with and without mugwort pollen allergy was 
determined. Results: Flow-cytometric analyses showed that HLA class II molecules, 
invariant chain::Art v 1 fusion proteins, and costimulatory molecules were expressed on 
293 cells. Biochemical analyses confirmed that these molecules were efficiently targeted 
to VLPs. The engineered VLPs activated Art v 1–specific T cells in a costimulation-
dependent manner. VLPs lacking costimulators induced T-cell unresponsiveness, which 
was overcome by addition of exogenous IL-2. Costimulation could be provided by CD80, 
CD86, or CD58 and induced distinct cytokine profiles in allergen-specific T cells. Unlike 
the other costimulatory molecules, CD58 induced IL-10/IFN-γ–secreting T cells. 
Conclusion: Virus-like particles represent a novel, modular, acellular antigen-presenting 
system able to modulate the responses of allergen-specific T cells in a costimulator-
dependent fashion. Allergen-specific VLPs show promise as tools for specific 
immunotherapy of allergic diseases. 
 
Key words: Artificial APC; Art v 1; HLA class II; mugwort pollinosis; T-cell modulation; 
costimulation; TCR tg T cells; type I allergy; virus-like particles 
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INTRODUCTION 
T lymphocytes play an important role in the pathogenesis of allergic diseases by providing 
TH2 cytokines that promote class switching to the ε immunoglobulin heavy chain in B 
cells and by contributing to late-phase reactions and allergic inflammation in target organs 
(1). Among other factors (eg, amount of allergen, cytokine milieu, and genetic background 
of the patient) T-cell activity is strongly influenced by the functional properties of antigen-
presenting cells (APCs) (2). In fact, the delicate balance between the MHC/peptide 
complex (signal 1) and costimulatory or inhibitory molecules (signal 2) for T-cell 
activation provided by APCs decides whether a specific T cell responds or remains 
unresponsive to antigen (3). Thus, APCs or derivatives thereof represent important tools to 
study activation and/or modulation of allergen-specific T cells to develop efficient 
strategies for allergen-specific immunotherapy (4, 5).  
The numerous activating and inhibitory molecules described on natural APCs (6, 7, 8) 
make their net effect not easy to predict and direct. Therefore, reductionist antigen-
presenting systems gained attractiveness during the last few years. For example, exosome-
based vesicular systems able to activate allergen-specific T lymphocytes have been 
described (9). However, exosome secretion from APCs occurs in a constitutive fashion, 
and their composition and especially their donor-dependent HLA allotypes are not easily 
modifiable (10). In contrast, recently we have devised a more flexible system consisting of 
inducible immunostimulatory virus-like particles (VLPs), which we refer to as 
immunosomes (11, 12). VLPs are released from 293 cells expressing Moloney murine 
leukemia virus (MoMLV) core proteins group-specific antigen/polymerase (gag/pol) (11) 
and preferentially incorporate extracellular and intracellular constituents of host cells, a 
phenomenon central to pseudotyping (13). We have shown that immunosomes can 
activate naive, antigen-specific CD8+ T lymphocytes and induce their differentiation to 
cytotoxic effector cells (11).  
In the current study, we asked whether HLA class II–restricted immunosomes could be 
generated by a comparable approach and whether omission of costimulatory elements 
would render VLPs able to induce allergen-specific T-cell unresponsiveness. Furthermore, 
we studied the impact of different costimulatory molecules expressed on allergen-
presenting VLPs on IL-2 promoter induction, proliferative responses, and cytokine 
responses of allergen-specific T cells. As a clinically relevant, molecularly well defined 
disease model, we chose mugwort (Artemisia vulgaris) pollen allergy. Mugwort is widely 
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spread in the northern hemisphere and is one of the main causes of hay fever in late 
summer and autumn. More than 95% of patients with mugwort allergy are sensitized to 
Art v 1, the major mugwort pollen allergen (14). Using a large panel of Art v 1–specific T-
cell lines generated from peripheral blood (PB) of patients with mugwort allergy, we have 
identified a single immunodominant epitope, Art v 125-36, that is preferentially presented 
by HLA-DRB1*01 (15, 16, 17). Moreover, we have recently cloned and characterized an 
Art v 1–specific T-cell receptor (TCR), which allows us to investigate cell fate and 
phenotype decisions in PB T cells of individuals without allergy instead of using 
repeatedly stimulated T-cell lines or clones from individuals with allergy (18).  
To the best of our knowledge, this is the first description of artificially induced, HLA class 
II restricted microvesicles (VLPs) able to modulate allergen-specific T-lymphocyte 
responses. Allergen-specific VLPs shall allow us to gain deeper insights into the 
pathophysiology of allergic diseases and to devise novel therapeutic approaches for the 
treatment of type I allergies. 
 
RESULTS 
Generation of HLA class II/allergen peptide–expressing 293 cells.  
First, producer cells for VLP generation were established and characterized. For the 
delivery of the antigen-specific signal 1 to CD4+ T cells, the HLA-DRA*0101/HLA-
DRB1*0101 heterodimer was expressed in 293 cells, which lack constitutive HLA class II 
and Ii expression (Fig 1). Surface expression of HLA class II molecules was observed 
when both DRA- and DRB-chains were coexpressed (Fig 1). Peptide-loading of HLA 
class II molecules was achieved by an Ii-based approach (18, 19). Cytoplasmic expression 
of control (Ii::class II associated Ii peptide) or allergen-specific (Ii::Art v 125-34) Ii was 
clear-cut in the absence of HLA class II coexpression (21). Coexpression of Ii did not 
significantly alter expression levels of HLA class II heterodimers (n = 5; P = .31, Mann 
Whitney U test, 2-tailed) (21), whereas HLA class II molecules reduced Ii levels by 
approximately 50% (P < .01). Additional coexpression of molecules providing second 
signals such as CD80::GPI (Fig 1) or CD86::GPI and CD58::GPI (not shown) did not 
influence HLA class II (n = 6; P = .70, Mann Whitney U test, 2-tailed) or Ii expression 
levels (n = 4; P = .77). 
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Fig 1. Expression levels of HLA class II 
molecules, Ii constructs, and CD80 on 
293 producer cells. The 293 cells 
transiently transfected with the indicated 
constructs were subjected to surface 
(HLA-DR, CD80) or intracellular (Ii) 
staining followed by flow-cytometric 
analysis. Histograms compare non-
binding control (thin lines) and specific 
mAb (thick lines) binding. Data show 
one representative experiment (n ≥ 4). 
Numbers indicate geometric mean 
fluorescence intensity. 
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VLPs are efficiently decorated with HLA class II and costimulatory molecules.  
Next, we assessed targeting of HLA class II and costimulatory molecules to VLPs. 
Transfected 293 producer cells as well as the MoMLV gag/pol–induced VLPs expressed 
HLA class II.  
 
Fig 2. Biochemical characteristics of HLA class II–expressing VLPs. The 293 cells were transfected with 
the indicated constructs or control plasmid (GFP). Cell lysates and corresponding cell culture supernatants 
(VLPs) were analyzed by SDS-PAGE followed by immunoblotting (IB) with HLA class II or CD80 mAbs. 
Vesicle induction and loading were controlled by detection of viral core protein p30Gag. Data show one 
representative experiment (n = 5). 
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molecules and CD80::GPI (Fig 2), CD54::GPI, CD86::GPI, and CD58::GPI (not shown), 
whereas lysates of control transfected 293 cells and their corresponding supernatants wer 
consistently negative for HLA class II and CD80 expression. A considerable fraction of 
the HLA class II molecules was organized as αβ-heterodimers on VLPs as demonstrated 
by binding of the conformation-dependent HLA class II mAb 8-79. In general, HLA class 
II expression levels on VLPs were comparable to lysates of 293 cell transfectants, lysates 
of HLA-DR1+ EBV-transformed B cells, and their corresponding exosome preparations. 
Immunoblotting for p30Gag and HLA class II demonstrated that cotransfection of 
CD80::GPI changed neither HLA class II expression levels nor VLP amounts produced. 
HLA class II/Art v 125–34–decorated VLPs activate TCR tg allergen-specific Jurkat T 
cells in a costimulation-dependent manner 
 
HLA class II/Art v 125–34–decorated VLPs activate TCR tg allergen-specific Jurkat T 
cells in a costimulation-dependent manner.  
To investigate whether HLA class II–decorated VLPs are functional, their ability to 
activate IL-2 promoter activity in Art v 1–specific TCR tg Jurkat T cells was tested (18). 
Significantly, the VLP preparations expressing Ii::Art v 125-34 in the context of HLA-
DRA*0101/-DRB1*0101 stimulated Jurkat T cells in a costimulation-dependent manner, 
similar to producer cells (Fig 3, A and B; P < .001). PMA plus PHA stimulation served as 
an independent positive control. Apart from CD80::GPI, IL-2 promoter activity was also 
strongly induced by CD86::GPI, but only weakly by CD58::GPI (not shown). In contrast, 
wild-type Jurkat T cells expressing the endogenous TCR remained unstimulated by Art v 
1–specific VLPs (not shown). Moreover, VLPs coexpressing Ii::influenza hemagglutinin 
309-317, used as an irrelevant HLA-DRA*0101/-DRB1*0101–restricted binding control, or 
VLPs, in which peptide loading was attempted by Art v 1–minigenes, were unable to 
stimulate Art v 1–specific TCR tg Jurkat T cells (not shown). Immunoblotting for p30Gag 
revealed that VLP preparations used for stimulation of Jurkat T cells contained 
comparable amounts of particles (Fig 3, C). 
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VLPs decorated with HLA class II/Art v 125-34 complexes activate allergen-specific T-
cell clones and TCR tg PB T cells.  
Next, VLPs were tested for their potential to induce proliferation of allergen-specific T 
cells. For that purpose, Art v 1–specific T-cell clones from individuals with mugwort 
pollen allergy or TCR tg PB T cells of individuals without  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. HLA class II/allergen peptide–decorated VLPs activate TCR tg Jurkat T cells. Art v 1–specific 
TCR tg Jurkat T cells harboring an IL-2 promoter/enhancer driving luciferase expression were 
coincubated with VLPs (A) or 293 producer cells (B) expressing the indicated molecules. PMA/PHA was 
used as positive and GFP transfection as negative control. Data show mean + SD of triplicate cultures of 1 
representative experiment (n = 3). ***P < .001, Student t test, paired, 2-tailed. C, Vesicle induction and 
loading were controlled by detection of viral core protein p30Gag. AU, Arbitrary units. 
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allergy were incubated with VLPs expressing HL A-DRA*0101, -DRB1*0101, Ii::Art v 
125-34, CD80::GPI, and CD54::GPI in combinations as indicated. In fact, VLP induced 
similar levels of T-cell proliferation in T-cell clones or TCR tg PB T cells compared to 
allergen-presenting 293 cells or microbeads coated with CD3 plus CD28 mAbs as 
stimulators (Fig 4, A and B). Similar to the IL-2 promoter assays described, induction of 
T-cell proliferation was significantly dependent on the presence of costimulatory 
molecules (P < .01 and P < .001, respectively): VLPs providing the antigen-specific signal 
1 alone were unable to induce T-cell proliferation, similar to nondecorated VLPs or 
medium alone. Apart from CD80::GPI, costimulation could also be provided by 
CD86::GPI (P < .001), the second ligand for CD28, or CD58::GPI (P < .001), the CD2 
ligand (22), but not by the adhesion molecule CD54::GPI. Furthermore, restimulation of 
bulk TCR tg PB T cells with Art v 125-34–specific VLPs coexpressing CD80::GPI and 
CD54::GPI and supplemented with IL-2 (100 U/mL) led to a 52.8 ± 11.8-fold expansion 
(n = 6) of T lymphocytes within 3 weeks (Fig 4, C). During the culture period, the fraction 
of allergen-specific Vβ18-expressing T cells within the bulk transfectants increased from 
29% to 84%. 
 
Induction of specific unresponsiveness by HLA class II/Art v 125-34–expressing VLPs 
lacking costimulatory molecules.  
In addition to activation/expansion of allergen-specific T cells, VLPs might be useful for 
anergizing such T cells. In proof of principle experiments, we observed that in primary 
cultures, allergen-specific T cells from HLA-DR1+ individuals with (Fig 5, A) or without 
(Fig 5, B) mugwort pollen allergy cocultivated with VLPs expressing signal 1 but no 
costimuli did not proliferate (P < .01 and P < .001, respectively), similar to cells cultivated 
with medium alone. Moreover, allergen-specific T cells treated in such a way were unable 
to proliferate in secondary cultures supplemented with anti-CD3/CD28–coated microbeads 
(P < .001). T-cell unresponsiveness could, however, be overcome by the addition of 
saturating concentrations of IL-2 (500 U/mL; P < .001), indicating that the cells were 
anergic but still alive. In marked contrast, T cells that received both signal 1 and 2 during 
the primary stimulation proliferated also after secondary stimulation (Fig 5, A and B). 
 
 
 
Klaus Schmetterer                                                                                                    Chapter 3 
 
      
 102  
 
 
Fig 4. Art v 1–specific VLPs activate allergen-specific T-cell clones and TCR tg PB T cells. VLPs decorated 
with the indicated molecules were incubated with an Art v 1–specific T-cell clone (A) or TCR tg PB T 
lymphocytes (B). CD3/CD28 mAb–coated microbeads or culture medium alone served as positive and 
negative controls, respectively. Cell proliferation is shown (mean + SD of triplicates; n = 3). **P < .01, ***P 
< .001, Student t test, paired, 2-tailed. C, Bulk TCR tg PB T cells (12 ? 106) stimulated 3 times (arrows) with 
Art v 1–specific VLPs and supplemented with IL-2 were cultured for 24 days, and total cell numbers were 
determined at different time points (squares). Insert compares flow-cytometric characteristics of starting 
culture (day 0) with cells obtained after 24 days. Numbers of CD3+/TCRV?18+ cells (not, vert, similar 2% in 
PB T cells) are indicated. Data show one representative experiment (n = 6). kcpm, Kilo counts per minute. 
 
View Within Article 
 
 
 
Klaus Schmetterer                                                                                                    Chapter 3 
 
      
 103  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allergen-specific VLPs expressing various types of costimulatory molecules modulate the 
cytokine profiles of allergen-specific T cells differently.  
In a final step, we investigated whether the expression of distinct costimulatory molecules 
on allergen-specific VLPs has a decisive impact on the cytokine profiles of TCR tg 
allergen-specific T cells from HLA-DR1+ individuals with and without mugwort pollen 
 
Fig 5. Induction of allergen-specific unresponsiveness by VLPs. Proliferation of TCR tg PB T cells from an 
individual with mugwort pollen allergy (A) and an individual without allergy (B) cultured with indicated 
primary stimuli for 4 days is shown (gray bars). Proliferation of T cells obtained on culture with indicated 
stimuli for 10 days, washed, and recultured with CD3/CD28 mAb–coated microbeads in the absence (white 
bars) or presence (black bars) of exogenous IL-2 (500 U/mL) is demonstrated. Data show one representative 
experiment (n = 4). ***P < .001, **P < .001, Student t test, paired, 2-tailed. kcpm, Kilo counts per minute. 
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allergy. Compared with signal 1 alone, allergen-specific VLPs coexpressing CD80::GPI 
induced significant levels of IFN-γ (P = .006), IL-13 (P = .002 and P < .001), and IL-2 (P 
= .001), whereas no IL-4 and only minute amounts of IL-10 were detectable (Fig 6, A and 
B). CD86::GPI induced a similar cytokine pattern, although IL-2 levels were lower.  
 
 
 
 
 
 
 
In marked contrast, CD58::GPI induced highly significant levels of IFN-γ (P = .002 and P 
< .001) and IL-10 (P = .001 and P < .001), whereas IL-2 and IL-13 levels were low, and 
IL-4 remained undetectable. Moreover, T-cell proliferation was high in the presence of 
either of the costimulators (P < .001 and P < .01, respectively), whereas proliferation 
Fig 6. Nature of the costimulatory molecule present on VLPs affects the cytokine profile of allergen-specific 
T cells. (A and B) Cytokine profiles and (C and D) proliferation of TCR tg allergen-specific PB T cells from 
an individual with mugwort pollen allergy (A and C) and an individual without allergy (B and D) upon 
incubation with VLPs expressing the indicated combinations of molecules. One representative experiment is 
shown (n = 5). ***P < .001, **P < .001, Student t test, paired, 2-tailed. kcpm, Kilo counts per minute; conc, 
concentration; n.d., not determined. 
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remained undetectable when cells received signal 1 alone (Fig 6, C and D). Thus, VLPs 
decorated with different flavors of costimulatory molecules might represent novel tools for 
the modulation of allergen-specific T-cell function. 
 
DISCUSSION 
In this study, we have devised a novel, acellular, antigen-presenting platform—VLPs—
and examined its potential to modulate allergen-specific T-cell responses. As a model for 
stimulation/modulation of HLA class II–dependent immune responses, we have used the 
immunodominant epitope of Art v 1, the major mugwort pollen allergen. To decorate VLP 
with T-cell ligands of choice, we have built on the recently elucidated mechanisms 
responsible for viral pseudotyping (13, 23-25), which we have successfully explored for 
the generation of MHC class I–expressing VLPs (immunosomes) in the past (11). We 
show that HLA-DR1/Art v 125-34–presenting VLPs, which coexpress CD80, induce 
vigorous T-cell activation even in the absence of natural APCs. In contrast, omission of 
costimulatory molecules rendered VLPs with anergizing potential for Art v 1–specific T 
cells. We also demonstrate that depending on the costimulator expressed on VLPs, 
allergen-specific T cells can be instructed to secrete different cytokine profiles. Similar to 
MHC class I–decorated VLPs (11), HLA class II–decorated VLPs are robust and can be 
prepared in a reproducible manner (not shown). 
T-cell activation is a delicately balanced process that involves the TCR and HLA/peptide-
complex (signal 1) as well as a variety of accessory molecules expressed on T cells and 
APCs (signal 2) (3). VLPs expressing signal 1 (HLA-DR1/Art v 125-34) alone induced 
unresponsiveness of Art v 1–specific T cells. This unresponsiveness could be overcome by 
addition of IL-2, which is in line with the functional definition of anergic cells (26, 27). 
 
What could be advantages of VLPs expressing preformed HLA/allergenic peptide-
complexes over other systems to influence allergen-specific T-cell function? A special 
advantage of the VLP platform is its modular nature, allowing accommodation of 
immunoregulatory molecules of choice adjacent to the HLA/allergenic peptide complex. 
Coexpression of the CD28 ligands CD80 or CD86 on allergen-specific VLPs induced 
clear-cut levels of IFN-?, IL-2, and IL-13, compatible with previous reports (28, 29), 
which allows strong expansion of specific T cells for further studies. In contrast, CD58 
expression on allergen-specific VLPs induced IL-10/IFN-?–secreting T cells, whereas 
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IL-2, IL-4, and IL-13 levels remained low. The cytokine profile obtained upon CD58 
costimulation is reminiscent of T-regulatory cells described by Groux et al (30). The same 
group described efficient induction of polyclonal IL-10/IFN-?–secreting T cells on 
triggering of the CD58/CD2 axis (31). Of clinical importance in that context are the 
reports describing induction of IL-10 and/or IFN-?–secreting T cells on allergen-specific 
immunotherapy (32-35). These findings have been further substantiated by reports 
demonstrating the preferential presence of IL-10 and/or IFN-?–secreting T cells in 
healthy individuals without allergy (36, 37). Our results obtained with allergen-presenting 
VLPs coexpressing CD58 suggest an important role of the CD58/CD2 signaling axis for 
the induction of allergen-specific IL-10/IFN-?–secreting T cells. On the other hand, the 
data imply that colocalization of distinct T-cell ligands on allergen-specific VLPs might be 
a valid strategy to modulate the function of allergen-specific T cells in future 
immunotherapy protocols. However, future studies will have to assess the detailed 
function and the reason for the pronounced proliferative behavior of the IL-10/IFN-?–
secreting T cells described. Moreover, because CD58/CD2 signaling also seems to 
augment T-cell responsiveness for distinct cytokines (38), it will be interesting to examine 
the impact on allergen-specific T cells of membrane-bound cytokines (12) expressed on 
VLPs. Of importance, we have recently confirmed the in vivo functionality of cytokine-
decorated VLPs in an antigen-specific, T-cell–dependent system (12). 
A further possible advantage of the VLP platform is the fact that peptide association with 
HLA class II molecules does not occur randomly. Instead, we have successfully adapted 
an Ii-based peptide delivery system (18, 20) guiding allergenic peptides into the endo-
/lysosomal compartment responsible for HLA class II peptide loading (MIIC) (39). The Ii-
based approach turned out to be superior to “minigene” approaches (11, 40), in which 
strong eukaryotic signal sequences were hooked up to the allergenic peptide sequence with 
the aim of delivering high concentrations of the peptide into the endoplasmic reticulum of 
the Ii negative 293 cell (not shown). Possible clinical applications of VLPs will be 
facilitated by the fact that the producer 293 cells used in this study (41) are suitable for 
large-scale, good manufacturing practice-adapted production and have been successfully 
used to prepare retroviruses and adenoviruses for clinical use in the past (42-43). 
That VLPs are potent inducers of B-cell–specific immune responses, even when applied 
via different routes (45), has been described in several studies in the past (46). In fact, 
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hepatitis B surface antigen (47), human papilloma (48, 49), and Norovirus (50) capsid 
proteins that assemble particles of defined icosahedral symmetry are currently clinically 
used as vaccine antigens. In the more recent past, chimeric VLPs used as platforms and 
chemically conjugated with antigens of microorganisms or allergens have been 
manufactured and successfully applied in vivo, as demonstrated by their induction of 
protective IgG antibodies (46, 51). Hence, with the exception of the antiviral influenza 
(52) and HIV approaches (53), VLP platforms studied so far mostly relied on 
nonenveloped viral cores. Although these particles either had intrinsic antiviral 
immunogenicity or became chemically coupled with antigens of interest, none of the 
approaches intended to target T cells with preformed HLA/peptide complexes of choice 
directly. 
In summary, we have shown that, in contrast with exosomes (54, 55), the molecular 
composition of VLPs can be designed easily at the level of producer cell transfection, 
which is particularly important for donor-dependent, allergen-presenting HLA allotypes. 
Furthermore, we present evidence that it is possible to modulate T-cell function directly 
using VLPs as an integrating platform (11), without the need for cross-presentation by 
APCs (56). Hence, the VLP platform permits the application or omission of selected 
costimulation pathways. In contrast with naturally occurring APCs, or exosomes derived 
from APCs, VLPs offer the possibility to modulate allergen-specific T-lymphocyte 
responses differentially in a predictable manner and might thus open new avenues for 
clinical application. 
 
CLINICAL IMPLICATIONS 
VLPs decorated with immune receptors of choice may be new tools for specific 
immunotherapy that offer considerable flexibility to regulate immune responses to 
antigens provoking allergic diseases. 
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MATERIALS AND METHODS 
Cell lines. Human embryonic kidney 293 cells, 293 OKT3scFv::GPI transfectants (11), 
Art v 1 TCR transgenic (tg) Jurkat T cells expressing an IL-2 enhancer/promoter driving 
luciferase (18), and EBV-transformed B cells were cultured as described (11). Art v 1–
specific T-cell clones were established from PBMCs of individuals with mugwort pollen 
allergy with a typical clinical history and positive skin prick test results (≥3 mm diameter) 
to mugwort pollen extract as described (15) (ethics committee approval: EK#497/2005). 
 
Expression constructs. Cloning and characterization of HLA-DR, ?? TCR, invariant 
chain (Ii), CD80::GPI, CD86::GPI, CD58::GPI, CD54::GPI, and green fluorescent protein 
(GFP) constructs has been described previously (18). Art v 1 minigenes were generated by 
inserting synthetic oligonucleotides coding for Art v 1 peptides with Nhe I and Not I 
compatible ends into the expression vector pEAK12 downstream of the CD5 signal 
sequence essentially as described previously (11). 
 
Generation of antigen-presenting 293 cells and VLPs. The 293 cells (3 ? 106) were 
transiently cotransfected with HLA-DRA*0101, HLA-DRB1*0101, CD54::GPI, 
CD80::GPI, CD86::GPI, CD58::GPI, cathepsin S (19), Ii constructs, minigenes, GFP 
control vector, or empty control vector (30 ?g DNA) by the calcium phosphate 
precipitation method in combinations as indicated and used 72 hours after transfection. 
VLP induction was achieved by cotransfection of MoMLV gag/pol (11, 12). Supernatants 
were harvested after 72 hours and cleared from cellular debris by filtration (0.45 ?m). 
VLPs were concentrated by ultracentrifugation at 1 ? 105g for 1 hour, resuspended in 
PBS, and recentrifuged. VLP concentration was determined by Micro BCA assay (Pierce, 
Rockford, Ill). 
 
Immunofluorescence analyses. MAbs CD3–fluorescein isothiocyanate (FITC; UCHT1) 
and control immunoglobulin FITC and phycoerythrin were obtained from ADG 
(Kaumberg, Austria); MAb CD80 (MEM-233) was obtained from Exbio (Praha, Czeck 
Republic), TCR V?18–phycoerythrin (BA62) was obtained from Immunotech (Marseille, 
France); and HLA class II–FITC (1/47), Ii–FITC (5-329), and VIAP-FITC (VIAP) were 
provided by Dr O. Majdic (Institute of Immunology, Medical University of Vienna, 
Austria). Oregon-green conjugated goat-anti-mouse IgG was obtained from Invitrogen 
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(Carlsbad, Calif). Surface and intracellular stainings as well as flow-cytometric analyses 
were performed on a FACS Calibur cytometer (Becton Dickinson, Palo Alto, Calif) as 
described (11). 
 
Biochemical analyses of producer cells and VLPs. Lysates from 293 cell transfectants and 
VLPs were obtained on 1% Nonidet P40 treatment as described previously (11). Cellular 
and VLP proteins, 1 ?g/slot, as determined by Micro BCA protein assay (Pierce) were 
resolved by 4% to 20% SDS-PAGE (Anamed, Darmstadt, Germany), transferred to 
nitrocellulose membranes (Biorad, Hercules, Calif), and probed with HLA class II ?-
chain specific mAb 2-12 and 8-79 (Dr O. Majdic), CD80 specific mAb MEM-233 
(Exbio), and MoMLV p30Gag-specific mAb R187 (ATCC), respectively. Horseradish 
peroxidase–conjugated secondary reagents were from DAKO (Glostrup, Denmark). Blots 
were developed with a luminol-based indicator system (Perkin Elmer, Boston, Mass) and 
exposed to X-ray films (Eastman Kodak, Rochester, NY). 
 
Jurkat luciferase activity assays. TCR tg Jurkat T cells (105/well) were incubated with 293 
cells (5 ? 104/well) or VLPs expressing HLA-DRA*0101, HLA-DRB1*0101, Ii::Art v 125-
34, Ii::influenza hemagglutinin 309-317, Ii::class II associated Ii peptide, Art v 125-34-
minigene, Art v 117-32-minigene, Art v 117-34-minigene, CD80::GPI, CD54::GPI, cathepsin 
S, or GFP combined as indicated in 96-well flat-bottom tissue culture plates for 6 hours. 
PHA (5 ?g/mL) plus phorbol 12-myristate 13-acetate (PMA; 10-7 mol/L) served as 
positive control, and GFP-transfected 293 cells or medium alone served as negative 
control. Luciferase activity was assayed as described (11). 
 
T-cell proliferation assays. Art v 1–specific TCR tg T cells were generated from 
nonallergic and mugwort pollen allergic HLA-DR1 positive individuals as described 
previously (18). Transduction efficiencies of CD3+ T cells were 29.5 ± 9.5% (n = 7). Art v 
1–specific T-cell clones from individuals with allergy or TCR tg PB T cells from 
individuals without allergy (5 ? 104/well) were incubated with irradiated (60 Gy) 293 cells 
(5 ? 104/well) or VLPs (2 ?g/mL) expressing HLA-DRA*0101, HLA-DRB1*0101, 
Ii::Art v 125-34, CD80::GPI, CD86::GPI, CD58::GPI, CD54::GPI, cathepsin S, or control 
plasmid combined as indicated in 96-well flat-bottom tissue culture plates for 3 days. 
During the last 18 hours, [3H]-thymidine (1 ?Ci/well) uptake was determined as 
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described (11). Medium alone or anti-CD3/CD28 microbeads (5 ? 104) served as controls. 
Supernatants from replica plates were harvested after 24 and 48 hours and were subjected 
to cytokine analyses by multiplex analysis using a Luminex 100 apparatus (Luminex, 
Austin, Tex) according to the manufacturers' recommendations. For expansion, TCR tg T 
cells (1 ? 106/well) were incubated in 24-well plates with Art v 1–specific VLPs (2 
?g/mL) coexpressing CD80::GPI and CD54::GPI and supplemented with 100 U/mL IL-2 
on day 0 and restimulated on days 8 and 16 of culture. On days 4, 8, 12, 16, and 20, 
aliquots were counted (Beckman Coulter Z2, Fullerton, Calif) and total numbers of cells 
calculated. 
 
Induction of T-cell anergy. T-cell receptor tg T cells (1 ? 106 cells/well) were cultured in 
24-well plates with VLPs (2 ?g/mL) decorated with the indicated molecules, ionomycin 
(100 ng/mL), anti-CD3/CD28 microbeads (1 ? 106/well) or medium alone for 10 days. 
Proliferation of primary cultures was determined in replica plates containing 1 ? 105 T 
cells and corresponding stimuli. After 10 days, cells from 24-well plates were harvested 
and washed, and 1 ? 105 cells/well were restimulated in 96-well flat-bottom plates with 
anti-CD3/CD28 microbeads (2.5 ? 104) alone or in the presence of IL-2 (500 U/mL) for 4 
days, and proliferation was determined. Culture supernatants of replica plates were 
harvested 24 hours after restimulation, and IL-2, IL-4, IL-10, IL-13, and IFN-? were 
determined by multiplex analysis. T-cell proliferation was measured as described. 
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ABSTRACT 
 
Background: Primary immunodeficiencies (PID) reveal the ‘molecular Achilles’ heels’ of 
human immunity. Detailed analyses of PID extend our knowledge of pivotal 
immunological processes, lead to novel diagnostic algorithms and shortens time-to-
diagnosis. Methods: Clinical/immunological phenotypes of two unrelated combined 
immunodeficiency (CID) patients from Austria were determined. Leukocyte 
subpopulations of patients, their parents and healthy controls were analyzed by flow 
cytometry. Patient-derived EBV transformed B cell lines were established and 
complemented by candidate cDNAs. Suspected mutations were confirmed by DNA 
sequencing. Results: Phenotyping revealed a lack of constitutive HLA class II expression 
on antigen presenting cells of both patients, compatible with MHCII deficiency. Rapid 
vector-based complementation of patients’ B cells identified HLA class II transactivator 
(CIITA)-deficiency in patient VIP1 and restriction factor X(RFX)AP-deficiency in patient 
VIP2. CIITA-deficiency was caused by a homozygous p.Glu381X mutation. RFXAP-
deficiency resulted from a homozygous p.Ser123ThrfsX15 mutation, not described in the 
Middle European population so far. Of note, HLA class II associated invariant chain (Ii) 
expression levels were significantly reduced in VIP1 and three additional EBV 
transformed B cell lines of CIITA deficient patients but normal in VIP2 EBV transformed 
B cells. In addition, peripheral blood B cells of VIP1’ parents showed significantly 
reduced HLA-DR and -DP expression levels compared to healthy controls. Conclusions: 
Analysis of patients’ intracellular Ii and parents surface HLA class II expression levels 
might help to identify CIITA-deficient patients already during initial phenotyping.  
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INTRODUCTION 
 
Human leukocyte antigen (HLA) class II molecules play a central role in the induction of 
adaptive immune responses by displaying extracellular/lysosomal antigens to CD4+ T 
helper lymphocytes [1]. Antigen presenting HLA class II molecules are encoded by a 
group of closely linked genetic loci (named DR, DQ and DP) on the short arm of 
chromosome 6. Constitutive expression of HLA class II heterodimers, consisting of 
polymorphic α- and β-chains, is restricted to professional antigen-presenting cells such as 
dendritic cells, B lymphocytes and cells of the monocytic lineage [2]. HLA class II 
expression can, however, also be induced on various other cell types in response to 
exogenous stimuli such as IFN-γ [3,4].  
 
The HLA class II locus is mainly regulated at the level of transcriptional initiation by four 
cis-acting elements termed W, X1, X2 and Y boxes. They serve as binding sites for 
several transcription factors including the multi-protein regulatory factors binding to the X 
box (RFX), the nuclear factor Y and the cyclic-AMP response element binding protein [5]. 
Additionally, the HLA class II transactivator (CIITA) protein is essential for the initiation 
of transcription serving as a scaffold by linking the above-mentioned factors to the 
transcriptional initiation and elongation machinery [6,7].  
 
HLA class II deficiency, formerly also called Bare Lymphocyte Syndrome II (BLS II), is a 
rare combined immunodeficiency (CID) marked by the complete absence of both 
constitutive and inducible HLA class II expression. Inability to present antigenic peptides 
to CD4+ T helper lymphocytes results in severely impaired adaptive cellular and humoral 
immune responses [8]. As a consequence, MHCII deficiency patients are highly 
susceptible to opportunistic infections with bacterial, viral and fungal pathogens already at 
an early age. Until today, therapy of MHCII deficiency consists of symptomatic antibiotic 
therapy and allogeneic stem cell transplantation [9]. 
 
MHCII deficiency results from mutations in the genes encoding trans-regulatory factors of 
the HLA class II promoter/enhancer [8]. Genetic complementation analyses of patient-
derived cell lines have led to the definition of four complementation groups, i.e. A-D. 
Group A patients carry mutations in the class II transactivator (CIITA) [10]. Mutations of 
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RFXANK (group B) [11,12], RFX5 (group C) [13] and RFXAP (group D) [14], constitute 
the remaining complementation groups.  
 
Here we describe the immunological phenotype and the molecular characteristics of two 
unrelated, recently identified MHCII deficiency patients from Austria who clinically 
presented as CID in their early months of life. Moreover, we present evidence that 
phenotypic analyses of a) intracellular invariant chain (Ii) expression levels of patient-
derived EBV transformed B cells as well as b) HLA class II expression levels on B cells 
and monocytes of the patients’ parents might help to assign patients to distinct 
complementation groups. 
Klaus Schmetterer                                                                                                    Chapter 4 
 
      
 119  
MATERIALS AND METHODS 
 
Patients  
The female patient VIP1 was born with normal birth weight to unrelated healthy parents of 
Austrian origin. VIP1 was hospitalized with six months due to acute viral bronchiolitis and 
pneumonia requiring artificial respiration. A hypoxia-induced cerebral atrophy was 
diagnosed resulting in a hydrocephalus e vacuo accompanied by tetraparesis and visual 
impairment. Immunologic evaluation revealed hypogammaglobulinaemia with leukocytes 
and leukocyte-subset numbers within the normal range (table 1). The CD4/CD8-ratio was 
inverted (0.22) with only 660/µl of CD4+ T cells indicating a dysregulation within the T 
cell compartment. PBMC of VIP1 reacted robustly but significantly lower than control 
PBMC to the HLA class II-independent stimuli PHA and PMA, while no proliferation was 
observed with superantigens SEA and SEB, indicating a defect in the HLA Class II – T 
cell receptor interaction (table 2). In addition, soluble CD3 mAb-induced proliferation was 
strongly reduced (10% of control). 
 
The male patient VIP2 was born after 41 weeks of gestation to unrelated healthy parents 
of Austrian origin and a healthy sibling of 3 years. VIP2 developed obstructive bronchitis 
at 2 months of age followed by recurring respiratory infections. A pneumocystis jirovicii 
pneumonia, which was exacerbated by cytomegalo- and adenovirus infections required 
hospitalization of VIP2. Immunological examination revealed marked 
hypogammaglobulinaemia and leukocyte, monocyte and lymphocyte numbers below the 
age-specific normal range (table 1). The CD4/CD8 T lymphocyte ratio was inverted with 
0.50 due to severe CD4+ T-lymphopenia (80/µl). Proliferation of peripheral blood T cells 
was comparable to the healthy control upon polyclonal stimulation with PHA, but clearly 
reduced to absent upon stimulation with PMA, soluble CD3 mAb or HLA class II-
dependent superantigens (table 2). 
 
Cell lines  
The 293 cell line (human embryonic kidney epithelial cells) was maintained in IMDM 
(Sigma Chemicals, St.Louis, MO) plus 10% fetal calf serum (Invitrogen, Carlsbad, CA) 
supplemented with 2 mM L-Glutamine, 50 µM 2-mercaptoethanol and 15 µg/ml 
gentamycin sulfate. Peripheral blood mononuclear cells (PBMC) were isolated from 
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heparinized blood by standard Ficoll density gradient centrifugation using Lymphoprep 
(Technoclone, Vienna, Austria). EBV transformed lymphoblastoid B cell lines (EBV B 
cells) were generated by supplementing PBMC with infectious Marmosett P95-8 
supernatant plus 200 ng/ml cyclosporine A (Sandimmune, Novartis, Vienna, Austria). 
After two weeks of incubation cells were washed, re-plated and further cultured in RPMI 
1640 medium supplemented with 10% fetal calf serum, 2 mM L-Glutamine and 100 µg/ml 
gentamycin sulfate. EBV B cell lines BLS-1 (RFXANK deficient), BLS-2 and BCH 
(CIITA deficient) and SJO (RFX5 deficient) were kindly provided by Dr. Walter Reith, 
Department of Pathology and Immunology, University of Geneva Medical School, 
Geneva, Switzerland. All cell lines were incubated at 37°C in 5% CO2.  
 
Expression constructs 
pEBO-CIITA, an SV40 promoter-driven eukaryotic expression vector containing the full 
length CIITA cDNA was a kind gift from Dr. Bernhard Mach (Geneva, Switzerland). The 
human RFXANK, RFX5 and RFXAP specific cDNAs were amplified with the respective 
primer pairs RFXANKfor (5’-CGCGGGAAGCTTGCCACCAT 
GGAGCTTACCCAGCCTGCAGAA-3’) and RFXANKrev (5’-CCCGCGGCGG 
CCGCTTTACTCAGGGTCAGCGGGCAC-3’), RFX5for (5’-CGCGGGAAGC 
TTGCCACCATGGCAGAAGATGAGCCTGATGCTAA-3’) and RFX5rev (5’-
CCCGCGGCGGCCGCTTTATGGGGGTGTTGCTTTTGGGTCTTTA-3’) and RFXAP 
for (5’-CGCGGGAAGCTTGCCACCATGGAGGCGCAGGGTGTAGCGGAGG-3’) and 
RFXAPrev (5’-
GCGCCCGTTAACTTTACATTGATGTTCCTGGAAACTGCTGTTGTC-3’) from a 
human dendritic cell cDNA library [15]. At the 5’-end of the cDNAs optimized 
translational initiation sites preceded by a Hind III restriction site were generated. 3’-ends 
were modified by an optimized TAAA STOP codon followed by a Not I restriction site 
(RFXANK and RFX5) or an Hpa I restriction site (RFXAP). CIITA cDNA was amplified 
and tailed by PCR from pEBO-CIITA with Bsp HI and Hpa I. cDNAs were digested with 
restriction endonucleases and ligated into the pMMP412 retroviral vector digested by 
enzymes creating compatible ends. MoMLV gag-pol and vesicular stomatitis virus 
glycoprotein (VSV-G) were expressed in 293 cells using the expression vector pMD (all 
kindly provided by Dr. Richard Mulligan, Children’s Hospital, Boston, MA) to create 
infectious virus-particles. 
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Lymphocyte proliferation assays 
PBMC (1 x 105) from patients and healthy control donors were incubated with 
staphylococcal superantigen A (SEA; 10 ng/ml; Sigma Chemicals), staphylococcal 
superantigen B (SEB; 20 ng/ml, Sigma Chemicals), phythemagglutinin (PHA; 12,5 µg/ml; 
Sigma), soluble CD3 mAb (OKT3, 2µg/ml; Ortho, Raritan, NY) or phorbol myristate 
acetate (PMA; 10-7 mol/L; Sigma Chemicals) or plain medium in 96-well round-bottom 
tissue-culture plates for 72 h. Cells were pulsed with [methyl-3H] thymidine (1 µCi per 
well) for another 18 h and processed as described previously [16]. 
For activation of Jurkat T cells, 5 x104 complemented VIP1 and VIP2 EBV-transformed B 
cells or alternatively EBV-transformed B cells from a healthy, HLA-DR1+ donor were co-
incubated with Jurkat T-cells (105) expressing a luciferase gene under the control of the 
IL-2 promoter in the presence of SEE (0.3 x 10-6 mol/L; Toxin Technologies, Sarasota, 
FL).  
 
Flow cytometic analyses  
The mAbs against CD14 (APC; TUK4) and CD19 (PE; SJ25-C1) were obtained from 
Caltag/Invitrogen. HLA-DQ (FITC; Leu10) and HLA-DM (PE; MaP.DM1) mAbs were 
obtained from BD Pharmingen (San Jose, CA), the mAb against HLA-DP (FITC; HI43) 
was from BioLegend (San Diego, CA). The HLA-DR specific mAb (FITC and PE; L-243) 
and the invariant chain mAb (FITC; 5-329) were kindly provided by Dr. Otto Majdic 
(Institute of Immunology, MUV, Vienna, Austria). Isotype matched control antibodies 
(FITC, PE and APC conjugated) were obtained from ADG (Kaumberg, Austria). Surface 
and intracellular stainings as well as flow cytometric analyses were performed as 
described previously [16].  
 
Complementation assays 
VIP1 and VIP2 EBV-transformed B cells (107) were incubated on ice with 20 µg of 
CIITA plasmid DNA for 5 min followed by electroporation at 300 V and 300 µF 
(GenePulser, BioRad, Vienna, Austria). Subsequently, cells were transferred to RPMI 
supplemented with 20% FCS and cultured for three days before assessment of transgene 
expression. For retroviral transduction, amphotropic RFXANK-, RFX5- RFXAP- and 
CIITA-delivering retroviruses were produced as described previously [17].  
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Genomic sequencing 
Genomic DNA was isolated from 2 x 106 EBV B cells (GenElute Mammalian DNA 
Extraction Miniprep Kit; Sigma Chemicals). Exon sequences of CIITA were determined 
using primers described previously [18]. Exon sequences of RFXAP were determined with 
the following primers: exon 1 for: 5’-TGACAGCCCGCGGGCGTACACACGCTGACG-
3’, exon 1 rev: 5’-AGATGCGGTTTGCGTTAAGATCGGGT-3’; exon 2 for: 5’-
CATCTTTGAAATACCTGTAATCATGACTTATTACGTTAACTGTT-3’; exon 2 rev: 
5’-AATCTCAATTGTTCCATTTATAACAAACGTTTGTTAACACAT-3’; exon 3 for: 
5’-CATATGTAGGGACACATCAGAGTAATTAGCATGAAAAC-3’, exon 3 rev: 5’-
ATTGGCACTGCGGGTGAGACAATCTTTAGTATG-3’. 
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RESULTS 
Lack of HLA class II expression on B lymphocytes and monocytes of two newly identified 
CID patients 
Immunological analysis of two immunodeficiency patients revealed an inverted 
CD4/CD8-ratio due to CD4+ lymphopenia, accompanied by a drastic reduction of 
superantigen-dependent T cell responses. CD3 mAb and PMA-induced T cell responses 
were low but deectable, while PHA-responses were within the normal range (table 2). 
Flow cytometric analyses revealed a lack of HLA-DR and –DQ expression on nearly all 
CD19+ B cells and CD14+ monocytes obtained from VIP1 and VIP2 compared to healthy 
controls (fig. 1). The absence of HLA class II cell surface expression together with the 
functional inability to mount a superantigen-driven T cell response was indicative of 
congenital MHC class II (MHCII) deficiency.  
 
 
Fig. 1. Defective surface expression of HLA class II molecules on peripheral blood B cells and 
monocytes of CID patients VIP1 and VIP2. Whole blood cells of patients and a healthy unrelated control 
individual were stained for major leukocyte subpopulations and analyzed by flow cytometry. Gating on 
lymphocytes and monocytes was performed according to typical forward-/side-scatter characteristics. HLA-
DR and HLA-DQ expression on CD19+ B cells or CD14+ monocytes is displayed with markers set 
according to non-binding isotype-matched control antibodies (control Ig). Numbers indicate percentage of 
HLA class II positive cells within lineage-positive cells. 
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Table 1. Laboratory findings in MHCII deficiency patients 
 
 
 
 
a cells per microliter 
b mg/dl 
c reference values for 2-6 
months old children according 
to [36]  
d not detectable 
 
 
 
Table 2. Lymphocyte proliferative function 
Mitogen VIP1 healthy control VIP2 healthy control b 
PHA 109±14a 279±9 225±1 276±7 
PMA 40±6 156±8 13±3 76±4 
SEA 2±0 205±2 1±0 27±5 
SEB 1±0 60±3 25±4 166±12 
OKT3 mAb soluble 6±1 50±3 7±7 52±2 
none (medium) 1±0 3±1 1±0 3±1 
 
a kilo cpm 
b adult healthy control individual 
 VIP1 VIP2 normal range 
leukocytes 9100a 3400 4300-10000 
granulocytes 2820 2620 1800-7300 
monocytes 820 30 200-1000 
lymphocytes 5460 750 1500-4000 
CD19+ B cells 1090 410 75-760 
CD3+ T cells 3440 270 690-3320 
CD3+CD4+ T cells 600 80 480-2480 
CD3+CD8+ T cells 2730 160 195-1800 
CD4+/CD8+-ratio 0.22 0.50 >1.0 
CD3-CD56+ NK cells 820 50 120-880 
    
Serum IgG (pre-IVIG) 92b  57 195-794c 
Serum IgM 85 n.d.d 9-212 
Serum IgA n.d n.d. 1-59 
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Rapid restoration of HLA class II expression in patient’s cell lines 
To analyze the underlying immunodeficiency, EBV lymphoblastoid B cell lines of both 
patients were either transfected with an HLA class II transactivator (CIITA) encoding 
expression plasmid or transduced with retroviral vectors encoding RFXANK, RFX5 and 
RFXAP (efficiency 5-10% and 30-40%, respectively). HLA-DR expression was restored 
in VIP1 by the CIITA cDNA, and in patient VIP2 by the RFXAP cDNA (fig. 2a). 
Furthermore, expression of CIITA in VIP1 EBV-blasts and RFXAP in VIP2 EBV-blasts 
also restored surface expression of HLA-DP and HLA-DQ and intracellular expression of 
HLA-DM (fig. 2b). Accordingly, VIP1 was assigned to complementation group A and 
patient VIP2 to complementation group D. Complementation of the respective genes also 
restored the superantigen response of patients’ EBV B cells as tested by IL-2 reporter 
activity in Jurkat T cells (not shown). 
 
VIP1 is homozygous for a nonsense mutation in amino acid codon 381 of CIITA 
 The only defect identified in patient VIP1 was a G to T point mutation at nucleotide 1256 
of the CIITA cDNA sequence in exon 11 (nomenclature according to GeneBank sequence 
accession number X74301) resulting in the conversion of codon 381 from a GAA into a 
TAA encoding a premature stop, i.e. p.Glu381X (fig. 3a). This mutation is identical to the 
point mutation in allele 1 of patient BCH, described by Bontron et al [19,20]. 
Homozygosity was confirmed by DNA sequence analyses of parental gDNA, which 
revealed that both parents carry one p.Glu381X allele  (fig. 3a). Thus, VIP1 is the first 
described MHCII deficiency patient with a homozygous p.Glu381X mutation of CIITA. 
 
In VIP2 a homozygous single-nucleotide deletion in codon 123 induces a premature out-
of-frame stop 
In patient VIP2 a single base deletion of a guanine in codon 123 of exon 1 of the RFXAP 
gene was identified, resulting in a frame-shift and premature translational stop signal 15 
codons downstream, i.e. p.Ser123ThrfsX15. Analyses of parental gDNA showed a 
heterozygous configuration from codon 123 onwards, compatible with a heterozygous 
single nucleotide deletion at position 484 (fig. 3b). This mutation is identical to the 
mutation described in three independent MHCII deficiency patients (SS, ZM and DA) all 
three of North African origin [21,22]. Thus, VIP2 is the first patient with a homozygous 
p.Ser123ThrfsX15 mutation of RFXAP identified within the Austrian population. 
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Fig. 2. Restoration of HLA class II expression on patients’ EBV B cells. (a) VIP1 and VIP2 EBV B cells 
transfected with the indicated plasmids and EBV B cells of a healthy unrelated control individual were 
stained with a HLA-DR specific mAb and analyzed by flow cytometry to assess complementation.  (b) HLA 
isotype expression upon complementation. Complemented or control transfected EBV B cells of VIP1 and 
VIP2 were stained with the indicated mAbs and analyzed by flow cytometry. EBV B cells of a healthy 
control individual were used as control. Surface expression of HLA-DR, -DP and -DQ and cytoplasmic 
expression of HLA-DM is shown. Markers were set according to nonbinding control mAbs. One out of three 
representative experiments is shown.  
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Fig. 3. Sequence analyses of gene mutations in MHCII deficiency patients. (a) VIP1: Sequence of 
CIITA, exon 11. The wt and mutated nucleotide (nt) 1256 contributing to p.Glu381 in the wt and a 
premature translational STOP in the patient VIP1 are highlighted (red). Both parents show a heterozygous 
G/T configuration at this nucleotide position. (b) VIP2: Sequence of RFXAP, exon 1. The wt nucleotide 484 
contributing to the Serine 123 codon is highlighted (yellow). In the patient VIP2 nt 484 is deleted causing a 
frame-shift-mutation leading to a pre-mature STOP at codon 137 (not shown). Both parents show the wt and 
the frame-shifted sequence from nt 484 onwards. Results were confirmed by repetitive bi-directional DNA-
sequencing. 
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Reduced HLA class II expression-levels due to heterozygosity for CIITA mutation 
So far, no phenotype has been associated with heterozygosity for a mutated, non-
functional CIITA allele. However, peripheral blood B cells obtained from the parents of 
patient VIP1, showed significantly lower cell surface expression of HLA-DR and -DP 
when compared to a collective of 20 healthy control individuals (fig. 4). A similar, albeit 
not significant tendency was found for monocytes. Of note, the parents of RFXAP-
deficient patient VIP2 had normal HLA class II expression levels on PB B cells and 
monocytes (not shown). Our findings might point to a gene dosage effect due to the 
expression of only one functional CIITA allele.  
 
Fig. 4. B cells and monocytes from 
VIP1 parents show decreased 
surface expression of HLA class II 
molecules. Box plots depict the 
geometric mean fluorescence 
intensities of HLA-DR, -DP and –DQ 
molecules on CD19+ B-cells and 
CD14+ monocytes of 20 healthy, 
unrelated control individuals (ten 
male, ten female; median age 27.7 
years; range 20.9  - 45.1). The 
respective geometric mean expression 
levels of the indicated HLA isotypes 
of VIP1 father (black squares; age: 
38,2) and VIP1 mother (black circles; 
age: 35,8) are indicated. Open 
diamonds represent statistical 
outliers.  
 
 
Different complementation groups reveal discoordinate intracellular invariant chain (Ii) 
expression levels  
When analyzing patient-derived EBV B cells differential gene expression was also 
observed for the invariant chain (Ii, CD74), which regulates peptide loading of HLA class 
II molecules [23]. Previous studies on the mRNA level have shown that Ii expression is 
subject to complex gene regulation governed by HLA class II-dependent and –
independent transcription pathways [24]. In fact, intracellular Ii expression levels in EBV 
B cells of patient VIP1 were significantly reduced (fig. 5a, 36.4 ± 4.3 % p < 0.01), when 
compared to healthy controls. To exclude a cell lines effect and to allow generalization of 
our finding, we tested EBV B cells of three additional CIITA deficient patients, i.e. VIP3 
(recently identified) and the prototype cell lines BLS-2 and BCH [10,20]. Fig. 5b shows 
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that VIP3, BLS-2 and BCH also presented with significantly reduced Ii-levels (p <0.001). 
In marked contrast, Ii expression levels in VIP2 EBV B cells were even slightly higher 
than that of healthy, unrelated control individuals (fig. 5a and b). The additionally tested 
cell lines BLS-1 and SJO, from RFXANK and RFX5 patients, showed a clear-cut, but less 
pronounced, reduction of Ii levels compared to healthy controls. Overall, complementation 
group A cell lines presented with the lowest Ii levels, complementation groups B and C 
with intermediate levels, while the group D showed no reduction of Ii expression (p < 0.01 
for A vs. B or C; and p < 0.001 for A vs. D). Complementation studies with retrovirally 
expressed CIITA led to a significant up-regulation of Ii in the complemented HLA-DR+ 
cell fraction (p = 0.018), further confirming the role of CIITA for regulation of Ii 
expression in B lymphocytes (fig 5c). Interestingly, EBV B cells of VIP1’ parents showed 
normal Ii-expression levels (not shown). Our findings substantiate the observation that the 
Ii is differentially regulated in hematopoietic cells. High levels of intracellular Ii 
expression depend on the presence of at least one wild type copy of the CIITA gene, but 
not on RFXAP gene products. Consequently, intracellular Ii expression levels might help 
to pre-assign MHCII deficiency patients to distinct complementation groups already 
during the flow cytometry-based phenotyping step. When combined with the above 
described analyses of HLA class II expression levels on PB B cells and monocytes of the 
patients’ parents, such assignments might even gain additional weight. 
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Fig. 5. Intracellular invariant chain (Ii) expression 
levels in MHCII deficiency patients’ EBV B cells. (a) 
Overlay histogram of patients’ (VIP1, thin solid line; 
VIP2, bold solid line) and healthy control (dashed line) 
EBV B cells upon intracellular staining with an Ii-
specific mAb. Dotted line represents nonbinding 
control mAb. (b) Relative geometric mean fluorescence 
intensities (geo MFI) + SD of patients’ cells, EBV B 
cell lines of previously described patients belonging to 
the indicated complementation groups compared to 
cells of healthy control individuals (n=2) stained and 
analyzed in triplicates are depicted. **, p < 0.01; ***, p 
< 0.001; Student’s t-test, two-tailed. Data are 
representative for three independently performed 
experiments including EBV B cells of five healthy 
control individuals. (c) Complementation of CIITA in 
EBV B cells of patient VIP1 leads to up-regulation of Ii expression. VIP1 EBV B cells transduced with 
CIITA retrovirus were stained for surface HLA-DR- and cytoplasmic Ii-expression. Complemented versus 
non-complemented cells were identified by HLA-DR expression and analyzed for Ii expression. Numbers 
indicate Ii geo MFI of HLA-DR+ and -DR- subsets. Right hand panel shows overlay histograms of 
complemented (bold line) versus non-complemented (thin line) cells, gated as indicated (left panel), and 
stained with Ii mAb. Dotted line represents staining obtained with nonbinding control mAb. 
 
 
DISCUSSION 
 
We have identified two non-related patients, designated VIP1 and VIP2, who showed the 
clinical course of CID owing to a complete lack of HLA class II expression on PB B cells 
and monocytes compatible with MHCII deficiency. Ectopic overexpression of candidate 
cDNAs revealed CIITA-deficiency in patient VIP1 (complementation group A) and 
RFXAP-deficiency in patient VIP2 (complementation group D). Significantly, Ii 
expression levels were reduced in EBV B cells of the CIITA-deficient but not of the 
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RFXAP-deficient patient. Moreover, also HLA class II expression levels were affected in 
the CIITA-deficient patient’s parents. 
 
A special advantage of vector-based complementation strategies is the fast assignment of 
patients to distinct complementation groups providing a cost-effective alternative to first-
line DNA-sequencing approaches [25]. Moreover, functional complementation approaches 
allow immediate conclusions concerning the mono- or oligogenicity of a given deficiency, 
a test-quality, which can only hardly be provided by gene-sequencing.  
 
The p.Glu381X mutation is identical to the mutation described by Bontron and colleagues 
in allele 1 of patient BCH [19,20]. Since both parents of VIP1 are heterozygous for the 
p.Glu381X mutation and no other mutation was found in VIP1, it can be assumed that 
patient VIP1 is homozygous for the p.Glu381X mutation. So far, only eight MHCII 
deficiency patients belonging to complementation group A have been described in the 
literature [26]. Each of them carries a unique set of either homozygous or heterozygous 
mutations in their CIITA genes. Patient VIP1 described here is the first patient with a 
homozygous p.Glu381X mutation leading to loss of the C-terminal nuclear localization 
domain (NLS) of the CIITA which prevents the recruitment of CIITA to the HLAII 
enhanceosome [7,27]. Since BCH, the first patient described with a (heterozygous) 
p.Glu381X mutation, is also of Austrian origin, it is well possible that this mutated allele 
is more widespread in the Austrian population than elsewhere. The assumption, however, 
that this distinct mutation occurred independently three times, i.e. in one parent of patient 
BCH and in both parents of patient VIP1, might also point to a region of increased genetic 
instability within the CIIITA gene, which therefore could be a target for fast primary 
genetic analysis of novel MHCII deficiency patients with a suspected CIITA-deficiency. 
Given the fact that the two Austrian CIITA deficiency patients VIP1 and VIP3 were born 
in the years 2005 and 2006, respectively, and given that in those two years a total of 
154002 births were reported for Austria (Statistik Austria, 
http://www.statistik.at/web_de/statistiken/bevoelkerung/geburten/index.html) this would – 
assuming Hardy-Weinberg equilibrium - correspond to a gene-frequency of 0.0036 and 
thus imply one heterozygous individual among 139 Austrians. Such estimations, although 
providing a rough picture on the possible genetic background of a population, will have to 
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be formally proven by future large-scale investigations. It remains also to be shown 
whether heterozygous individuals might be endowed with altered immune function.  
 
In patient VIP2 a p.Ser123ThrfsX15 mutation, which leads to a premature translational 
stop and thus a non-functional RFXAP gene product was identified. So far, three different 
mutations in eight RFXAP-deficient patients from six unrelated families have been 
described with three patients carrying the same mutation as patient VIP2 [21,26]. 
Interestingly, those three patients were all of North African origin. The fact that VIP2 is a 
homozygous carrier of the p.Ser123ThrfsX15 mutation with both parents showing a 
heterozygous configuration suggests that also this mutation is more widespread within the 
Middle European population. 
 
Until today, no phenotype has been associated with heterozygosity for CIITA mutations. 
We noticed decreased HLA Class II expression-levels on VIP1’ parental B lymphocytes 
compared to cells from healthy control individuals. This points to a gene dosage effect due 
to the heterozygous loss of CIITA-activity. In contrast, normal HLA class II expression-
levels were observed on B lymphocytes of the parents of the RFXAP-deficient patient. 
Our finding, although based only on two families, could form the basis for initial carrier 
identification in individuals with suspected CIITA mutations. Moreover, parents’ HLA 
expression levels might give a first hint, which gene might be affected in a given patient. 
 
Moreover, intracellular Ii-expression levels were reduced in EBV B cells of the CIITA-
deficient but not of the RFXAP-deficient patient. Previous reports have shown, that CIITA 
expression is necessary and sufficient for HLA class II expression [28], while Ii 
expression can also be regulated in a CIITA-independent fashion [21,29].  In the 
physiological context, the CIITA-independent transcription of Ii might be required in 
order to exert the other biological functions described for the Ii, e.g. as a ligand for MIF 
[30] and CD44 [31]. It has been shown in the past that mutations in the CIITA gene lead 
to a partial block in Ii expression on the mRNA level [18,32], however, information on the 
protein level, especially in hematopoietic cell types, remained scarce. Similarly, the role of 
the RFX-complex members for Ii expression is only poorly described. One report 
described that the RFX-B mutant B cell line BLS-1 had an approx. 50% reduction of Ii 
mRNA [33], while fibroblasts from two different patients were found to be negative for Ii 
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mRNA [34]. In RFXAP or RFX5 mutant patients, no Ii mRNA could be detected in IFN-γ 
treated fibroblasts [21,29,35]. However, no information on intracellular Ii-expression 
levels of B cells from RFXAP-deficient patients exists. We here show, that Ii expression 
levels in EBV B cells of the CIITA-deficient but not of the RFXAP-deficient patient are 
significantly reduced when compared to healthy control cells. Similar results were 
obtained with three additional EBV B cell lines of unrelated CIITA deficient patients. A 
less pronounced reduction of Ii expression levels was also found in one RFXANK- and 
one RFX5-deficient cell line. Thus, strongly reduced Ii expression levels in hematopoietic 
cells of patients might be indicative of CIITA-deficiency, while they might exclude 
RFXAP-deficiency. Intermediate Ii-levels might point to RFXANK- or RFX5-deficiency. 
In fact, reduced Ii expression levels of CIITA-deficient cell lines could be restored to wild 
type levels by retroviral complementation with CIITA (fig. 5c). Future studies with more 
patients/cell lines will have to substantiate the findings presented here. However, in 
combination with the above-described reduction in cell surface HLA class II expression 
levels on PB B cells of heterozygous parents, our findings might lead to novel algorithms 
for the quick identification of subsets of MHCII deficiency disorders. 
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ABSTRACT 
We describe for the first time fluorescent virus-like particles (VLP) decorated with 
biologically active mono- and multi-subunit immune-receptors of choice and the basic 
application of such fluorosomes (FS) to visualize and target immune-receptor/ligand 
interactions. For that purpose, human embryonic kidney (HEK)-293 cells were stably 
transfected with Moloney murine leukemia virus (MoMLV) matrix protein (MA) green 
fluorescence protein (GFP) fusion constructs. To produce FS, interleukins (IL), IL-
receptors (IL-R) and co-stimulatory molecules were fused to the glycosyl phosphatidyl 
inositol (GPI) anchor acceptor sequence of CD16b and co-expressed along with MoMLV 
group specific antigen-polymerase (gag-pol) in MA::GFP+ HEK-293 cells. We show that 
IL-2 decorated but not control-decorated FS specifically identify normal and malignant 
IL-2 receptor positive  (IL-2R+) lymphocytes by flow cytometry. In addition to cytokines 
and co-stimulatory molecules, FS were also successfully decorated with the heterotrimeric 
IL-2R, allowing identification of IL-2+ target cells. Specificity of binding was proven by 
complete inhibition with non-labeled, soluble ligands. Moreover, IL-2R FS efficiently 
neutralized soluble IL-2 and thus induced unresponsiveness of T cells receiving full 
activation stimuli via T-cell antigen receptor (TCR) and CD28. FS are technically simple, 
multivalent tools for assessing and blocking mono- and multi-subunit immune-
receptor/ligand interactions with natural constituents in a plasma membrane context. 
 
Key words 
lipid-rafts, viral pseudotyping, glycosyl phosphatidyl inositol anchored proteins, flow 
cytometry, fluorescent proteins. 
Klaus Schmetterer                                                                                                    Chapter 5 
 
      
 139  
INTRODUCTION 
Virus-like particles (VLP) are noninfectious enveloped particles that can be induced in 
mammalian cells by the expression of viral structural proteins in the absence of viral 
nucleic acid. They have proven to be powerful tools for the display and transport of 
diverse biologically active immunomodulatory molecules (1-3). We have shown in the 
past that VLP can be engineered to modulate immune responses by judicious 
incorporation of additional membrane-associated proteins that sustain stimulatory or 
inhibitory immune responses. We have named the resulting engineered microvesicles 
immunosomes and anergosomes respectively (1-3). Because direct interaction between 
leukocyte receptors and VLP-resident ligands was found to be a prerequisite for effective 
receptor triggering, we have in this study explored whether it would be possible to 
visualize the interaction between VLP decorated with specific ligands and cells expressing 
the cognate receptors. We hypothesized that sufficient quantities of fluorescently labeled 
VLP would be detectable once bound to cells, and that such particles might represent both 
a versatile staining tool and a traceable agent for the efficient modulation of immune 
responses. 
In this study we have focused on VLP labeled in vivo by recombinant fluorescent proteins 
of cnidarian origin (4-6), demonstrating their utility for the visualization of specific 
immune-receptor/ligand interactions. Translational fusions of viral proteins with GFP have 
been broadly used to elucidate infectious pathways of viruses (7-10). Since lipid-rafts are 
the meeting points for GPI-anchored surface molecules and viral core proteins (11) we 
hypothesized that fluorescent proteins linked to raft-targeted viral core proteins might 
accumulate in sufficiently high abundance to generate fluorescently labeled VLP that 
could be used to track the interactions of VLP in different settings. For efficient decoration 
of VLP, immune-receptors or ligands of choice were fused at their C-termini to the 
glycosyl phosphatidyl inositol (GPI) anchor attachment sequence of CD16b, a well-
defined GPI-anchored molecule of human granulocytes (12). Previous reports have shown 
that GPI-anchored molecules are efficiently targeted to the lipid-raft regions of producer 
cells and consequently to VLP (11). 
To illustrate the potential of this approach we have chosen cytokine/cytokine-receptor 
interactions as model system. Cytokines are small to medium sized proteins or 
glycoproteins, that mediate potent biological programs upon binding to their specific 
receptors (13). Cytokine receptors are differentially expressed on various cell types and 
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can be visualized and their density determined by receptor specific mAbs. Flow 
cytometric detection of cytokine receptors on normal and malignant cells using mAbs has 
been widely applied in the past (14-16). However, many growth factor receptors consist of 
multisubunit receptors and frequently similar receptor-chains (subunits) are used by 
different receptors, e.g. the common γ-chain (CD132) (17), which is part of the IL-2, IL-4, 
IL-7, IL-9, IL-13, IL-15, IL-21 receptors; or the IL-2R β-chain which is part of the IL-2 as 
well as the IL-15 receptor (13). Thus, the identification of single receptor components 
does not always allow determination of overall receptor composition. 
Consequently, precise enumeration and visualization of growth factor receptors has 
required radioligand-, affinity- or fluorochrome-based (18, 19) binding assays with in 
vitro-modified cytokines in the past. Modification of cytokines requires, for the most part, 
that the molecule of interest be available in sufficient quantity and purity. The most widely 
used labeling-techniques rely on the existence on the target molecule of a sufficient 
number of reactive residues susceptible to chemical modification. Alterations to protein 
sidechains, which in most cases is a random process, can cause changes of the 
physiological or biophysical properties of the natural protein.  
In addition to assessing their staining potential we were interested in determining whether 
VLP could also be decorated with more complex structures, e.g. multichain cytokine 
receptors, and whether such particles would bind and neutralize the respective cytokines. 
The potential utility of this approach has been suggested by recent reports that cytokine 
deprivation may be one of the mechanisms by which CD4+CD25+Foxp3+ regulatory T 
cells (Treg) (20) and myeloid dendritic cells (mDC) (21, 22) exert their regulatory 
function on effector T cells. 
 
MATERIALS AND METHODS 
Cell lines and primary cells. The human embryonic kidney epithelial cell line 293 and 
the murine HT-2 cell line (ATCC, CRL-1841, American Type Culture Collection, 
Manassas, VA, USA) were maintained in IMDM (Sigma Chemicals, St. Louis, MO, USA) 
plus 10 % FCS (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-glutamine, 
50 µM 2-mercaptoethanol and 15 µg/ml gentamycin sulfate. HT-2 cells were re-plated 
every 48 h at a cell density of 1 x 105 cells/ml in the presence of 100 U/ml human IL-2 
(Peprotech, London, UK). BW5147 (23) and BW5147 CTLA-4 cells were described 
previously (24, 25) and were cultured in RPMI 1640 medium plus 10 % FCS (Invitrogen), 
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2 mM L-glutamine, 50 µM 2-mercaptoethanol and 15 µg/ml gentamycin sulfate. PBMC 
were isolated from heparinized blood of healthy adult donors upon informed consent by 
standard density gradient centrifugation with Lymphoprep (Technoclone, Vienna, 
Austria). Whole blood samples of chronic lymphocytic leukemia (CLL) patients obtained 
upon informed consent were collected with EDTA anticoagulant and analyzed in standard 
whole blood stainings using ADG-Lyse (An der Grub, Kaumberg, Austria). 
 
Expression constructs. The modified cytokine expression constructs have been described 
previously (2). Briefly, the specific cDNAs for human IL-2 and IL-7 were amplified with 
primers as specified in supplement Table 1 from clone pTCGF-11 (ATCC #39673) and 
pHumLP-1 (ATCC#67546), respectively. At the 5’-ends, optimized translational initiation 
sites preceded by a Hind III restriction site were inserted. The 3’stop-codons were 
replaced with a polyglycine linker sequence followed by a Nhe I restriction site for direct 
fusion to the minimal CD16 GPI-anchor acceptor sequence (IL-2R constructs) or 
alternatively to the CD16 GPI-anchor preceded by two Ig-like domains of CD16 
(membrane-bound cytokines; D. Haiderer, manuscript in preparation). The DNA-
fragments were ligated into the pEAK12-CD80::CD16 plasmid from which the CD80 
ectodomain had been released (1). Original MoMLV gag-pol (OGP) was expressed from 
pMD.gagpol (26) kindly provided by Dr. R. Mulligan, Childrens’ Hospital, Boston, MA, 
USA. IL-2R subunits were amplified by RT-PCR using mRNA from PHA plus IL-2 
activated (24 h) PB T cells as template and were modified in a similar fashion (primers in 
supplement Table S1). Full length human CD16b served as a control (12). The MA::GFP 
fusion construct was generated by PCR  using pMD.gagpol  and pEAK12.GFP as a 
templates (27). Hind III and Nhe I, or Nhe I and Not I restriction sites, incorporated in the 
PCR primers allowed the resulting fragments to be inserted into the pEAK12 expression 
plasmid at the location of the cognate sites in the vector.  
 
Stable 293 transfectants. 293 cells stably expressing MA::GFP, GFP or IL-2::GPI (single 
cell clones) were generated by transfection with plasmids linearized by digestion with Sfi I 
(New England Biolabs, Ipswich, MA, USA) (28), selection in puromycin (1 µg/ml, Sigma 
Chemicals) and analysis by flow cytometry (FACS Calibur; Becton Dickinson, Palo Alto, 
CA, USA) using the CellQuest software. 
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Generation of GFP-labeled VLP decorated with cytokines or co-stimulatory 
molecules (fluorosomes, FS).  For the generation of fluorosomes (FS), 293 cells stably 
expressing MA::GFP or GFP were transiently transfected using the calcium-phosphate 
coprecipitation method (28). Briefly, one day prior to transfection, 293 cells were seeded 
onto 100 mm cell culture dishes (3 x 106 cells/plate) and were transfected the following 
day with 2 ml transfection mix. For generation of IL-, IL-R- or CD80-decorated FS 293 
cells were transfected with a total DNA amount of 30 µg per dish including 7.5 µg of the 
MoMLV original gag-pol (OGP) encoding plasmid pMD.gagpol and 22.5 µg of the 
indicated IL::GPI or CD80::GPI pEAK12 expression plasmid. For generation of IL-R 
decorated FS, 293 cells were transfected with 30 µg DNA per dish including 7.5 µg 
pMD.gagpol and 7.5 µg of each IL-2R subunit expression plasmid. If necessary, DNA 
amounts were adjusted with control vector (empty pEAK12 vector or, where indicated, 
full length CD16b in pEAK12). Control particles were generated by transfection of 293 
cells with 7.5 µg pMD.gagpol and 22.5 µg of control vector. 18-24 h after transfection, the 
medium was changed, and transfectants were cultured for another 48 hours before FS-
containing supernatants were harvested. 
 
Flow cytometric analysis of 293 producer cells. For membrane staining, 5 x 105 293 
cells in 50 µl were incubated at 4°C with fluorochrome conjugated mAbs (20 µg/ml, 
supplement Table S2) for 30 min. After two washes with staining buffer (PBS, 1 % BSA, 
0.05 % NaN3) membrane fluorescence was analyzed by flow cytometry. Treatment of 293 
cells with phosphatidylinositol specific phospholipase C (PI-PLC)  from Bacillus 
thuringiensis (American Radiolabeled Chemicals, St. Louis, MO, USA) was performed 
according to the manufacturer’s recommendations. Briefly, 293 cells were washed in PBS 
w/o Ca2+ and Mg2+ and resuspended at a concentration of 1 x 107 cells/ml in PBS. 100 mU 
of PI-PLC were added to 1 x 107 cells and the cells incubated at 37˚C for 2 h. 
Subsequently cells were washed in PBS/ 1 % BSA and subjected to membrane staining. 
 
Isopycnic separation of producer cell lysates. Preparation of lipid raft fractions was 
performed as described (29). Aliquots of 20 µl of individual fractions collected from top to 
bottom of 5-40% sucrose gradients were analyzed by SDS-PAGE on 4-20 % gradient gels. 
Proteins were transferred to PVDF membranes (Millipore, Billerica, MA, USA) and 
subjected to Western blotting using mAbs specific for IL-2 (supplement data Table S2), 
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p30gag, GFP, CD59 and CD147. HRP conjugated secondary reagents (supplement data 
Table S2) were used at a dilution of 1:104. Blots were developed with a luminol based 
indicator system (Western Lightning, Perkin Elmer, Boston, MA, USA) and exposed to x-
ray films (Eastman Kodak, Rochester, NY, USA). 
 
Purification of VLP/FS. Supernatants (10 ml/culture plate) were harvested 72 hours after 
transfection and cleared of cellular debris by filtration through 0.45 µm syringe filters 
(Millipore), concentrated by ultracentrifugation in a Beckman-Optima LE-80K centrifuge 
(Beckman Instruments, Palo Alto, CA, USA), using a SW41 Ti rotor, at 100.000 g for 1 h 
and washed twice in a large volume of PBS. Amounts of VLP/FS were determined by 
standard protein assay (Micro BCA-Pierce, Thermo Scientific, Rockford, IL, USA) and 
adjusted to protein concentrations as described in individual experiments. For functional 
tests, VLP/FS preparations were sterile filtered (0.22 µm syringe filters, Millipore) before 
use. 
 
Confocal microscopy. 293 cells stably transfected with MA::GFP or GFP  were seeded at 
a density of 4 x 104 cells/cm2 in a PeCon POC-R cell cultivation chamber, grown 
overnight and analyzed on an Axiovert 100 M confocal microscope using a 63x/1.40 oil 
immersion objective (Carl Zeiss, Göttingen, Germany).  
 
Fluorosome (FS) based staining assays. HT-2 cells (1 x 105cells)  were resuspended in 
staining buffer (PBS, 0.5% BSA, 0.05% NaN3) and were incubated at room temperature 
with ) of titrated amounts of either cytokine-decorated or non-decorated FS (starting with 
400 µg) in a total volume of 100 µl  for > 1 hour until equilibrium binding was reached. 
Control stainings were performed with IL-2R alpha chain-specific (CD25, supplement 
data Table S2) or nonbinding control mAb all used at  1 µg in a total volume of 100 µl for 
30 min. The ED50-value was calculated from mean fluorescence intensity values using 
nonlinear regression analysis fitted to classical Michaelis-Menten kinetics (Prism 5.0b, 
GraphPad software, San Diego, CA, USA). Specificity of binding reactions was 
determined by pre-incubation of HT-2 cells with soluble IL-2 (5 x 103 U in 100 µl 
volume). Off-rates were determined by first labeling HT-2 cells (1x 105) with 400 µg IL-2 
decorated MA::GFP+VLP at 4°C for > 1 hour and by washing them extensively. 
Following initial binding HT-2 cells were chased in an excess of staining buffer (4 ml) at 
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4°C, room temperature, 37°C and 37°C in the presence of 4 x 104 U soluble IL-2 
(Peprotech, London, UK) for 0, 15, 30, 60 and 120 min and analyzed by flow cytometry. 
Staining of 293 IL-2R transfectants with VLP (20 µg/1 x 105 cells) was performed in a 
similar fashion, except that control stainings were performed with mAbs against human 
CD25, CD122, CD132. BW5147 CTLA-4 transfectants were control stained with a 
CTLA-4 mAb or negative control mAb. Subsequently, cells were washed two times with 4 
ml staining buffer (4°C) by centrifugation (300 g for 5 min), resuspended in 150 µl 
staining buffer and 20 µl propidium iodide (0.5 µg/ml) and analyzed immediately on a 
FACS Calibur flow cytometer supported by CellQuest software (Becton Dickinson). 
Activated T cells were generated by incubation of 1 x 106 PBMC/ml with anti-mouse IgG 
magnetic beads (Dynabeads, Invitrogen, Carlsbad, CA, USA) coated at 150 fg per bead 
with CD3 and CD28 mAb at a bead to cell ratio of 1:1. After 72 h of stimulation cells 
were compared to resting cells for their binding of FS  (20 µg/1 x 105 cells). Activation 
status of T cells was determined by double staining for CD3 and CD25 or CD3 plus 
CD69. Peripheral blood of chronic lymphocytic leukemia patients (n=10) was analyzed by 
the whole blood method using ADG-Lyse (An der Grub, Kaumberg, Austria). CD19+ B 
lymphocytes from patient samples were immunophenotyped with a panel of diagnostic 
mAbs (e.g. CD5, CD20, CD23, CD25, CD43, surface Ig, surface Ig-kappa, surface Ig-
lambda), and were reacted with IL-2 decorated GFP+ FS or control FS (above). After one 
wash in PBS, cells were re-suspended in 200 µl sheath fluid, and immediately analyzed 
(15 x 103 cells) by flow cytometry (FACSCalibur, CellQuest software, Becton Dickinson). 
Lymphocytes were identified by typical forward and right-angle scatter characteristics.  
 
IL-2 sequestration experiments. PBMC (105) of healthy volunteers were co-cultured 
with αCD3/αCD28 mAb microbeads at a 1:1 ratio and with titrated amounts of IL-2R 
αβγ::GPI,  IL-2R α::GPI or CD16::GPI (control) expressing FS (starting with 2µg/well) or 
medium alone. Cell proliferation was determined after 4 days by [3H]-thymidine uptake. 
For antigen-specific experiments Art v 1-specific TCR tg T-cells were generated from 
non-allergic HLA-DR1 positive individuals as described previously (30). TCR tg T-cells 
(1 x 106 cells/well) were cultured in 24-well plates with VLP (2 µg/ml) decorated with 
HLA-DRA*0101, HLA-DRB1*0101, Ii::Art v 125-34, CD80::GPI, CD86::GPI, 
CD58::GPI, CD54::GPI, cathepsin S or control plasmid combined as indicated or medium 
alone for ten days. Proliferation of primary antigen-specific cultures was determined in 
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replica plates containing 1 x 105 T-cells and corresponding stimuli. After ten days, cells 
from 24-well plates were harvested, washed and 1 x 105 cells/well were re-stimulated in 
96-well flat bottom plates with anti-CD3/CD28 microbeads (2.5 x 104) alone or in the 
presence of IL-2 (500 U/ml) for four days and proliferation was determined. Cell 
proliferation was determined after 4 days by [3H]-thymidine uptake. 
The binding capacity of IL-2R αβγ:GPI FS was determined with the help of radioactively 
labeled 125I IL-2 (Perkin Elmer, Boston, MA, USA). For that purpose, constant amounts of 
125I IL-2 corresponding to 25 U IL-2 (i.e. 2,5 ng) were incubated at room temperature with 
titrated amounts of IL-2R αβγ:GPI FS starting from 30 µg for 1 hour. FS-bound 125I IL-2 
was determined (Packard Cobra II gamma-counter, Packard, Meriden, CT, USA) from the 
retentate upon size exclusion filtration using Amicon Microcon YM-100 filter units 
(Millipore) according to the manufacturer’s recommendations. 
Alternatively, 5 ng non-labeled IL-2 (Peprotech, London, UK) was used to stimulate 
proliferation of HT-2 cells (5x103/well) in the presence of titrated amounts of IL-2R 
αβγ:GPI FS. Inhibition of HT-2 cell proliferation was taken as a measure to determine the 
IL-2 binding capacity of IL-2R αβγ:GPI FS compared to co FS. Proliferation is expressed 
as [3H]-thymidine uptake after 64 hours of co-cultivation.  
 
RESULTS 
Generation of fluorescent VLP. To generate VLP with high membrane fluorescence we 
amplified and fused the coding sequence of Moloney murine leukemia virus (MoMLV) 
matrix protein (MA) and GFP (Fig. 1A). Expression of MA::GFP in 293 cells resulted in 
pronounced membrane-associated fluorescence (Fig. 2A), whereas expression of untagged 
GFP led to evenly distributed cytoplasmic fluorescence (Fig. 2B). MA::GFP expression in 
293 cells was approximately 3-fold lower than expression of soluble GFP (Fig. 2C, D). As 
a model ligand for testing specific interactions we coexpressed human interleukin (IL)-2 
fused by a poly-glycine spacer to the GPI-anchor acceptor sequence of human CD16b (2) 
preceded by two CD16b Ig-like domains (Fig. 1A). Membrane fractionation experiments 
with 293 transfectants showed that IL-2::GPI, MA::GFP, the MoMLV capsid proteins and 
the GPI-anchored, constitutively expressed CD59 molecule were all targeted to the lipid-
raft fractions of 293 cell lysates (Fig. 2E) while soluble GFP and the non-lipid-raft marker 
molecule CD147 (31) remained excluded.  
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Binding of IL-2 decorated VLP to IL-2R+ target cells. In the next set of experiments we 
induced secretion of IL-2 decorated fluorescent VLP and asked whether such particles 
would bind to and stain IL-2R+ cells. For that purpose we induced particle formation by 
transfection (28) of either 293-MA::GFP or 293-GFP stable transfectants with 
pEAK12_IL-2::GPI and pMD_gag/pol(MoMLV) (production according to Fig. 1B).  
 
 
 
Figure 1. A) Diagram of expression 
constructs. DNA sequences encoding 
MoMLV matrix protein (MA, p15) 
were PCR amplified and endowed 
with flanking Hind III and Nhe I 
restriction sites. For optimal 
expression levels, the consensus 
transcriptional initiation site GCCACC 
was introduced upstream of the ATG 
codon. The MA coding region was 
fused to green fluorescent protein 
(GFP) sequences previously inserted 
in the pEAK12 expression vector. 
Cytokine coding sequences were 
similarly PCR amplified and prepared 
for vector insertion. At the 3’-ends of 
the cytokine cDNAs, the intrinsic stop 
codons were replaced by a polyglycine 
linker sequence allowing fusion to a 
CD16b GPI-anchor acceptor sequence 
(in the case of interleukins preceded 
by two CD16b Ig-like domains) 
previously inserted in the pEAK12 
vector. B) Production scheme for 
fluorosomes. FS production is initiated 
by transfection of MoMLV gag-pol. 
FS bud from the lipid-raft regions of 
293 producer cell membranes. 
MA::GFP is targeted to the lipid-rafts 
and consequently to nascent FS by 
virtue of its fusion to MA. Similarly, 
the cytokines, cytokine receptors and 
co-stimulatory molecules fused to the 
GPI-anchor acceptor sequence of 
CD16b become enriched in lipid-rafts 
and FS. After collection and 
purification from 293 producer cell 
supernatants, FS can be used to 
visualize receptor-ligand interactions 
by standard flow cytometry and 
microscopy, or, alternatively, for 
cytokine sequestration. 
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Subsequently, the IL-2R+ murine T cell line HT-2 (32) was incubated with varying 
amounts of IL-2::GPI decorated VLP derived from either of the two producer cell lines 
(1). Binding was analyzed by flow cytometry. Background binding was assessed by 
comparison to fluorescence resulting from CD16b decorated VLP produced by either of 
the two cell lines. Binding to > 95 % of HT-2 cells was achieved with 4 µg (by protein 
mass) of MA::GFP+VLP decorated with IL-2::GPI per 1 x 105 HT-2 cells (Fig. 3A, D), 
with 50 % positive cells obtained with 1 µg VLP. No binding was observed with control 
MA::GFP+VLP (p = 0.001; Mann Whitney (MW) U-test, two-tailed), although similar 
amounts of VLP were applied (not shown). In marked contrast, IL-2::GPI decorated VLP 
from 293 cells expressing soluble GFP (GFP+VLP) produced significantly weaker signals,  
 
Figure 2. Analysis of 293 producer cells. 
293 cells stably transfected with A) 
MA::GFP, or B) GFP were seeded in a 
cell cultivation chamber, grown 
overnight and analyzed by confocal 
microscopy (63x/1.40 oil immersion). 
Pictures (inset: high magnification) show 
characteristic morphology and 
fluorescence pattern. Scale bar 50 µm. 
Flow cytometric determination of GFP 
expression levels in 293 producer cells.  
Overlay histograms show green 
fluorescence intensity of 293 cells stably 
expressing C) MA::GFP or D) GFP 
(solid lines) compared to native 293 cells 
(dotted lines) as determined by flow 
cytometry. Numbers indicate geometric 
MFI. GPI anchor attachment or fusion 
to MA targets modified molecules to 
lipid rafts. E) 293 cells transfected with 
IL-2::GPI, MoMLV gag/pol, MA::GFP 
or GFP, respectively, were lysed at 4°C 
in Triton X-100 and fractionated on 5 to 
40 % sucrose gradients into nine 
fractions (top to bottom). Equal amounts 
of each fraction were resolved by SDS-
PAGE, blotted, and probed by 
immunoblotting (IB) with mAbs specific 
for IL-2 (all antibodies used are listed in 
Table S2, supplemental material), 
p30Gag, GFP, CD59 or CD147, 
respectively. Binding of antibodies was 
visualized by HRP-conjugated secondary 
reagents followed by a luminol-based 
detection reaction. One out of several 
representative experiments is shown. 
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Figure 3. Binding of IL-2 decorated 
fluorescent VLP to IL-2R+ HT-2 cells. 
Dose-dependent binding. Saturation 
binding isotherms were generated by 
reacting two-fold dilutions of the 
indicated amounts of purified IL-
2::GPI MA::GFP+VLP (closed 
squares), control MA::GFP+VLP 
(open squares), IL-2::GPI GFP+VLP 
(closed circles) and control GFP+VLP 
(open circles) with HT-2 cells (starting 
with 400 µg VLP / 1 x 105 HT-2 cells) 
followed by flow cytometric analyses. 
A) Percent positive cells and B) 
geometric mean fluorescence 
intensities (geo MFI) obtained are 
plotted against the VLP concentrations 
applied. Native HT-2 cells exhibited a 
geo MFI of 5 (< 2 % positive cells). 
ED50 is shown as dotted line. 
Statistical significance was calculated 
by the two-tailed Mann Whitney U-
test; ** p > 0.01; *** p < 0.001. C) 
VLP-based detection of IL-2R on HT-2 
cells by standard microscopy. HT-2 
cells were incubated and processed 
with IL-2::GPI MA::GFP+VLP or 
control MA::GFP+VLP as described 
above. Cell morphology was 
determined by light microscopy 
(right), membrane fluorescence by 
fluorescence microscopy (left). Scale 
bar 10 µm. D) Overlay histograms of 
HT-2 cells (1 x 105) incubated with 30 
µg IL-2::GPI-MA::GFP+VLP or 
control MA::GFP+VLP (left), IL-
2::GPI-GFP+VLP or control GFP+VLP 
(middle), and anti-CD25 mAb or 
control mAb (right) are shown. 
Specific fluorescence (solid lines) is 
compared to the respective control 
(dotted lines). Numbers indicate geo 
MFI values of specific reagents. E) 
Differential targeting of MA::GFP 
and GFP to VLP. 293 cells were 
transfected  with  the indicated expres-  
sion plasmids or control plasmid and cell lysates (cells) and corresponding VLP preparations were analyzed by 
SDS-PAGE under reducing conditions followed by immunoblotting (IB) with a GFP-specific goat antiserum 
or the p30 Gag specific mAb R187, respectively. Bound antibodies were detected by HRP-conjugated 
secondary reagents and a luminol-based detection system. Statistical significance was calculated by the paired, 
two-tailed Student’s t-test; *** p < 0.001. F) Exogenous IL-2 inhibits binding of IL-2::GPI MA::GFP+VLP. 
Native HT-2 cells (1 x 105) or HT-2 cells pre-incubated with recombinant soluble human IL-2 (5 x 103 U) 
were incubated with IL-2::GPI decorated MA::GFP+VLP and analyzed by flow cytometry. Results show 
binding of IL-2::GPI decorated MA::GFP+VLP to IL-2 pre-incubated relative to native HT-2 cells (mean + 
SD). G) Temperature dependent dissociation of IL-2::GPI MA::GFP+VLP from HT-2 cells. The dissociation 
of IL-2::GPI MA::GFP+VLP from HT-2 cells was monitored after removing excess VLPs and chasing at 4°C, 
room temperature (RT), 37°C and 37°C in the presence of 4 x 104 U soluble IL-2. MFI was determined and 
plotted as percentage of maximum, corresponding to the values obtained at start of chase. t1/2 denotes 
dissociation half-life. 
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with only 30 % positive cells at a concentration of 25 µg (p = 0.002; MWU-test, two-
tailed). Saturating binding with a geometric mean fluorescence intensity (geo MFI) of 
1.842 was reached with 400 µg of IL-2 decorated MA::GFP+VLP, compared to a MFI of 
38 for IL-2 decorated GFP+VLP (p < 0.001; MWU-test, two-tailed; Fig. 3B), and a MFI 
35 for VLP lacking IL-2 (p < 0.001; MWU-test, two-tailed). Very similar results showing 
clear-cut membrane pronounced fluorescence of HT-2 cells preincubated with IL-2::GPI 
MA::GFP+VLP but not control MA::GFP+VLP were obtained by fluorescence microscopy 
(Fig. 3C). The reduced fluorescence intensity of VLP bearing soluble GFP compared to 
MA::GFP was confirmed by GFP-specific immunoblotting (Fig. 3E). Specificity of 
binding reactions was confirmed by pre-incubation of HT-2 cells with 5000 U soluble IL-
2, which completely inhibited subsequent binding of IL-2 decorated MA::GFP+VLP (p < 
0.001; Student’s t-test, paired, two-tailed; Fig. 3F). The interaction of IL-2 decorated 
MA::GFP+VLP with HT-2 cells was remarkably stable at 4°C and room temperature (Fig. 
3G). At 37°C clear-cut dissociation rates became, however, apparent with a dissociation 
half-life t1/2 = 44.4 min in the absence and t1/2 = 6.2 min in the presence of excess amounts 
of of soluble IL-2 (4 x 104 U) used as competitor (Fig. 3G).  
For convenience in subsequent exposition we will identify the MA::GFP-expressing VLP 
as fluorosomes (FS). Importantly, IL-2::GPI FS displayed a high degree of physical 
stability. Their initial staining activity was reduced by only 8.8 ± 3.0% and 4.0 ± 14.4 %  
(geo MFI) upon freezing and re-thawing or storage at 4°C for 3 weeks, respectively (not 
shown). A rapid decline in staining intensity was evident only upon storage at room 
temperature.  
 
IL-2::GPI FS discriminate between cells expressing different forms of the IL-2R. To 
determine whether IL-2::GPI FS are also able to discriminate between different IL-2 
receptor subunit combinations (16) we evaluated their binding to respective 293 cell 
transfectants. Fig. 4A and B show that similar amounts of IL-2::GPI  FS derived from the 
same production batches bound significantly more strongly to IL-2R αβγ-transfectants 
than to IL-2R βγ-transfectants, and not to control transfected 293 cells (p  < 0.001; t-test), 
which mirrors the affinities of IL-2 for the different receptor types (16, 33). In contrast, no 
binding of control FS to either of the transfectants was evident (p < 0.001; t-test).  
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IL-2::GPI FS identify activated IL-2R+ T lymphocytes and B non-Hodgkin 
lymphoma (B-NHL)-chronic lymphocytic leukemia (CLL) cells. The results above 
suggest that IL-2::GPI FS could be used to identify distinct leukocyte subpopulations of 
healthy or diseased individuals. Fig. 5A demonstrates that IL-2::GPI FS indeed bound to a 
small subset of CD3+ T lymphocytes in freshly isolated PBMC of healthy individuals, 
likely representing the CD4+CD25+ Treg fraction (34). Upon polyclonal activation with 
CD3 plus CD28 coated microbeads for 48 h, binding of IL-2::GPI FS and CD25 mAb, but 
not of control FS, to the majority of CD3+ T cells was observed (Fig. 5B).  
 
In addition to its action on T cells, IL-2 is also an important stimulatory cytokine for B 
lymphocytes (35, 36). Expression of IL-2R by chronic lymphocytic leukemia (CLL) B 
cells is one of the distinguishing characteristics of the disease (37-39). IL-2::GPI FS 
combined with a CD19-APC mAb could clearly identify the IL-2R positive B cell 
populations in peripheral blood (Fig. 5C) and bone marrow (not shown) of CLL patients 
(11 of 11 patients positive). Compared to the standard staining procedure with CD25 
mAbs, somewhat lower overall numbers of positive cells were identified with IL-2::GPI 
FS (69,4 ± 22,6 % vs. 50,3 ± 16,4 %). However, in some patients, the staining intensity 
obtained with IL-2::GPI FS was identical or even exceeded that obtained with CD25 mAb. 
 
Figure 4. IL-2::GPI FS discriminate 
between target cells expressing low- 
or high-affinity IL-2R. A) Panel 
shows overlay histograms of 293 
cells transfected with control 
plasmid (upper panel), IL-2R βγ-
chain (middle panel) or IL-2R αβγ-
chain (lower panel) stained with 
identical batches of either IL-2::GPI 
(solid line) or control (dotted line) 
FS. B) Geometric MFI-values of 
indicated 293 cell transfectants 
stained with IL-2::GPI (black bars) 
or control (white bar) FS from three 
independently performed 
experiments + SD are shown. 
Statistical significance was 
calculated by paired, two-tailed 
Student’s t-test; ns p > 0.05; * p < 
0.05; *** p < 0.001. 
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It will be interesting to explore whether the observed differential binding of IL-2::GPI FS 
to CLL-B cells correlates with disease progression and/or severity (40) and possibly 
reflects differences in receptor composition. 
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Generality of the FS approach shown by specific binding of IL-7::GPIFS and 
CD80::GPI FS to respective target cells. To determine whether the approach can be 
generalized, we decorated FS with ligands other than IL-2 and investigated their binding 
characteristics to respective targets. For this we constructed IL-7::GPI (Fig. 1) and took 
advantage of a CD80::GPI construct described previously  (1). Fig. 5D shows that the IL-
7::GPI FS, unlike control FS, specifically bound to resting CD3+ T cells (p < 0.001; t-test), 
and binding could be specifically inhibited by addition of exogenous soluble IL-7 (not 
shown). The IL-7R is expressed as a low (Ka ~ 1 x 10-6 M) and a high (Ka ~ 5 x 10-9 M) 
affinity receptor on lymphocytes (13). The clearly weaker signal obtained with IL-7::GPI 
FS as compared to parallel stainings performed with IL-7R α-chain specific mAb might be 
a reflection of the differential binding of IL-7 to these receptors. Moreover, CD80::GPI FS 
bound to CTLA-4 transfected (as described in (25)) but not to control transfected BW cells 
(p = 0.01; t-test, Fig. 5E). Addition of 2 µg soluble CD80-Ig fusion protein or blocking 
CD80 mAb 7-480 (not shown) inhibited the binding of CD80::GPI FS to CTLA-4 
expressing BW cells to background levels (Fig. 5E).  
 
FS probes comprising functional multi-subunit receptors. Conventional labeling 
approaches typically use monomeric or homomultimeric reagents to identify single 
epitopes on analyzed cell populations. To establish whether FS probes could be 
constituted from heteromultimeric reagents we produced FS decorated with various 
combinations of IL-2R-chains (modified by GPI-anchor acceptor sequences according to  
Figure 5. IL-2::GPI FS identify activated T lymphocytes and CLL B cells. Two-parameter dot-plot analyses 
of freshly isolated A) or activated (CD3/CD28 coated beads, 48 hours) B) PBMC upon incubation with IL-
2::GPI FS, control FS, or CD25 FITC-conjugated mAb and counterstained with a CD3 APC-conjugated 
mAb are shown. Gating for lymphocytes was performed according to typical FSC/SSC-characteristics. 
Markers were set according to non-binding control mAbs or control FS. Data are representative of three 
experiments. C) Whole blood of a CLL-patient was stained with IL-2::GPI FS, control FS or CD25 FITC-
conjugated mAb and counterstained with a CD19 APC-conjugated mAb. Lymphocytes were gated 
according to typical FSC/SSC characteristics. Markers were set according to staining of non-binding control 
mAbs or control FS. Data are representative of multiple individuals (n=11). IL-7::GPI FS or CD80::GPI FS 
specifically bind to target cells expressing their respective receptors. D) Two-parameter dot-plot analyses of 
whole blood cells gated on lymphocytes of a representative healthy donor incubated with IL-7::GPI FS, 
control FS or CD127 PE-conjugated mAb and counterstained with CD3 APC-conjugated mAb are shown. 
Lymphocytes were gated according to typical FSC/SSC characteristics. Data are representative of four 
experiments. E) Overlay histograms of CTLA-4 transfected BW cells incubated with CD80::GPI FS, control 
FS or CTLA-4 mAb plus anti-mouse-Ig conjugated to OG are shown (bold lines). Dotted lines show 
fluorescence obtained with native BW cells. Pre-incubation of CTLA-4 transfected BW cells with soluble 
CD80-Ig fusion protein (2 µg) was used as specificity control. Data are representative of four experiments. 
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Fig. 1) and analyzed whether they would specifically bind to target cells expressing 
membrane-anchored IL-2. Fig. 6A and B show that this is the case. FS expressing the 
high-affinity IL-2R (IL-2R αβγ-chain) showed strong and highly significant binding to the 
 
Figure 6. FS decorated with 
complex combinations of the IL-2R 
bind to target cells expressing 
membrane-bound IL-2 and dose-
dependently bind soluble IL-2. A) 
Panel shows overlay histograms of 
293 cells expressing membrane-
bound IL-2::GPI (single cell clone), 
which were incubated with control 
FS (upper panel), IL-2R γ-
chain::GPI FS  (upper-middle 
panel), IL-2R βγ-chain::GPI FS 
(lower-middle panel), or IL-2R αβγ-
chain::GPI FS (lower panel), 
respectively  (bold lines). Dotted 
lines represent fluorescence of 
control transfected 293 cells 
incubated with the respective FS. B) 
Geometric mean fluorescence values 
of IL-2::GPI (black bars) or control 
(white bar) 293 transfectants stained 
with the indicated FS from three 
independently performed 
experiments + SD are shown. 
Statistical significance was 
calculated by the paired, two-tailed 
Student’s t-test; ns p > 0.05; * p < 
0.05; *** p < 0.001. C) Dissociation 
kinetics  of IL-R FS from IL-2+ 
target cells. The dissociation of IL-
2R αβγ::GPI FS and IL-2R βγ::GPI 
from IL-2+ 293 cells was monitored 
after removing excess FS and 
chasing at room temperature (RT), 
37°C and 37°C in the presence of 4 
x 104 U soluble IL-2. MFI was 
determined and plotted as 
percentage of maximum, 
corresponding to the values obtained 
at start of chase. t1/2 denotes 
dissociation half-life. Binding 
capacity  of  IL-2R αβγ::GPI  FS. 
D)  Constant  amounts   of 125I IL-2 
(2.5 ng) were incubated with titrated  
  amounts of IL-2R αβγ::GPI FS or control FS for 1 h at RT. Subsequently, FS were collected by size exclusion 
filtration and FS-bound 125I IL-2 determined by γ-counting. E) Constant amounts of soluble IL-2 (5 ng) were 
incubated with titrated amounts of IL-2R αβγ::GPI FS or control FS and added to 5 x 103 HT-2 cells cultured 
in 96-well plates. After 48 hours [3H]- thymidine was added, cells were harvested 16 hours later and cell 
proliferation was determined. Data show mean values ± SD of triplicate cultures (n = 2). ED50 denotes 
effective dose 50 percent. 
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IL-2+ target cells when compared to control FS (p < 0.001; t-test). FS decorated with the 
low-affinity IL-2R (IL-2R βγ-chain) revealed intermediate but still significant binding (p = 
0.03; t-test), whereas IL-2R γ-chain decorated FS similar to the control FS displayed no 
significant binding (p = 0.2; t-test). In contrast to the staining intensities no significant 
differences in dissociation rates between IL-2R αβγ::GPI FS and IL-2R βγ::GPI FS in the 
presence or absence of excess amounts of soluble IL-2 (4 x 104 U) used as competitor 
were detectable (Fig. 6C). To obtain a more accurate estimate also of the valency of FS we 
have resorted to binding studies using IL-2R FS and 125I-labeled IL-2 as the ligand. In 
parallel experiments the IL-2 binding capacity of IL-2R αβγ::GPI FS was tested in 
functional assays using HT-2 cell proliferation as the indicator system. The experiments 
with 125I-labeled IL-2 revealed that 1 µg of IL-2R αβγ::GPI FS bind 6,25 ng IL-2 (Fig. 
6D). Assuming a mean mass for C-type retrovirus particles of 6.5 x 107 Dalton (41) this 
would indicate that one IL-2R αβγ::GPI FS has approximately 26 binding sites for 125I-IL-
2. The functional experiments revealed a 3.25-fold lower IL-2 binding capacity, i.e. 
approximately 8 sites per FS (Fig. 6E). However, these experiments had a much longer 
duration than the binding assays (64 h versus 1 h) and had to be carried out at 37°C (as 
opposed to room temperature for binding assays) presumably causing considerably higher 
off-rates (Fig. 3G) making more IL-2 bio-available. In fact, the obtained data are well in 
line with our previous findings, in which we detected up to 15 IL-2 molecules on one VLP 
as determined by immuno-gold staining followed by electron microscopy (2). 
 
IL-2 αβγ-chain::GPI FS neutralize soluble IL-2 and thereby induce novel functional 
T cell programs. We also examined whether IL-2R decorated FS are capable of 
neutralizing soluble IL-2. Recently, IL-2 neutralization/depletion has been shown to be 
one of the effector mechanisms of regulatory T cells (Treg) (20). To determine whether FS 
decorated with IL-2R components are able to interfere with T cell activation programs we 
stimulated PBMC of healthy individuals with microbeads coated with CD3 and CD28 
mAbs in the presence of IL-2R αβγ-chain::GPI+FS or control FS. In marked contrast to 
control FS, high concentrations of IL-2R αβγ-chain::GPI+FS almost completely abrogated 
T cell proliferation. (Fig. 7A). Next we asked whether a similar inhibition would take 
place after antigen-specific T cell stimulation (3) and whether IL-2 deprivation from T 
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cells receiving a full activation stimulus would render T cells unresponsive during 
secondary stimulation provided by αCD3 plus αCD28 coated microbeads. Fig. 7B shows  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
that allergen-specific T cells react with VLP expressing Art v 1 in the context of HLA-
DR1 and CD80 both in primary and secondary T cell stimulation assays. In contrast, the 
presence of IL-2R αβγ-chain::GPI FS during primary stimulation not only significantly 
inhibited the primary, antigen-specific but also completely abrogated secondary polyclonal 
T cell responses (Fig. 7B, p < 0.05 and p <0.01, respectively, t-test). T cells did, however, 
survive the FS-mediated IL-2 deprivation, since they proliferated well upon addition of 
exogenous IL-2 (500 U/ml, p < 0.001, t-test). Similar results were obtained with antigen-
specific T cells receiving only antigen stimulation during the primary stimulation, which is 
in line with our previous results (3), and served as a control. Thus, immune-receptor 
 
Figure 7. A) IL-2R αβγ::GPI+FS neutralize proliferation of polyclonally activated PB T cells. PBMC (105) 
were co-cultured with αCD3/αCD28 mAb substituted microbeads and varying amounts of IL-2R αβγ::GPI 
or CD16::GPI (control) expressing FS (starting with 2µg/well) or medium alone. Cell proliferation was 
determined after 4 days by [3H]-thymidine uptake. Data show mean values ± SD of triplicate cultures (n = 
3); ** p < 0.01; Student’s t-test, paired, 2-tailed, comparing cultures supplemented with IL-2R αβγ::GPI FS 
to co FS. B) Induction of antigen-specific unresponsiveness by FS. Art v 1 allergen-specific Vα17/vβ18 
TCR tg PB T cells (105) were cultured with the indicated primary stimuli and proliferation was measured by 
[3H]-thymidine incorporation for the last 12 h of a 72 h incubation (gray bars). Proliferation of T cells 
obtained on culture with indicated stimuli for 10 days, washed, and re-cultured with αCD3/αCD28 mAb 
substituted microbeads in the absence (white bars) or presence (black bars) of exogenous IL-2 (500 U/mL) 
is demonstrated. Data show one representative experiment (n = 3). *** p < 0.001; ** p < 0.01; * p < 0.05; 
Student’s t-test, paired, 2-tailed. kcpm, Kilo counts per minute. 
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decorated FS bind and sequester their respective ligands, shaping the evolution of 
responses in T cells exposed to these agents.  
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DISCUSSION 
In this work we introduce a technology for the facile preparation of analytical reagents that 
have high ligand affinity and functional activity. In addition to their specific binding to 
cell surface receptors, FS are also able to sequestrate soluble ligands, such as IL-2, with 
high efficiency, and thereby induce altered cellular programs in T cells that have been 
activated via their T cell antigen receptor (TCR) and CD28 molecules.  
 
Production of FS relies on the preferential incorporation of the MoMLV MA::GFP fusion 
protein as fluorochrome into the lipid rafts of 293 producer cells. Co-expressed immune-
receptors/ligands of choice can be targeted to FS by attachment of a GPI-anchor. FS can 
be produced quickly - within four days - and in large amounts - 9.8 ± 4.5 µg per milliliter 
of producer cell supernatant (not shown). The production procedure relies on transfection 
of the easy-to-handle 293 embryonic kidney epithelial cell line (42) with an optimized 
Ca2PO4-precipitation method (28). The strong fluorochrome accumulation in VLP allows 
direct visualization of fluorescence without the need for secondary reagents, which makes 
the FS staining procedure quick, typically completed within one hour. In this study, 
normal and malignant lymphocyte subsets could be identified by IL-2+FS. FS containing 
membrane-targeted GFP were significantly more efficient than FS containing soluble 
GFP. The generality of the approach was demonstrated by successful application of 
ligands other than IL-2, i.e. IL-7 and the type I, or single pass, transmembrane T cell 
surface expressed co-stimulatory molecule CD80.  
 
In contrast to labeled antibodies usually identifying single receptor subunits, FS directly 
measure receptor/ligand interactions between natural interaction partners, and thereby 
offer the possibility of a more accurate assessment of activity of the targeted receptor. 
Interleukin receptor components such as the IL-2R α-chain (CD25) and IL-7R α-chain 
(CD127) are differentially represented among human T cell subsets (43), and it has been 
reported that the CD4+CD25hiCD127lo (IL-2RαhiIL-7Rαlo) phenotype identifies natural 
Treg cells (43). Determination of IL-2R composition in Treg cells based on both IL-2+FS 
and CD25 monoclonal antibodies might lead to new insights into the biology of Treg 
function, a possibility suggested by a recent report that cell types expressing partial IL-2R 
with regulatory function can be identified (22). It should also be interesting to explore the 
possibility of establishing multi-color FS for double or triple staining purposes in the 
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future. The recently described ‘fruit’-colors developed by Tsien and co-workers and 
relying on Discosoma sp. appear to be interesting candidates in this respect (44). 
 
Another potential application of FS is the characterization of so far unknown receptor-
ligand interactions. As shown here, the VLP platform can accommodate multisubunit-
ligands or receptors, which are otherwise not easy to express in the appropriate 
configuration. The membrane environment of VLP should also permit the convenient 
expression of type III integral membrane proteins, which pass the plasma membrane two 
to seven times (45) and are associated with lipid rafts (46, 47), for staining purposes and 
ligand screens. The multivalent nature of FS as such might facilitate the detection of low-
affinity interactions between monomeric receptor-ligand pairs. 
 
Reagents that can neutralize biological activity are frequently useful and antibodies can 
often be found with this capacity, although antibodies rarely achieve the extremely high 
binding affinity exhibited by natural receptors (48). These studies have shown that IL-2R 
αβγ-chain::GPI+FS very effectively sequester IL-2 from T cell cultures upon polyclonal 
and antigen-specific activation. This culminates in a nearly complete inhibition of T cell 
proliferation. Similar results have been obtained with non-fluorescent IL-2R αβγ-
chain+VLP (not shown). T cells exposed to these FS were unresponsive when restimulated 
in secondary cultures. The state of unresponsiveness could, however, be overcome by the 
addition of exogenous IL-2. This seems to be of special interest, since Treg cells have 
been shown to exert their regulatory function on activated effector CD4+ T cells - among 
other mechanisms - by binding and neutralizing of IL-2 and other common γ-chain (γc, 
CD132) associated cytokines (20). Our results indicate that i) IL-2R αβγ-chain::GPI FS 
not only bind but also functionally neutralize soluble IL-2;  ii) IL-2R αβγ-chain::GPI FS 
have functional capabilities usually associated with regulatory cells and iii) the regulatory 
function of FS is independent of classical transmembrane signaling events, since the 
intracellular and transmembrane regions of the individual IL-2R chains have been 
exchanged by GPI anchor acceptor sequences. An advantage of the VLP platform - over 
other forms of binding reagents - is their ability to accommodate several different 
functionally active molecules at a time, which potentially allows complex regulatory 
instructions to be imparted to a given cell by a single type of particle. Because FS are 
Klaus Schmetterer                                                                                                    Chapter 5 
 
      
 159  
functionally inert otherwise (compared to intact cells), the effects of their administration to 
target populations are more easily interpreted. 
 
We here describe for the first time fluorescent VLP decorated with biologically active 
mono- and multi-subunit immune-receptors of choice and the basic application of such 
fluorosomes to visualize and functionally block immune-receptor/ligand interactions. Due 
to their simple generation and broad applicability, FS might open new avenues in various 
fields of basic immunological research as well as for diagnostic purposes. 
 
SUPPLEMENTARY DATA 
 
Table S1. List of primers used in this paper 
Primer Sequence a RE site 
GFP for 5'-CCCGCGGCTAGCGTGAGCAAGGGCGAGGAG-3' Nhe I 
GFP rev 5'-GCGCCCGCGGCCGCTTTACTTGTACAGCTCGTCCATG-3' Not I  
IL-2 for 5'-CGCGGGAAGCTTGCCACCATGTACAGGATG-CAACTCCTG-3' Hind III 
IL-2 rev 5'-CCCGCGGCTAGCGCCGCCGCCAGTCAGTGTTGAGATGATGC-3' Nhe I 
IL-2Rα for 5'-CGCGGGAAGCTTGCCACCATGGATTCATACCTGCTGATGTGGGGA-3' Hind III 
IL-2Rα rev 5'-CCCGCGGCTAGCGCCGCCGCCCTGGTACTCTGTTGTAAATATG-3' Nhe I 
IL-2Rβ for 5'-CGCGGGAAGCTTGCCACCATGGCGGCCCCTGCTCTGTC-3' Hind III 
IL-2Rβ rev 5'-CCCGCGGCTAGCGCCGCCGCCGGTGTCCTTCCCAAG-3' Nhe I 
IL-2Rγ for 5'-CGCGGGAAGCTTGCCACCATGTTGAAGCCATCATTACCATTCACATCCCTC-3' Hind III 
IL-2Rγ rev 5'-CCCGCGGCTAGCGCCGCCGCCATTCTCTTTTGAAGTATTGCTCC-3' Nhe I 
IL-7 for 5'-CGCGGGAAGCTTGCCACCATGTTCCATGTTTCTTTTAGG-3' Hind III 
IL-7 rev 5'-CCCGCGGCTAGCGCCGCCGCCGTGTTCTTTAGTGCCCATC-3' Nhe I 
MLV MA for 5'-CGCGGGAAGCTTGCCACCATGGGCCAGACTGTTACCACT-3' Hind III 
MLV MA rev 5'-GCGCCCGCTAGCGGATCGAGGCGGGGTCG-3' Nhe I 
 
 a The underlined regions indicate the restriction enzyme (RE) sites  
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Table S2. List of mAbs, primary and secondary antisera used. 
Specificity Clone name Species conjugated to Source 
mAbs     
CD3 OKT3 mouse - eBioscience, San Diego, CA 
CD3 UCHT1 mouse PE a An der Grub, Kaumberg, Austria 
CD3 S4.1 mouse APC Invitrogen (Caltag), Carlsbad, CA 
CD19 SJ25-C1 mouse APC Invitrogen (Caltag), Carlsbad, CA 
CD25 2A3 mouse FITC BD-Pharmingen, San Diego, CA 
CD28 28.2 mouse - BD-Pharmingen, San Diego, CA 
CD59 MEM-43/5 mouse - Exbio, Praha, Cech Republic 
CD80 MEM-233 mouse - Exbio, Praha, Cech Republic 
CD80 7-480 mouse - Dr. Majdic, Inst. Immunol, Vienna, Austria 
CD122 27302 mouse FITC RD, Minneapolis, MN 
CD127 R34.4 mouse PE Beckman-Coulter (Immunotech), Fullerton, CA 
CD132 TUGh4 mouse PE BD-Pharmingen, San Diego, CA 
CD147 MEM-M6/6 mouse - Exbio, Praha, Cech Republic 
CIAP VIAP mouse FITC Dr. Majdic, Inst. Immunol, Vienna, Austria 
CTLA-4 BN-13 mouse - BD-Pharmingen, San Diego, CA 
IL-2 MQ1-17H12 rat PE  BD-Pharmingen, San Diego, CA 
IL-2 IL-2.1F10 mouse - Dr. Majdic, Inst. Immunol, Vienna, Austria 
IL-7 BVD10-40F6 rat - BD-Pharmingen, San Diego, CA 
p30 Gag MoMLV R187 rat - ATCC, Raritan, NY 
control 4H1-A7/VIAP mouse FITC/PE An der Grub, Kaumberg, Austria 
primary antisera     
GFP - rabbit - antibodies-online, Aachen, Germany 
secondary antisera     
Mouse Ig - goat Oregon Green Invitrogen (Molecular Probes), Eugene, OR 
Mouse Ig - goat HRP DAKO, Glostrup, Denmark 
Rabbit Ig - goat HRP DAKO, Glostrup, Denmark 
Rat Ig - goat Oregon Green Invitrogen (Molecular Probes), Eugene, OR 
Rat Ig - rabbit HRP DAKO, Glostrup, Denmark 
 
a Abbreviations: PE, phycoerythrin; FITC, fluorescein isothiocyanate; APC, 
allophycocyanine; OG, Oregon green; HRP, horse radish peroxidase. 
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Supplement Figure 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Expression levels 
of GPI-anchored interleukin-
2 receptor α−, β− and γ-
chains on 293 producer cells. 
293 cells were transfected by 
the calcium phosphate pre-
cipitation method with IL-2R 
α::GPI, IL-2R β::GPI or IL-
2R γ::GPI. Seventy-two hours 
later, transfectants were 
harvested, and aliquots (1 x 
107) were treated with 100 
mU/ml of PI-PLC at 37°C for 
2 h. Subsequently, both PI-
PLC-treated and non-treated 
cells (5 x 105) were incubated 
with the IL-2R α chain-
specific mAb 2A3, the IL-2R 
β chain-specific mAb 27302 
and the IL-2R γ chain-
specific mAb TUGh4. In 
addition, the constitutively 
expressed molecules CD59 
(GPI anchored) and CD99 
(type I transmembrane mole-
cule) were probed with mAbs 
MEM-43 and 3B2/TA8, 
respectively. The resulting 
cellular fluorescence was 
analyzed by flow cytometry. 
Dead cells were excluded 
from the analyses by means 
of propidium iodide staining. 
Overlay histograms show PI-
PLC-treated (solid lines) and 
untreated cells (dotted lines). 
The percent values indicate 
the degree of release upon PI-
PLC treatment. The data 
shown are representative of 
three independently per-
formed experiments. 
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ABSTRACT  
Background: T-regulatory cells (Treg) establish and maintain tolerance to self-antigens 
and many foreign antigens, e.g. allergens, by suppressing effector T-cell proliferation and 
function. We have previously shown that human T-cell receptor (TCR) αβ-chains specific 
for allergen-derived epitopes confer allergen specificity upon peripheral blood (PB) T-
cells of allergic and non-allergic individuals.  
Objective: To study the feasibility of generating allergen-specific human Treg by 
retroviral transduction of a transcription unit encoding Foxp3 and allergen-specific TCR 
αβ-chains.  
Methods: cDNAs encoding the α− and β-chains of a Bet v 1142-153-specific TCR 
(TRAV6/TRBV20) and human Foxp3 were linked via picornaviral 2A-sequences and 
expressed as single translational unit from an internal ribosomal entry site-green 
fluorescence protein containing retroviral vector. Retrovirally transduced PB T-cells were 
tested for expression of transgenes, Treg phenotype and regulatory capacity towards 
allergen-specific effector T-cells. 
Results: Transduced T-cells displayed a Treg phenotype with clear-cut up-regulation of 
CD25, CD39 and CTLA-4. The transduced cells were hyporesponsive in cytokine 
production and secretion and, like nTreg, did not proliferate following antigen-specific or 
antigen-mimetic stimulation. However, proliferation was inducible upon exposure to 
exogenous IL-2. In co-culture experiments, TRAV6+TRBV20+Foxp3+ transgenic (tg) T-
cells, unlike Foxp3+ single tg T-cells or nTreg, highly-significantly suppressed T-cell 
cytokine production and proliferation of corresponding allergen-specific effector T-cells in 
an allergen-specific, dose-dependent manner.  
Conclusions: We demonstrate a transgenic approach to engineer human allergen-specific 
Treg that exert their regulatory function in an activation-dependent manner. Customized 
Treg might become useful for tolerance-induction therapies in individuals suffering from 
allergic and other immune-mediated diseases.  
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INTRODUCTION 
 
Naturally occurring CD4+CD25highFoxp3+ regulatory T-cells (Treg) orchestrate and 
maintain tolerance to self-antigens by suppressing effector T-cell proliferation and 
function. Depletion of Treg in mice has been shown to lead to overt multiorgan 
autoimmunity,1 consistent with widely held views that Treg restrain the evolution of 
autoimmune disorders,2 play a key role in tolerance against allo-antigens after 
transplantation,3 and modulate allergic immune responses.4 Specific immunotherapy (SIT) 
has been shown to increase regulatory T-cell prevalence, which correlates with 
amelioration of clinical symptoms.5-11 In addition several primary immunodeficiencies are 
characterized by an apparent lack of functional Treg subsets.12 Consequently, protocols to 
induce Treg function and elevate their numbers have gained increased attractiveness as 
therapeutic options in recent years. Strategies applied include expansion of Treg lines 
from sorted CD4+CD25+ populations by stimulation with different forms of antigen-
presenting cells and cytokines 13-16 or the de novo generation of ‘inducible’ Treg (iTreg) 
from CD4+CD25- T-cells by TCR mediated stimulation in the presence of TGF-β 17, 18 or 
rapamycin 19.  
 
A recent key finding was that the retro- or lentiviral introduction of Foxp3 was sufficient 
to generate artificial Treg.20, 21 Such tg Treg display the typical features of naturally-
occurring Treg – hyporesponsiveness and suppression of effector cells – and can be 
cultivated and expanded in vitro over prolonged periods of time. However, these tg Treg 
represent a polyclonal population with a broad range of antigenic specificities, some 
representing important targets for normal immune function. On the other hand, Treg cells 
with the desired antigen-specificity would most probably only be found at a low 
frequency.  
 
The antigen specificity of T-cells is determined by the T-cell antigen receptor (TCR). In 
fact, transfer of TCRαβ genes22 has become a convenient tool for transferring designated 
antigen specificities to PB T-cells. While first developed to generate large numbers of 
tumor-reactive T-cells for therapy,23-26 TCR transfer approaches can be used to generate 
T-cells reactive against peptides derived from the major allergens in mugwort (Art v 125-
36)27 and birch pollen (Bet v 1142-153), respectively, in order to study signal requirements 
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and plasticity of allergen-specific T-cells. These TCRs were chosen because both 
allergens, their respective HLA restriction elements and their major epitopes are well-
characterized,28, 29 and allergy to mugwort and birch-pollen are among the main causes of 
pollinosis in the Northern Hemisphere.30 In fact, more than 95% of birch pollen-allergic 
individuals elicit an IgE antibody response against Bet v 1, the major birch pollen 
allergen.31 
 
It is well-established that Treg-mediated suppression of effector T-cells (Teff) is based on 
a functional program that requires the activation of the Treg via the TCR or agonistic 
ligands to CD3 1, 32, 33. We aimed to exploit these principles to generate customized, 
allergen-specific, human Treg by co-introduction of Foxp3 to provide the regulatory 
program in concert with TCRαβ chains to provide allergen-specificity. To ensure reliable 
and balanced expression of all three transgenes (i.e. the TCR αβ-chains and Foxp3) a 
multicistronic vector-based approach was applied34 which allows to express several genes 
from a single expression unit. The cDNAs encoding TRAV6 and TRBV20 (IMGT 
nomenclature35) and Foxp3 were linked via picornaviral 2A sequences34 upstream of an 
IRES-GFP element into a retroviral expression vector. PB T-cells were transduced with 
these constructs, monitored for transgene expression and immunophenotype, tested for 
hyporesponsiveness, and evaluated for their ability to suppress proliferation and cytokine 
production of allergen-specific effector T-cells.  
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RESULTS 
 
Generation of multicistrons encoding allergen-specific TCRα/β and Foxp3 cDNAs 
The cDNA sequences for a TCR (TRAV6/TRBV20) specific for the Bet v 1142-153 peptide 
of the major birch pollen allergen Bet v 1 in the context of HLA-DRB1*07:01 
(Neunkirchner et al., manuscript in preparation) were linked via a picornaviral P2A 
sequence to a bicistronic expression construct and expressed from the retroviral vector 
pMMP (Fig 1). Additionally, the cDNA encoding Foxp3, was linked to the TCR construct 
using a picornaviral T2A element. The tricistronic construct  and the respective Foxp3 
single-construct were transferred into the pMMP-IRES-GFP vector to allow transduction 
and to facilitate detection and sorting. 
 
 
FIG 1. Scheme of 
multicistronic retroviral 
expression constructs used 
in this study. Function of 
the respective genes is 
indicated; open boxes, 
genes; closed boxes, 
interposed picornaviral 2A 
or IRES elements 
 
 
Transduced T-cells express the introduced transgenes 
The majority of TRAV6/TRBV20-transduced effector T-cells (72 ± 14%; Fig 2, A) and of 
the GFPhigh fraction of TRAV6/TRBV20/Foxp3-transduced T-cells (82 ± 12%; Fig 2,B) 
expressed the tg TCR on their surface as detected by staining for the TRBV20-chain, 
while the GFPhigh fraction of control-transduced (7 ± 1%) or Foxp3-transduced (8 ± 2%) 
T-cells contained only low numbers of TRBV20+ T-cells, corresponding to the 
endogenous levels of polyclonal TRBV20+ T-cells (Fig 2, B). Similarly, intracellular 
staining for Foxp3 revealed high levels of Foxp3 in the GFPhigh fractions of Foxp3-
transduced (78 ± 3%) and TRAV6/TRBV20/Foxp3-transduced T-cells (89 ± 8%) (Fig 2, 
B) whereas control-transduced T-cells exhibited negligible (1 ± 1%) expression. 
Importantly, the expression in the non-transduced GFPneg fractions of both TRBV20 and 
Foxp3 were low and compatible with endogenous levels (Fig 2, B).  
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FIG 2. Transgene expression-levels and gating strategy for retrovirally transduced PB T-cells. (A) 
TRAV6+TRBV20+ T-cells (B) TRAV6+TRBV20+Foxp3+, Foxp3+ and control T-cells. In B GFP expression 
served as additional gating marker. Surface TCR expression (TRBV20) and intracellular Foxp3 expression 
are displayed as two parameter dot-plots. Numbers indicate cell-percentages in respective quadrants 
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Foxp3-transduced T-cells display a Treg cell-surface phenotype 
Flow cytometric analyses performed on resting transduced PB T-cells revealed that the 
CD3+CD4+GFPhigh fraction of both Foxp3-transduced and TRAV6/TRBV20/Foxp3-
transduced T-cells exhibited elevated expression of the Treg markers CD251, CD39 41 and 
CTLA-4 (CD152)42 compared to the CD3+CD4+GFPneg non-transduced fraction (Fig 3) or 
to TRAV6/TRBV20-transduced or mock-transduced PB T-cells (not shown). Furthermore, 
and in accordance with a regulatory phenotype, we also observed a discrete down-
regulation of CD127 expression43 on the tg Treg. No changes in GITR expression levels44 
were observed. In all further functional experiments the flow-cytometrically sorted 
GFPhigh fractions of Foxp3-transducted T-cells were used and termed Foxp3+ or 
TRAV6+TRBV20+Foxp3+, respectively. 
 
FIG 3. Immunophenotype of transduced T-cells. PB T-cells gated for CD3+CD4+GFPneg or 
CD3+CD4+GFPhigh subsets and analyzed for expression of indicated Treg markers. Blue line, GFPhigh subset 
from TRAV6/TRBV20/Foxp3-transduced T-cells, specific mAb; Red line, GFPhigh subset from Foxp3-
transduced T-cells, specific mAb; Green line, GFPneg subset, specific mAb; Grey line, 
TRAV6/TRBV20/Foxp3-transduced T-cells, control mAb. 
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TRAV6+TRBV20+Foxp3+ T-cells are hyporesponsive to antigen-specific and polyclonal 
activation  
Treg are hyporesponsive to TCR-dependent stimulation.1 Upon stimulation with aAPC 
expressing HLA-DRA*01:01, HLA-DRB1*07:01, CatS, Ii-Bet v 1142-153 and CD80, 
TRAV6+TRBV20+ T-cells proliferated vigorously while TRAV6+TRBV20+Foxp3+ T-
cells were significantly less responsive (p<0.001) (Fig 4, A). Importantly, aAPC-
dependent stimulation was highly specific, as control-transduced, Foxp3 single-transgenic 
T-cells devoid of the Bet v 1-specific TCR expression and nTreg showed only minimal 
proliferation (p<0.001) (Fig 4, A). Moreover, polyclonal stimulation using anti-CD3/CD28 
coated microbeads led to a strong proliferative response of both TRAV6+TRBV20+ and 
control-transduced T-cells while TRAV6+TRBV20+Foxp3+, Foxp3 single-tg T-cells or 
nTreg did not proliferate (p<0.001) (Fig 4, B.) In eight experiments using cells from four 
non-related, non-allergic donors, proliferation of TRAV6+TRBV20+Foxp3+ T-cells was 
reduced by 73.7 ± 17.3% (p<0.001) and 92.9 ± 6.6% (p<0.001) respectively compared to 
TRAV6+TRBV20+ effector T-cells in response to allergen-specific and polyclonal 
stimulation. In agreement with previous reports, the addition of exogenous IL-2 led to a 
significant induction of proliferation of Foxp3+T-cells (p<0.001) and 
TRAV6+TRBV20+Foxp3+ T-cells (p<0.001) in both settings,16, 20 while freshly isolated 
nTreg required a polyclonal stimulus plus exogenous IL-2 to proliferate (p<0.001) (Fig 4).  
 
FIG 4. Foxp3-transduced T-
cells are hyporesponsive. 
Proliferation of retrovirally 
transduced PB T-cells or 
nTreg stimulated with (A) 
aAPC expressing indicated 
molecules or (B) anti-
CD3/CD28 coated 
microbeads in the absence 
(black bars) or presence 
(white bars) of recombinant 
hIL-2 (250 U/ml). Mean + 
SD of triplicates; control, 
empty IRES-GFP vector; 
asterisks indicate 
significance compared to 
TRAV6+TRBV20+ effector 
T-cells (- IL-2). n.s., not 
significant; ***, p < 0.001. 
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Similarly, both Foxp3 transgenic T-cell populations secreted only minimal levels of TNF-
α, IFN-γ, IL-2 and IL-13, compared to TRAV6+TRBV20+ or control-transduced T-cells 
following allergen-specific or polyclonal activation (Table I). In accordance with previous 
reports on Foxp3-transduced T-cells, both TRAV6+TRBV20+Foxp3+ and Foxp3+ T-cells 
did not secrete significant amounts of IL-10 upon stimulation.16, 20 Moreover, no 
significant differences in TGF-β secretion levels between the different cell populations 
studied were observed (not shown). 
 
Table I. Cytokine secretion by retrovirally transduced T-cells after 24 h 
 
 
 
TRAV6+/ 
TRBV20+ 
control Foxp3+ 
TRAV6+/ 
TRBV20+/Foxp3+ 
TNF-α 94 ± 29a <1 <1 1 ± 1 
IFN-γ 1138 ± 733 <1 <1 <1 
IL-2 226 ± 86 5 ± 2 <1 <1 
IL-4 <13 <13 <13 <13 
IL-10 <1 <1 <1 <1 
aA
PC
 
IL-13 143 ± 58 11 ± 9 7 ± 6 14 ± 12 
TNF-α 73 ± 16 61 ± 32 5 ± 3 3 ± 2 
IFN-γ 968 ± 598 537 ± 428 3 ± 3 3 ± 2 
IL-2 35 ± 12 36 ± 12 <1 5 ± 2 
IL-4 <13 <13 <13 <13 
IL-10 <1 <1 <1 <1 an
ti-
C
D
3/
C
D
28
 
IL-13 67 ± 29 68 ± 23 4 ± 2 2 ± 1 
 
a pg/ml; control, IRES-GFP empty vector; data show mean values ± SD (n=3) 
 
TRAV6+TRBV20+Foxp3+ suppress allergen-specific transgenic effector cell proliferation 
in response to allergen-specific stimulation 
To assess the suppressive capacity of the tg Treg, TRAV6+TRBV20+ tg effector T-cells 
were stimulated in the absence or presence of TRAV6+TRBV20+Foxp3+ T-cells, Foxp3+ 
T-cells or CD4+CD25+ nTreg from the same donor. Upon Bet v 1-specific stimulation 
using aAPC, TRAV6+TRBV20+Foxp3+ T-cells strongly suppressed allergen-specific 
effector T-cell proliferation while Foxp3+ T-cells and nTreg expressing a non-cognate T-
cell receptor showed only weak suppressive capacity at a 1:1 ratio (Fig 5, A). Significant 
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suppression by TRAV6+TRBV20+Foxp3+ T-cells was evident up to an effector-to-
regulator ratio of 4:1 (Supplementary data Fig E1). Using anti-CD3/CD28 coated 
microbeads as polyclonal stimulus, TRAV6+TRBV20+Foxp3+, Foxp3+ T-cells and nTreg 
suppressed effector T-cell proliferation to a similar degree (Fig, 5, B). In eight experiments 
using PB T-cells from four non-allergic donors allergen-specific activation in the presence 
of TRAV6+TRBV20+Foxp3+ T-cells elicited 67.3 ± 15.1% suppression of effector T-cell 
proliferation compared to 19.9 ± 11.8% suppression by Foxp3+ T-cells (p<0.001) and 2.4 
± 11.2% by nTreg (p<0.001). In response to polyclonal activation 
TRAV6+TRBV20+Foxp3+ T-cells, Foxp3+ T-cells and nTreg showed a similar degree of 
suppression of effector cell proliferation (71.6 ± 15.5%, p<0.001, 74 ± 15.8%, p<0.001 
and 65.0 ± 2.9%, p<0.001). The obtained results were similar irrespective whether 
magnetic beads-purified CD4+CD25- T-cells (purity >95%) or bulk PB T-cells were used 
as the starting population (not shown).  
 
 
FIG 5.  
TRAV6/TRBV20/Foxp3-
transduced T-cells unlike 
Foxp3-transduced T-cells 
suppress Bet v 1-specific 
effector T-cells upon 
allergen-specific 
activation. Proliferation of 
TRAV6+TRBV20+ tg 
effector T-cells (Teff) 
cultured in the absence or 
presence of Foxp3+, 
TRAV6+TRBV20+Foxp3+ 
T-cells or nTreg at a 1:1 
ratio upon stimulation 
with (A) Bet v 1-
presenting aAPC or (B) 
anti-CD3/CD28 coated 
microbeads. Data show 
means + SD from 
triplicates. 
 
 
 
 
Similarly, proliferation of eFluor670 CPD-labeled effector T-cells was suppressed by 
TRAV6+TRBV20+Foxp3+ T-cells but not by Foxp3+ T-cells or nTreg upon Bet v 1-
specific activation (Fig 5, C). Moreover, upon polyclonal stimulation all assessed Treg 
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populations suppressed effector T-cell proliferation. (Fig 5, D). This suppressive capacity 
could, however, be overcome by exogenously added IL-2 (Fig 5, C and D lower panel). 
 
 
FIG 5. Flow 
cytometric analyses 
of eFluor 670 CPD-
labeled Teff in the 
absence (black line) 
or presence of 
Foxp3+ (red line), 
TRAV6+TRBV20+ 
Foxp3+ (blue line) T-
cells or nTreg (green 
line) at a 1:1 ratio 
upon stimulation 
with (C) Bet v 1-
presenting aAPC or 
(D) anti-CD3/CD28 
coated microbeads 
in the absence 
(upper panel) or 
presence (lower 
panel) of exogenous 
IL-2 (250 U/ml). 
n.s., not significant; 
***, p < 0.001. 
 
 
TRAV6+TRBV20+Foxp3+ T-cells efficiently suppress cytokine production of tg Bet v 1-
specific effector T-cells 
Upon allergen-specific activation, significantly decreased levels of the cytokines TNF-α, 
IFN-γ, IL-2 and IL-13 (range of inhibition: 72-95%) were found in supernatants of co-
cultures of TRAV6+TRBV20+ effector T-cells with TRAV6+TRBV20+Foxp3+ regulatory 
cells (Fig 6, A). Co-culture with Foxp3+ Treg showed a much less pronounced inhibition 
of cytokine secretion (range 32-55%) while nTreg did not affect cytokine secretion at all. 
To assess whether the observed results were caused by decreased effector cell cytokine 
production or by cytokine depletion,45 intracellular cytokine expression levels were 
monitored by flow cytometry. Discrimination between non-fluorescent effector T-cells 
and GFP+ tg Treg cells or CFSE-labeled nTreg allowed a strong and significant reduction 
of TNF-α, IFN-γ, IL-2 and IL-13 production to be detected in the effector T-cell 
population (GFP-, non-fluorescent). Thus, activated tg Treg have the capacity to directly 
and highly significantly inhibit cytokine production by effector cells. 
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FIG 6. Suppression of cytokine secretion of effector T-cells by engineered Treg. (A) Cytokine levels from 
cell-culture supernatants collected after 24 h (TNF-α, IL-2) or 48 h (IFN-γ, IL-13). (B) Intracellular staining 
of indicated cytokines. Numbers indicate percentage of cytokine positive cells among GFPneg (effector) cells. 
One representative experiment out of several is shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001 
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DISCUSSION 
 
We show that co-introduction of human TCR αβ-chains of predefined allergen specificity 
in concert with human Foxp3, the master regulator of Treg, into human PB T-cells 
generates tg allergen-specific Treg. These cells show the characteristic phenotype and 
functional properties of regulatory T-cells, i.e. Treg-marker expression, 
hyporesponsiveness to both allergen-specific and polyclonal stimulation, low cytokine 
secretion levels, and suppression of effector T-cell proliferation and cytokine production. 
While it has been well-documented in several transgenic mouse models 1, 32, 33 that Treg-
mediated suppression is an activation-dependent process, the general applicability of this 
understanding to human allergen-specific Treg has not, to date, been explored. This may 
be due to the fact that, although TCR transfer technologies have been described some 25 
years ago 22, molecular information about human allergen-specific TCR has been slow to 
develop. 
 
We here used the Bet v 1-reactive TRAV6/TRBV20 TCR (Neunkirchner et al., manuscript 
in preparation) to establish a proof-of-principle system. TRAV6+TRBV20+Foxp3+ PB T-
cells showed a strong regulatory capacity for Bet v 1-specific effector T-cells upon 
allergen-specific and polyclonal stimulation. Importantly, Foxp3 single-tg T-cells, which 
express their endogenous, non-cognate TCR, as well as CD4+CD25+ nTreg from the 
respective donors showed only weak regulatory capacity in the allergen-specific test-
system but were able to suppress tg effector T-cell proliferation to a similar degree as 
TRAV6+TRBV20+Foxp3+ T-cells upon polyclonal stimulation. This observation indicates 
that suppression by allergen-specific Foxp3 tg T-cells is - for the most part - an activation-
dependent process and that signaling via the tg human TCR can be indeed used as a 
specific ‘molecular switch’ to turn on allergen-specific T-regulatory programs in response 
to the defined allergen. The data obtained herein are thus in perfect agreement with Treg 
studies in the murine system, showing that Treg exert their suppressive function only upon 
TCR/CD3 engagement. 1 However, once appropriately activated, both antigen-specific and 
non-specific Treg show equal suppressive capacity.  
Allergen-specific tg Treg could become potent, highly specific immunotherapeutic tools. 
One could envision to re-infuse Treg engineered from autologous T-cells of severely 
affected individuals by TCR/Foxp3 transduction. Upon seasonal exposure to birch pollen, 
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transferred Treg would become specifically triggered and start to exert their regulatory 
program leading to tolerance against the immunodominant epitope of Bet v 1, i.e. Bet v 
1142-153.  
Will such an epitope/mono-specific therapeutic tool benefit poly-sensitized individuals 
suffering from multiple allergies?  
Larché and co-workers have demonstrated that tolerization against one epitope of an 
allergen induces also tolerance to adjacent epitopes, a phenomenon termed ‘linked 
suppression’.46 Whether a similar mechanism might also be induced by epitope/mono-
specific tg Treg remains to be determined. In favor of this proposal, in a collagen-induced 
arthritis model, a B47 TCR tg Treg recognizing a non-collagen autoantigen induced 
remission of the collagen-induced disease.47 
 
Although allergen-specific for the most part, the regulatory potential of Foxp3 tg T-cells 
was not entirely dependent on TCR-mediated activation. This might be due to ‘bystander’ 
effects of activated effector T-cells secreting IL-2 and/or providing cellular contact and 
thus supporting initial activation of co-localized Treg.48 Both possible mechanisms will be 
the focus of future studies. Transgenic Treg directly modulated cytokine production which 
may be the main mechanism of suppression rather than cytokine consumption.45 Like 
nTreg, Foxp3 tg T-cells are responsive to IL-2 (Fig 4), which should facilitate expansion 
and longevity in vivo. The observation that the tg Treg described here are suppressive in 
the absence of changes in significant secretion of IL-10 or TGF-β (not shown) supports 
the view, that secretion of ‘regulatory’-cytokines represents a tissue-specific auxiliary 
mechanism rather than a critically required core-feature of Treg.49 
  
In conclusion, given the well-documented relation between impaired Treg function and 
allergy11 and the fact that Treg play an important role in the efficacy of SIT5-10, our 
approach could add a novel tool to the still poorly endowed therapeutic armamentarium 
for treatment of allergies. While our studies suggest that nTreg and Foxp3 tg Treg are 
functionally equal, we cannot exclude certain differences in fine specificity and/or 
transcriptional signature as has been suggested.50 This aspect will be the focus of detailed 
future studies. The human origin of the introduced functional transgenes should minimize 
their immunogenicity and thus in addition to their IL-2 responsiveness allow longevity of 
customized Treg upon transfer in vivo. The approach presented here could help pave the 
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way for novel therapeutic strategies to abrogate undesired immune responses in the setting 
of allergy, autoimmunity and transplant rejection.  
 
CLINICAL IMPLICATIONS  
 
Transgenic expression of allergen-specific TCRs and Foxp3 generates customized 
allergen-specific Treg cells, which may help to develop adoptive immunotherapy 
protocols for allergic diseases. 
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SUPPORTING INFORMATION 
 
Table EI. List of primers  
Primer Sequence a 
RE 
site 
Foxp3 for 5'- CGCGGGAAGCTTGCCACCATGCCCACCCCCAGGCC -3' Hind III 
Foxp3 rev 5'- CGCGGGGCGGCCGCTTTAGGGGCCAGGTGTAGGG -3' Not I 
Foxp3 E1 rev 5'- CGTGGGCATCCACCGTTGACAGCTGCAGCTGCGATGG -3'  
Foxp3 E3 for 5'- CCATCGCAGCTGCAGCTGTCAACGGTGGATGCCCACG -3'  
TRAV6 for 5'- CGCGGGAAGCTTGCCACCATGGAGTCATTCCTGGGAGGTGT -3' Hind III 
TRBV rev 5'- CCCGCGGCGGCCGCTTTAGAAATCCTTTCTCTTGACCATGGC -3' Not I 
P2A-TRAV6 rev 5'- GTCTCCTGCTTGCTTTAACAGAGAGAAGTTCGTGGCTCCGGATC 
CGCTGGACCACAGCCGCAGC -3' 
 
P2A-TRBV20 for 5'- GCCACGAACTTCTCTCTGTTAAAGCAAGCAGGAGACGTGGAAG 
AAAACCCCGGTCCTATGCTGCTGCTTCTGCTGCTTCTG -3' 
 
T2A-TCRBV rev 5'- GTCACCGCATGTTAGCAGACTTCCTCTGCCCTCTCCGGATCCGAA 
ATCCTTTCTCTTGACCATGGCCAT -3' 
 
T2A-Foxp3 for 5'- GAGGGCAGAGGAAGTCTGCTAACATGCGGTGACGTCGAGGAGAA 
TCCTGGCCCAATGCCCAACCCCAGGCCTG -3' 
 
 
 a The underlined regions indicate the restriction enzyme (RE) sites  
 
 
FIG E1. Percent suppression of titrated amounts of indicated transgenic Treg co-cultured with Teff upon 
stimulation with (A) Bet v 1-presenting aAPC or (B) anti-CD3/CD28 coated microbeads. n.s., not 
significant; *, p < 0.05; ***, p < 0.001. 
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MATERIALS AND METHODS 
 
Molecular cloning and generation of multicistronic vectors 
The Foxp3 cDNA was amplified from a human T-cell cDNA library (primer sequences 
Supplemental Table I). Multicistronic constructs were generated via 2-step overlapping 
PCR using P2A and T2A sequences.34 and the Bet v 1142-153-specific DRB1*07:01-
restricted TCR constructs (TRAV6/TRBV20) (Neunkirchner et al., manuscript in 
preparation). All constructs were digested with Hind III and Not I and ligated into either 
the retroviral pMMP 36 vector or the pMMP-IRES-GFP vector. 
 
Cell lines and primary cells 
The HEK-293 cell line (human embryonic kidney cells) were cultured as described. 36, 37 
PBMC were isolated from healthy HLA-DR7+ volunteers in compliance with the ethics-
committee of the Medical University of Vienna. CD4+CD25+ nTreg and CD4+CD25- T-
cells were isolated by using the CD4+CD25+Regulatory T Cell Isolation Kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany). 
 
Transfection of 293 cells 
293 cells were transfected as described.27, 36, 37 For the generation of aAPC, 293 cells were 
transfected with 5µg each of pEAK12.HLA-DRA*01:01, pEAK12.HLA-DRB1*07:01, 
pcDNA.Ii::Bet v 1142-153, pcDNA.CatS and pEAK12.CD80.38 Amphotropic T-cell 
transducing retroviruses using multicistronic expression cassettes were produced, purified 
and applied as described.27, 36, 37, 39 
  
Retroviral transduction of peripheral blood T-cells 
CD4+CD25- or PB-T cells (5 x 106/well) were stimulated in 6-well flat bottom plates with 
5 x 106 anti-CD3/CD28 coated microbeads (Dynabeads, Invitrogen, Camarillo, CA) and 
300 U/ml IL-2 (Peprotech, London, United Kingdom) for 48 hours. Transduction leading 
to stable integration of transgenes into the genome of PB T-cells was performed as 
described.27  
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Flow cytometric analyses 
Cells were stained as described40 using the mAbs indicated in Supplementary Table II (20 
µg/ml). Foxp3 was detected by the Foxp3 Staining Set (eBioscience, San Jose, CA). 
Intracellular cytokine production was analyzed after pre-treatment for 6 h with Golgi-Stop 
(1:1500; Becton Dickinson, Palo Alto, CA) using Fix and Perm Kit (An der Grub, 
Kaumberg, Austria). 
 
Determination of cytokine secretion 
Transduced T-cells (5 x 104) were stimulated in 96-well plates with either allergen-
specific aAPC (5 x 104 irradiated with 60 Gy) or anti-CD3/CD28 coated microbeads (5 x 
104). After 24, 48 or 72 hours supernatants were harvested and cytokine concentrations 
determined by multiplex analysis (Luminex 100IS; Biomedica, Vienna, Austria). 
 
Proliferation and suppression assays 
Transduced T-cells or nTreg (5 x 104) were stimulated in 96-well plates with allergen-
specific aAPC (5 x 104 irradiated with 60 Gy) or anti-CD3/CD28 coated microbeads (5 x 
104) in the absence or presence of IL-2 (250 U/ml; Peprotech, London, UK) for 72 h, 
pulsed with [methyl-3H] thymidine (1 µCi per well, Perkin Elmer, Boston, MA) and 
processed as described.36 To test the suppressive capability of tg Treg, 5 x 104 
TRAV6+TRBV20+ effector T-cells were co-cultured with flow cytometrically-sorted 
TRAV6+TRBV20+Foxp3+, Foxp3+ T-cells or CD4+CD25+ nTreg and stimulated with 
aAPC or anti-CD3/CD28 coated microbeads and processed as above. Similarly, 
TRAV6+TRBV20+ effector T-cells were labeled with the far-red cell proliferation dye 
eFluor 670 (eBioscience; 1,5µM), co-cultured with tg Treg or CFSE-labeled nTreg 
(Invitrogen; 1 µM) and analyzed by flow cytometry after 96 h.   
 
Statistical analysis 
For multiple group comparisons ANOVA followed by Bonferroni correction was 
performed (SPSS, IBM, Chicago, IL). Two-group comparisons were performed using the 
Student’s t-test or the Mann-Whitney U-test. Data represent mean values ± SD. 
Statistically significant values are denoted as follows: *, p<0.05; **, p<0.01; ***, 
p<0.001. 
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ABBREVIATIONS 
 
APC: antigen presenting cell; aAPC: artificial antigen presenting cell; CatS: Cathepsin S; 
CD: cluster of differentiation; CFSE: carboxyfluorescein succinimidyl ester; CPD: eFluor 
670 cell proliferation dye; CTLA-4: cytotoxic T-lymphocyte antigen-4; Foxp3: forkhead 
box P3; GFP: green fluorescent protein; HLA: human leukocyte antigen; Ii: invariant 
chain; IL: interleukin; IRES: internal ribosomal entry site; kcpm: kilo counts per minute; 
PB: peripheral blood; SD: standard deviation; TCR: T-cell receptor; tg: transgenic; 
Treg: T regulatory cell; nTreg: naturally occurring T regulatory cells 
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Conclusion and Synopsis 
 
Although a broad range of symptomatic and therapeutic strategies for the treatment of 
allergic disorders are currently in use, severely affected patients still pose a considerable 
problem in medical care. In this respect the exact understanding of the pathophysiological 
mechanisms operative in allergy is clearly needed and thus remains a field of interest in 
basic research. To the day in vivo studies of respiratory allergy mostly rely on mouse 
models using the hen egg derived ovalbumin as model allergens1-5. While these studies 
have significantly helped to elucidate mechanisms of allergy and potential treatment 
strategies, they do not entirely reflect the actual situation in respiratory allergy. 
Ovalbumin, which belongs to the serpin protein family6 and represents a major food 
allergen7, considerably differs in its source, glycosylation pattern and structure from most 
major respiratory allergens8-10. Thus, experimental models based on the use of human-
relevant allergens and immune receptors are well warranted. Consequently, we have 
initially set out to develop an in vitro system of the human ‘allergen-specific’ synapse by 
cloning the relevant HLA-molecules, immunodominant peptides and correlating T-cell 
receptor α and β chains for the ragweed allergen Art v 1 (TRAV17/TRBV18)11 and the 
major birch pollen allergen Bet v 1 (TRAV6/TRBV20) (Neunkirchner et al; in press). 
Respective cDNAs were derived from T-cell clones and EBV transformed B-cell lines 
obtained from allergic individuals. Using human 293 cells transfected with the cloned 
HLA-molecules, allergenic peptides and costimulatory signals as artificial antigen-
presenting cells, we could demonstrate the antigen-specific and costimulation-dependent 
reaction pattern of TCR-transduced T-cells and T-cell lines11. In contrast to generation of 
allergen-specific T-cell clones/lines, which is a time-consuming and sometimes tedious 
process, TCR-transgenic T-cells can be generated in large quantities independently of the 
allergen season. Furthermore, retroviral transduction of TCR α/β chains should allow to 
target distinct T-cell populations and thus to study the influence of diverse modulatory 
strategies on different T-cell subsets (e.g. Th1,Th2, Th17 and Treg).  
In a first study we have relied on the recently established technique of targeting HLA-
molecules, costimulatory molecules and cytokines via GPI-anchoring to virus-like 
particles (VLP)12, 13 in order to target and modulate T-cell responses of Art v 1-specific 
transgenic T-cells. In these experiments we could show that VLP expressing HLA-DR1 
plus invariant-chain borne Art v 125-34 peptide were able to activate Art v 1-specific tg T-
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cells in a costimulatory dependent manner, thus validating the ability of HLA-decorated 
VLP to specifically target T-cells. Importantly, omission of costimulatory molecules on 
such stimulatory VLP led to the induction of anergy, which concurs with the classical 
observations summarized in the ‘two-signal hypothesis’. Additionally, we made use of the 
recently published observation that costimulation of CD4+ T-cells solely with CD58 
induces a Tr1-like phenotype14. Indeed, we could show that VLP decorated with CD58 
induced an IL-10highIFN-γintIL-2lowIL-13low phenotype in Art v 1-specific TCR tg T-cells15. 
However, whether such CD58-induced T-cells constitute a fully functional regulatory 
population has not been assessed in our laboratory so far. Given recently aired doubts that 
CD58 costimulation might not induce bona fide Tr1 cells16 it seems possible that we have, 
similar to Groux et al., observed a phenotype which resembles but does not constitute 
regulatory T-cells. Still, it would be tempting to speculate that such CD58-induced T-cells, 
although per se not regulatory to other effector T-cells, might be able to modulate Th2-
mediated diseases in vivo due to their production of the anti-inflammatory cytokine IL-10 
and the Th1 polarizing cytokine IFN-γ.  
In a second VLP-based approach we made use of the ability of VLP to accommodate 
multiple GPI-anchored proteins on the same particles. This observation allowed us to 
decorate VLP with multimeric receptors such as the high affinity IL-2 receptor consisting 
of the IL-2 receptor α, β and γ chain (CD25, CD122, CD132)17. In order to visualize the 
impact of different receptor compositions on binding and affinity, we used an influenza 
matrix protein:GFP fusion protein (MA:GFP) as fluorescence marker. With this approach 
we could assess that VLP expressing the high-affinity IL-2 receptor showed a 2.5-fold 
higher staining intensity of IL-2 transfected 293 cells when compared to VLP expressing 
only the IL-2R β and γ chain.  
The IL-2R is of special importance in T-cell homeostasis and activation and regulatory T-
cells can be distinguished from effector T-cells by their constitutive expression of the 
CD25 molecule18. This seems to be of mechanistical importance, as recent reports 
indicated that regulatory T-cells use this higher affinity to IL-2 to deplete effector T-cells 
from this important cytokine, which consequently undergo apopotosis19. We hypothesized 
that this function could be mimicked by VLP decorated with the high affinity IL-2R. 
Indeed, addition of VLP decorated with CD25:GPI, CD122:GPI and CD132:GPI to Artv1-
tg T-cells stimulated with artificial antigen-presenting cells strongly abrogated 
proliferation. However, in contrast to the report by Pandiyan et al., we could show in 
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restimulation experiments that IL-2 depleted CD4+ T-cells were not apoptotic but 
anergic17.  
While VLP-based IL-2 depletion thus seems to be a promising strategy to modulate T-cell 
responses, several practical questions have to be further assessed. First, systemic 
application of IL-2R decorated VLP could probably result in a general 
immunosuppression, a state that would certainly not be tolerable for the treatment of 
allergic diseases. Recent reports indicate that IL-2/anti-IL-2 immune-complexes favor the 
induction and expansion of regulatory T-cells in vivo 20, 21. In this light it seems 
conceivable that IL-2 bound to VLP may have similar functions, thus even potentiating the 
level of immunosuppression. Consequently, targeting of such VLP to specific T-cells 
poses a strict requirement. Whether additional decoration with MHC:peptide molecules is 
sufficient to meet this requirement will be the focus of further studies. Secondly, it 
remains to be shown whether the induction of anergy/hyporesponsiveness in allergen-
specific T-cells can fully abrogate pathological T-cell responses. As an ongoing allergic 
inflammation may provide a highly stimulatory environment with potent antigen-
presentation, this could potentially override anergy-inducing signals. Thus strategies to 
induce allergen-specific Treg may be more promising in the long run. 
While VLP-based approaches have potent immunomodulatory capacity in vitro, so far no 
data about kinetics and dynamics in vivo especially regarding tissue distribution and 
stability of VLP have been obtained. Given that decoration with MA:GFP allows to follow 
the fate of VLP, further studies will elucidate the in vivo behaviour of VLP and will aim to 
optimize these parameters. 
VLP-based strategies represent artificial antigen-presenting platforms of well-defined and 
thus predictable stimulatory/modulatory potential. However, during T-cell activation, APC 
derived signals are complemented by the crosstalk of different T-cell subsets, which have 
the ability to potentiate, polarize or modulate each other. As outlined in the chapter 
Introduction, regulatory T-cells offer huge promise in experimental models of a multitude 
of immune-mediated diseases and disorders. A broad range of different approaches to 
induce, generate or propagate regulatory T-cells with or without pre-defined antigen-
specificity has been described. The cloning and characterization of allergen-specific TCRs 
endowed us with the unique opportunity to generate allergen-specific regulatory T-cells by 
genetic engineering of purified human CD4+ T-cells. We hypothesized that co-
introduction of Foxp3 in concert with an allergen-specific TCR would result in transgenic 
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allergen-specific regulatory T-cells. In order to achieve a reliable expression of the three 
transgenes we fused the cDNAs encoding the Bet v 1142-153-specific TCR α and β chains 
(TRAV6/TRBV20) to the cDNA encoding Foxp3 using the recently described 
picornaviral 2A elements.  
Since its implementation as biotechnological tool in 200422, the use of 2A elements in 
multicistronic expression elements has gained increased attractiveness and has been used 
in studies to express transgenic TCRs. This may be due to the fact that transgenes linked 
via 2A elements were found to show a higher correlation of expression than transgenes 
linked via IRES elements22. However, in contrast to IRES elements, 2A elements are 
translatable sequences, which add a short amino-acid sequence to the C-terminus of the 5’ 
expressed protein after translation. This additional sequence has not been reported to 
interfere with the function of the linked transgenes (in our case the transgenic TCR α and 
β chains). However, the introduction of an additional foreign sequence may create novel 
antigenic peptides, which could limit the viability of transgenic cells in vivo, a notion that 
so far has not been thoroughly investigated.  
In order to achieve a facile detection and sorting possibility for positively transduced cells, 
the TCR/Foxp3 expression element was cloned upstream of an IRES-GFP element into a 
retroviral vector. Indeed, positively-transduced (GFP+) CD4+ T-cells showed strong co-
expression of the introduced transgenes and displayed the typical phenotype of nTreg 
(CD25highCTLA-4highCD39highCD127low). In functional experiments using Bet v 1142-153 
presenting artificial APC or anti-CD3/CD28 coated microbeads as polyclonal stimulus, 
these cells were found to be hyporesponsive in both proliferation and cytokine secretion. 
Importantly, TCR/Foxp3 tg T-cells were highly suppressive in co-cultures with 
TRAV6/TRBV20 tg effector T-cells both upon allergen-specific (aAPC-mediated) and 
polyclonal (microbeads-mediated) stimulation. In control experiments, Foxp3 tg or 
CD4+CD25+ nTreg, expressing their ectopic, polyclonal TCR repertoire, showed only 
minimal suppression upon antigen-specific activation but equal suppression when 
activated polyclonally. These findings validate that Treg suppressive activity is an 
activation-dependent process and that over-expression of a tg TCR can indeed serve as a 
‘molecular switch’ for Treg function23. While direct transduction of pre-sorted nTreg 
represents another strategy that has already proven feasible, our ‘fully transgenic 
approach’ offers several advantages in our eyes: Firstly, the use of nTreg sorted for the 
CD4+CD25+ phenotype denotes an ill-defined population, which potentially contains 
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‘contaminating’ activated effector T-cells. The additional use of markers such as CD127 
might result in a more pure nTreg population but considerably decreases the already low 
yield. In this respect CD4+CD25- T-cells, as used in our study, represent a more well-
defined population, which is readily available at high yields. Secondly, as backed by 
several studies, nTreg from allergic individuals or individuals suffering from autoimmune 
diseases might be compromised in their suppressive function and might thus be not 
suitable for therapeutic application24-26. Consequently, the high level overexpression of 
Foxp3, as practiced in our approach, could prove to be superior.   
Yet, several points of concern remain. Firstly, a TCR tg approach demands the exact 
knowledge about all factors involved in the ‘pathology-specific synapse’, i.e. the 
restriction element, the auto-antigenic/allogeneic/allergenic peptides and the 
corresponding TCRs. Although some allergies might present as rather uniform disorders in 
this respect27-30 other allergies and especially autoimmune diseases could be more 
heterogenous and would thus demand for a large collection of allergen/autoantigen-
specific TCRs. Secondly, Foxp3 overexpression does not reconstitute the complete gene 
expression profile of nTreg31, thus raising questions whether Foxp3 tg T-cells can be used 
as therapeutic tools for all mentioned applications. Whether additional introduction of 
genes involved in T-cell tolerance (for example ubiquitin ligases like Cbl-b32 or signaling 
molecules like STAT333) can overcome this deficiency will be the focus of further studies. 
Thirdly, the retro- or lenti-viral introduction of transgenes harbors the risk of insertional 
mutagenesis, which could at least theoretically lead to potentially severe complications 
such as malignant transformation. However, clinical trials in cancer patients receiving 
TCR transduced CD8+ T-cells have so far proven to be safe in this respect34. 
In conclusion, by building an in vitro system of the allergen-specific synapse we have 
succeeded in developing a system to study human allergen-specific T-cell responses. 
Consequently, we have developed and evaluated aAPC/VLP- and Treg-based strategies 
for the immunomodulation of Art v 1- and Bet v 1-specific T-cell responses. First studies 
show that these approaches have the capacity to modify or suppress allergen-specific T-
cell responses in vitro. However, questions about the in vivo applicability of VLP- or Treg 
based strategies concerning stability and disease-modifying potential remain to be 
experimentally addressed. To be able to study these issues in detail, we have recently 
developed a novel mouse model based on the introduction of the human 
TRAV17/TRBV18 TCR (Art v 1-specific) into HLA-DR1 tg mice, thereby rebuilding the 
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human allergen-specific synapse in vivo. First evaluations of TCR/HLA-DR1 tg mice have 
shown that T-cells show high expression levels of the respective transgenes and react 
specifically to Art v 1 protein and the Art v 124-36 peptide. This may enable us to take the 
next step in the “bench-to-bedside” process and ultimately develop novel therapies for 
immune-mediated disorders. 
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Zusammenfassung 
 
T-Lymphozyten spielen eine entscheidende Rolle im Ablauf einer allergischen 
Immunantwort. In Folge der Präsentation von Allergenen an spezifische T-Helfer Zellen, 
kommt es in Allergikern zur Polarisierung in Richtung einer T-Helfer 2 (Th2) Antwort. 
Die daraus resultierenden Effektormechanismen, vor allem die Sekretion von Th2-
Zytokinen wie IL-4, IL-5 und IL-13, tragen entscheidend zu sowohl der Akut-Phase 
Reaktion als auch zu Spät-Phasen Reaktionen der allergischen Immunantwort bei. Daher 
könnten Strategien, die diese pathologische Th2-Antwort modulieren, für die Behandlung 
von allergischen Patienten von therapeutischem Wert sein. Um solche Ansätze zu 
untersuchen, besteht dringender Bedarf nach Modellsystemen, die auf human-relevanten 
Allergenen, Präsentationsmolekülen und T-Zell-Rezeptoren (TZR) basieren. Daher wurde 
von uns die „allergen-spezifische Synapse“ von zwei klinisch äußerst relevanten 
Allergenen, dem immun-dominanten Beifuss-pollen Allergen (Art v 1) und dem Haupt-
Allergen des Birkenpollens (Bet v 1), auf molekularer Ebene nachgestellt. Dafür wurden 
die relevanten antigen-präsentierenden HLA-Moleküle und die korrespondierenden TZR 
aus Zell-Linien von Beifuss- bzw. Birkenpollen-Allergikern kloniert. Artifizielle antigen-
präsentierende Zellen (APZ) wurden durch Transfektion von 293 Zellen mit den 
jeweiligen HLA-Restriktionselementen, Allergenen und kostimulatorischen Molekülen 
hergestellt, während die dazugehörigen TZR in CD4+ T-Zellen retroviral transduziert 
wurden. Dieses Modell-System erlaubte uns, die Vorgänge der allergen-spezifischen T-
Zell Aktivierung unter definierten Bedingungen in vitro zu untersuchen. Zunächst konnten 
wir zeigen, dass TZR transgene T-Zellen in ihrer Aktivierung von der Erkennung des 
passenden Peptids und dem Vorhandensein von kostimulatorischen Signalen abhängig 
waren. Aufgrund dieser Beobachtungen konnten wir schließen, dass TZR transgene T-
Zellen in ihrem Verhalten dem physiologischen Verhalten von T-Zellen entsprachen.  
 
In einem ersten Ansatz zielten wir darauf ab, die Funktion von transgenen T-Zellen durch 
das Anbieten von unterschiedlichen kostimulatorischen Signalen zu modulieren. Dafür 
verwendeten wir ein in unserem Labor etabliertes System, bei dem Virus-ähnliche Partikel 
(‚virus-like particles’; VLP) als artifizielle antigen-präsentierende Plattform verwendet 
werden. In diesen Experimenten konnten wir zeigen, dass VLP optimal geeignet sind, die 
Rolle von APZ zu übernehmen und je nach ihrer spezifischen Ausstattung allergen-
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spezifische T-Zellen modulieren können. Während die Ausstattung von VLP mit antigen-
präsentierenden HLA/Peptid-Komplexen und CD80 als kostimulatorischem Molekül zu 
einer massiven Expansion der TZR transgenen T-Zellen führte, konnten antigen-
präsentierende VLP ohne Ko-Signale spezifisch einen Zustand der Anergie, induzieren. 
Ebenso führte VLP-mediierte Aktivierung mit CD58 als kostimulatorischem Molekül zu 
einer Polarisierung der antigen-spezifischen T-Zell Antwort in Richtung einer T 
regulatorischen Typ I (Tr1) Antwort. Dies ist von besonderem Interesse, da Tr1 Zellen 
wichtige Stellglieder in der Unterdrückung von allergischen Reaktionen darstellen.  
Weiters konnten wir zeigen, dass die Ausstattung von VLP mit dem hochaffinen IL-2 
Rezeptor uns erlaubte, dieses wichtige Zytokin in Kulturen von aktivierten allergen-
spezifischen T-Zellen zu neutralisieren. Das hatte zum Effekt, dass die T-Zell Aktivierung 
unterbunden wurde, und diese T-Zellen in den Zustand der Anergie übergingen. Damit 
konnten wir zeigen, dass VLP auch die Kapazität haben, wichtige Effektor-Mechanismen 
von T regulatorischen Zellen (Treg) zu übernehmen. 
 
In einem weiteren Unterprojekt untersuchten wir die Regulation des HLA Klasse II 
Komplexes, wovon wir uns Rückschlüsse für eine effektive Erstellung von artifiziellen 
antigen-präsentierenden Systemen erhofften. Zu diesem Zweck untersuchten wir B-Zell-
Linien von HLA Klasse II defizienten Individuen. Dabei konnten wir beobachten, dass die 
Invariante Kette im Gegensatz zu den anderen Molekülen des HLA Klasse II Locus in 
diesen Zellen nicht vollständig fehlte, sondern, abhängig vom auslösenden Gendefekt, 
verschieden stark exprimiert war. Dieses Resultat erlaubt nicht nur ein besseres 
Verständnis der Biologie des antigen-präsentierenden HLA Klasse II Komplexes, sondern 
könnte auch von diagnostischem Wert sein.  
 
Zusätzlich zu den Signalen, die von APZ an T-Zellen präsentiert werden, wird die T-Zell-
Antwort auch durch das Zusammenspiel von verschiedenen T-Zell-Untergruppen 
beeinflusst. Eine besonders wichtige Rolle in diesem Zusammenhang spielen Treg, die 
Aktivierung von T Zellen auch unter optimalen stimulatorischen Bedingungen 
unterbinden können. Aus diesem Grund bieten Treg ein attraktives Ziel zur Entwicklung 
von Therapien für Erkrankungen, die durch das Immunsystem vermittelt werden, wie 
Autoimmunerkrankungen, Allergien und Transplantatabstossung.  
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Vor kurzem konnte von zwei Gruppen unabhängig gezeigt werden, dass sich durch die 
Einbringung des Forkhead Box Protein 3 (Foxp3) Gens in T-Zellen, diese in Treg 
konvertieren lassen. Diesem Prinzip folgend erstellten wir allergen-spezifische Treg durch 
die Einbringung von einem Bet v 1-spezifischen TZR gemeinsam mit Foxp3 in CD4+ T-
Zellen. Eine verlässliche Einbringung und Expression aller drei Transgene (TZR α/β 
Ketten und Foxp3) erreichten wir durch die Konstruktion eines multicitronischen 
Expressionselements bei dem die entsprechenden cDNAs über 2A-Elemente fusioniert 
wurden. Um Identifizierung und Isolierung von transgenen Zellen zu erleichtern, wurde 
diese Expressionskassette 5’ vor ein IRES-GFP Element als Fluoreszenzmarker inseriert. 
Durch Transduktion mit diesem Konstrukt erstellte und isolierte TZR/Foxp3 transgene T-
Zellen zeigten die typischen Eigenschaften von Treg. Dazu gehört sowohl das spezifische 
Profil von hoher Expression von CD25, CD39 und CTLA-4 und die verminderte 
Expression von CD127, als auch das verminderte Ansprechen auf antigen-spezifische und 
polyklonale Stimulation. Weiters zeigten diese allergen-spezifischen Treg hohe 
suppressive Kapazität in Ko-Kulturen mit allergen-spezifischen T-Zellen. Von besonderer 
Signifikanz erwiesen sich Beobachtungen, dass nur TZR/Foxp3 transgene T-Zellen nach 
allergen-spezifischer Aktivierung suppressiv wirkten, während Foxp3 transgene T-Zellen, 
die einen nicht-spezifischen TZR exprimierten, keinen Effekt in solchen Ansätzen zeigten. 
Das validiert nicht nur die bekannte Beobachtung, dass Treg-mediierte Suppression 
Aktivierungs-abhängig ist, sondern beweist auch, dass ein künstlich eingebrachter TZR in 
Treg als molekularer Schalter für deren Funktion wirken kann.  
Aus diesen Experimenten gewonnene Schlüsse könnten entscheidend dazu beitragen, neue 
therapeutische Ansätze für Allergien, aber auch für andere Erkrankungen, in denen T-
Zellen eine wichtige pathophysiologische Rolle spielen, zu finden. Um diese Hypothese 
weiter zu überprüfen, sind wir zur Zeit damit beschäftigt, ein Mausmodell zu entwickeln, 
das auf dem in vitro System der „allergen-spezifischen Synapse“ basiert.  
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